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Abstract
Follicle stimulating hormone (FSH) promotes granulosa cell (GC) proliferation,
differentiation, and steroidogenesis. This series of events is critical for female fertility,
and culminates in the formation of mature follicles responsive to the surge of luteinizing
hormone (LH) that triggers ovulation. Ephrins (Efn genes) and Eph receptors (Eph genes)
are membrane-associated signaling molecules that mediate communication at sites of
cell-cell contact, and have been extensively studied in the context of embryonic
development. The published literature contains several reports of ovarian Eph and Efn
expression, although their precise roles in the ovary are unknown. Dysregulation of Efna5
in GCs of the subfertile Esr2-/- mouse suggests a role for Eph-ephrin signaling in ovarian
function. We sought to investigate Eph receptors and ephrins in the mouse ovary using
gonadotropin-stimulated animal models and cultured GCs. We identified several Efn and
Eph genes for which expression is enhanced in GCs of the gonadotropin-stimulated
mouse. Furthermore, we determined that cultured GCs stimulated with recombinant
ephrin-A5 or EphA5 exhibit reduced cell spreading or adhesion, respectively, indicating a
cell-autonomous response to Eph-ephrin stimulation. In order to ascertain the importance
of ephrin-A5 in female fertility, we performed a reproductive assessment of females
lacking Efna5, the sole ephrin-encoding gene upregulated by FSH in GCs. Efna5-/females are subfertile and exhibit an impaired response to LH, displaying attenuated
ovulatory potential, reduced ovarian expression of Pgr, Ptgs2, and Adamts4, as well as
abnormal follicle rupture. We also found an increased incidence of multi-oocyte follicles
in adult, but not juvenile, Efna5-/- females, indicating follicle merging. Finally, we
determined that the mouse genomic region upstream of Epha5 is transcriptionally
activated by cAMP in a protein kinase A-dependent manner. Transcriptional activation of
Efna5, Epha3, Epha5, Epha8, and Ephb2 is reduced in GCs of eCG-treated Esr2-/females, which exhibit impaired cAMP production. These results suggest that cAMP is a
novel transcriptional regulator for several Eph and Efn genes. Our findings establish a
place for ephrins and their receptors within the current model of gonadotropin-dependent
follicle growth and ovulation, and identify cAMP as a novel transcriptional regulator of
Epha5 and possibly other Efn and Eph genes.
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1 Chapter 1: Introduction
1.1 Stages of Ovarian Follicle Growth
1.1.1 Introduction to Folliculogenesis
In female mammals, the ovary has two primary functions. The first is the synthesis
of steroid hormones such as testosterone, 17β-estradiol, and progesterone. These
hormones are necessary for the development of secondary sex characteristics,
communication with the neuroendocrine components of the reproductive system, and
communication with the uterus to induce changes that are necessary for establishing and
maintaining pregnancy. The second function is the ovulation of a healthy and fertilizable
oocyte. Both functions are performed by the functional unit of the ovary, the follicle. The
ovarian follicle is an aggregate unit of a germ cell and its associated somatic cells,
consisting of an oocyte, surrounded by granulosa cells (GCs), which are in turn
surrounded by a basement membrane and thecal cells (Figure 1-1). The formation and
maturation of the follicle, known as folliculogenesis, begins in the developing embryo.
This process culminates in the generation of one or more mature follicles that are
competent to ovulate and produce a fertilizable oocyte.
1.1.2 Formation of primordial follicles
In female mammals, folliculogenesis begins during embryonic development.
Within the embryo, mitotic division of primordial germ cells (PGCs) gives rise to clusters
of germ cells, known as “oocyte nests” (1). Prior to birth in humans and at birth in
rodents (2), these clusters break down into individual germ cells called oogonia. Oogonia
are then enclosed by a single layer of flat pre-granulosa cells derived from the ovarian
stroma, forming a primordial follicle (3) (Figure 1-2). The mechanisms underlying these
events are not fully understood, but loss-of-function studies have identified some factors
that are required for this process (4). After formation, primordial follicles remain dormant
and will not mature until they are activated at puberty. It is thought that this pool of
primordial follicles will provide all of the oocytes required for the duration of the
female’s reproductive life (5). However, some evidence indicates that adult mouse and
human ovaries contain small numbers of stem cells that have the capacity to give rise to
1

oocytes in culture and in vivo (6). Whether this population of stem cells contributes to
and/or replenishes the pool of primordial follicles in adults is not known.
1.1.3 Follicle-stimulating hormone-independent follicle growth
Once a female mammal reaches sexual maturity, cohorts of quiescent primordial
follicles are selected for activation, acquiring the potential to grow, mature, and ovulate.
The current body of evidence suggests that primordial follicles are maintained in a state
of dormancy by inhibitory pathways within the follicle. One primordial follicle may
remain dormant while the follicle adjacent to it is recruited for activation, suggesting
inhibition by intra-ovarian factors (7). Deletion of the Amh gene in mice, which encodes
the anti-mullerian hormone, results in decreased numbers of primordial follicles and
increased numbers of growing follicles (8). Furthermore, oocyte-specific deletion of the
phosphoinositide 3-kinase (PI3K) pathway inhibitor gene Pten in mice results in
recruitment and activation of all primordial follicles, depletion of the ovarian reserve and
infertility (9). Therefore, recruitment of primordial follicles likely involves relief of these
and possibly other pathways that suppress activation.
Once a primordial follicle has been recruited, a series of events is initiated that
results in the formation of primary and then secondary follicles (Figure 1-2), which
occurs independently of gonadotropins. This is supported by histological observations in
ovaries from Fshb-/- mice, which lack the follicle-stimulating hormone (FSH) beta
subunit and therefore do not produce FSH. Ovaries from these mice contain follicles at
the primordial, primary, and secondary stages, indicating that FSH is not required for
growth up to the secondary stage (10). During the transition from the primordial to the
primary stage, the morphology of the single layer of pre-granulosa cells changes from flat
to cuboidal, followed by Foxl2 (forkhead box L2)-dependent granulosa cell proliferation
(11). Progression to the secondary stage involves continued proliferation of GCs and
recruitment of cells from the ovarian stroma to the outer periphery of the follicle. These
cells differentiate into thecal cells (12). This stage of growth is dependent on GDF9
(growth differentiation factor 9), an oocyte-secreted protein and member of the TGFB
(transforming growth factor beta) family. The requirement for GDF9 is supported by the
observations that Gdf9-/- female mice are infertile, have ovaries that contain only follicles
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at the primordial and primary stages (13), and lack markers for thecal cells (14).
Importantly, it is generally accepted that the secondary follicle stage is also the stage at
which GCs begin to express Fshr, which encodes the FSH receptor (FSHR) (15),
although some evidence suggests that primordial follicles respond to FSH (16). This
permits the follicle to acquire responsiveness to FSH, the gonadotropin that promotes
continued follicle growth.
1.1.4 FSH-dependent follicle growth
In contrast to growth of primordial and primary follicles, growth of secondary
follicles to the antral stage is dependent on FSH, an idea supported by the observation
that ovaries from Fshb-/- female mice contain primordial, primary, and secondary follicles
but lack antral follicles (10). Acting through FSHR, its cognate G protein coupled
receptor in GCs, FSH initiates a number of changes in the secondary follicle, including
increased proliferation of GCs, differentiation of GCs into more specialized cell types,
increased production of autocrine, paracrine and endocrine messengers, formation of a
fluid-filled antrum, and acquisition of responsiveness to LH (17).
As GCs continue to proliferate, they differentiate into two specialized subtypes:
mural GCs and cumulus cells. These GC subtypes comprise distinct populations that are
spatially segregated and serve different purposes in the follicle. Spatially, they are
separated by the formation of a fluid-filled antrum, or cavity. The fluid within the antrum
has a composition similar to that of serum, but with much lower concentrations of plasma
proteins that have molecular weights greater than 100 kDa (18).
Several layers of mural GCs line the interior periphery of the follicle and are the
primary site of estradiol synthesis in the ovary, producing increasing amounts of estradiol
as the follicle grows. During early FSH-dependent follicle growth, estradiol output from
the follicle is low and has a suppressive effect on hypothalamic GNRH (gonadotropinreleasing hormone) secretion. In this way, GNRH secretion is reduced but pulse
frequency is unaltered, resulting in reduced pituitary FSH secretion (19). As follicle
growth proceeds, estradiol production rises due to the increasing number of GCs and
increased expression of steroidogenic genes (20). In contrast to low serum estradiol
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concentration, high concentrations have the effect of increasing GNRH production and
frequency, favouring production of LH (21). In addition to estradiol, mural GCs also
produce the peptide hormones activin, inhibin, and follistatin, which are members of the
TGFβ family. These hormones were named based on their effect on FSH production,
with activins having a stimulatory effect and inhibins having an inhibitory effect (22).
Follistatin, which is present in serum, binds to activins with high affinity (23) and
“neutralizes” them by preventing their interaction with activin receptors (24). Ovarian
production of inhibins increases during FSH-dependent follicle growth (25), and acts to
suppress FSH secretion (26). Therefore, mural GCs are responsible for producing the
endocrine messengers that feed back on the hypothalamus and anterior pituitary.
In contrast to mural GCs, cumulus cells surround and are closely associated with
the oocyte. Cumulus cells exhibit different patterns of gene expression compared to
mural GCs, thought to be caused by a currently unidentified oocyte-secreted factor that
establishes opposing gradients of FSH- and SMAD2/3-dependent signaling in the follicle,
such that expression of FSH-responsive genes is strong in mural granulosa cells and weak
in cumulus cells (27). During FSH-dependent follicle growth, the primary purpose of
cumulus cells is to provide nutrients to the oocyte via gap junctions (28). Later in
folliculogenesis, cumulus cells play crucial roles in the events leading to ovulation.
1.1.5 LH-dependent oocyte maturation, cumulus expansion, ovulation, and corpus
luteum formation
Once the follicle reaches the preovulatory stage, estradiol levels are sufficiently
high to trigger an acute release of LH from the anterior pituitary, known as the LH surge.
Within the follicle, LH acts primarily on mural GCs, which express high levels of LH
receptor (LHR). In cumulus cells, expression of Lhcgr is much lower than in mural GCs
(29). LH promotes secretion of epidermal growth factor (EGF) and EGF-like factors from
mural GCs, which are delivered to cumulus cells via the follicular fluid. These factors,
which include amphiregulin, epiregulin, and betacellulin, activate EGF receptors
expressed by cumulus cells (30). Therefore, the LH response in cumulus cells is mediated
largely by these mural granulosa cell-derived, EGF-like factors. These and other factors
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initiate several events that are critical for fertility: resumption of oocyte meiosis, cumulus
expansion, follicle rupture, and formation of the corpus luteum.
1.1.5.1 Resumption of meiosis
During primordial follicle formation, oocytes are arrested during meiosis I (31),
and resumption only occurs following the LH surge. Meiotic resumption is necessary for
the production of a fertilizable oocyte, although the exact mechanism by which meiotic
resumption is initiated has not been elucidated. The current body of evidence indicates
that follicle-derived factors maintain the oocyte in a state of meiotic arrest. Arrested
oocytes removed from the follicle and placed in culture resume meiosis spontaneously,
suggesting that a follicle-derived factor inhibits meiotic resumption in oocytes (32,33).
Presumably, the LH surge inhibits the production or activity of this factor, resulting in
meiotic resumption. While this factor has not been identified, there is evidence
suggesting that its action on the oocyte is dependent on GPR3 (G-protein coupled
receptor 3) (34-36), since oocytes from mice lacking GPR3 undergo meiotic resumption
within antral follicles independently of LH, indicating that oocyte-expressed GPR3 is
required for suppression of meiotic resumption (37). In addition, mouse oocytes cultured
in the presence of the GPR3 ligands sphingosylphosphorylcholine or sphingosine-1phosphate exhibit delayed meiotic resumption (38).
1.1.5.2 Cumulus expansion
Cumulus expansion involves the production of an extracellular matrix by the
cumulus cells, resulting in increased COC volume (39). This matrix is rich in hyaluronan
and hyaluronan-binding proteins including TNFAIP6 (tumor necrosis factor-inducible
gene 6 protein) (40), VCAN (versican) (41), as well as laminins and FN1 (fibronectin)
(42). Cumulus expansion is critical for ovulation. Pharmacological blockade of
hyaluronan precursor synthesis during expansion in mice reduces ovulation and fertility
(43). Furthermore, knockout mouse studies have revealed that many genes critical for
ovulation are involved in cumulus expansion (44), including Has2 (hyaluronan synthase
2), Tnfaip6, Ptx3 (pentraxin 3), and Ptgs2 (Prostaglandin-endoperoxide synthase 2).
Cumulus expansion also requires the presence of oocyte-derived factors. Removal of the
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oocyte from COCs blocks cumulus expansion in culture (45). More recent evidence
suggests that the role of the oocyte in promoting cumulus expansion is dependent on
SMAD2/3 signaling in cumulus cells (46). This finding is consistent with evidence
indicating that a gradient of SMAD2/3 signaling occurs in GCs of the antral follicle, with
SMAD2/3 phosphorylation highest near the oocyte and lowest at the periphery of the
follicle near the basement membrane (27). The cumulus matrix has been proposed to
facilitate extrusion from the follicle and its capture by oviductal fimbria (47). This idea is
supported by evidence indicating an association between cumulus expansion and a
transient increase in COC invasiveness and motility, properties that may be necessary for
oocyte release from the follicle (48).
1.1.5.3 Follicle rupture
Successful ovulation requires release of the oocyte and its associated somatic cells
to the exterior of the follicle, necessitating rupture of the follicle wall at a location
adjacent to the exterior periphery of the ovary (the apical follicle surface). Degradation of
the ECM at the site of rupture results in the formation of a rounded protuberance known
as the stigma, which ruptures and releases the oocyte. This event is mediated by proteases
that are expressed in the follicle in response to LH, including members of the MMP
(matrix metalloproteinase) and ADAMTS (a disintegrin and metalloproteinase with
thrombospondin-like repeats) families. Several members of these families are upregulated
during follicle rupture in rhesus macaques, and injection of the dominant follicle with an
MMP inhibitor blocks ovulation (49). The observation that multiple proteases are
upregulated suggests that all are involved in follicle rupture, however only one protease
knockout model has been reported to exhibit a reproductive phenotype. Adamts1-/- female
mice are subfertile and exhibit reduced ovulation and fertilization rates, indicating that
this protease is critical for ovulation (50). Knockout mouse models lacking other LHinduced MMP- and ADAMTS-encoding genes do not exhibit reproductive phenotypes
(51-55), suggesting that other proteases may compensate for their loss.
1.1.5.4 Luteinization and formation of the corpus luteum
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Following ovulation, the remaining cells of the follicle form a structure known as
the corpus luteum (CL). The CL contains two types of steroid-producing luteal cells:
those derived from mural GCs (granulosa-luteal cells), and those derived from thecal
cells (thecal-luteal cells). Like the parental cells from which these luteal cells arise, they
play different roles in the CL. Granulosa-luteal, but not from thecal-luteal cells, exhibit
strong immunoreactivity against CYP19A1, suggesting that granulosa-luteal cells are the
primary sites of estradiol synthesis in the CL. In the macaque CL, luteal cells derived
from thecal cells exhibit strong immunoreactivity against CYP17A1 (cytochrome P450,
family 17, subfamily A, polypeptide 1), suggesting that thecal-luteal cells are the primary
sites of androgen synthesis. Both luteal cell types exhibited immunoreactivity against
CYP11A1 (cytochrome P450, family 11, subfamily A, polypeptide 1) and HSD3B
(hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase), indicating
that both cell types produce progesterone (56). Progesterone produced by the CL is
required for the initiation and maintenance of pregnancy, while estradiol and inhibins
produced in the CL suppress FSH secretion. As a result, FSH-dependent follicle growth
is generally inhibited until the CL regresses and its endocrine influence diminishes.
In addition to producing endocrine messengers, the CL also undergoes extensive
neovascularization. This is driven primarily by an increase in both VEGF (vascular
endothelial growth factor) and FGF (fibroblast growth factor), which is stimulated by the
LH surge (57-59). This provides the CL with a direct interface to the circulation, allowing
efficient access to cholesterol for steroid synthesis and release of endocrine messengers
into the blood.
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Figure 1-1: Histology of an antral follicle.
The antral follicle consists of an oocyte, surrounded by granulosa cells, a basement
membrane, and thecal cells. Under the influence of FSH, granulosa cells that are in close
proximity to the oocyte differentiate into cumulus cells. Granulosa cells that line the
interior periphery of the follicle differentiate into mural granulosa cells.
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Figure 1-2: Stages of ovarian follicle growth.
Primordial follicles undergo FSH-independent growth (A-C), becoming responsive to
FSH at the secondary stage. FSH-dependent growth (D-E) results in the formation of a
large follicle responsive to LH. Under the influence of LH (F-G), cumulus expansion
occurs, followed by ovulation.

9

1.2 The hypothalamic-pituitary-gonadal axis
In all reproductively mature, non-pregnant female mammals, follicle growth and
ovulation are controlled by communication between the hypothalamus, the anterior
pituitary, and the ovaries. In general, communication between these organs is mediated
by GNRH, FSH, LH, and steroid hormones including estradiol and progesterone. The
hypothalamus is the “master regulator” of female reproductive function, and may thus
serve as a control point to integrate external information about stress and resource
availability in order to modulate reproductive function. This integration of information
may allow fertility to be limited during times of physiological stress or poor nutrition
(60).
At the onset of puberty, a subset of cells within the hypothalamus called GNRH
neurons begin to secrete GNRH into the circulation in a pulsatile manner, with the
frequency of release determining the gonadotropin secreted. Pulsatile GNRH secretion is
dependent on KISS1 (kisspeptin), a hormone that is secreted by kisspeptin neurons also
located in the hypothalamus and acts on GNRH neurons which express Kiss1r (KISS1
receptor). Engineered mice with a GNRH neuron-specific depletion of Kiss1r fail to
undergo puberty (61). GNRH secreted from the hypothalamus reaches the anterior
pituitary and stimulates gonadotrope cells that express Gnrhr (gonadotropin-releasing
hormone receptor). Upon stimulation, these gonadotrope cells synthesize and secrete
gonadotropins into the circulation. Low GNRH pulsatile frequency favours secretion of
FSH and high frequency favours secretion of LH.
When FSH reaches the ovaries via the circulation, growth of several preantral
follicles is initiated, which may vary with respect to size and responsiveness to FSH. The
exact number is species specific, with a range of 4-14 preantral follicles recruited in
humans (62). Ultimately, most of these follicles will undergo apoptosis during a process
known as atresia. These are known as subordinate follicles. Only a small subset of
recruited follicles, and in some species only one, will reach the preovulatory stage. These
are known as dominant follicles. These follicles are likely to be the ones that were the
largest and/or most mature when FSH levels began to rise.

10

Once growth of preantral follicles has been initiated, proliferation of GCs and
expression of Cyp19a1 (cytochrome P450, family 19, subfamily A, polypeptide 1) is
enhanced. CYP19A1, commonly referred to as aromatase, catalyzes the aromatization of
testosterone and is the rate-limiting step in estradiol biosynthesis. The combination of
increased numbers of GCs and increased expression of Cyp19a1 results in elevated serum
estradiol, which serves as a messenger to the hypothalamus to secrete GNRH at a higher
frequency. Increased frequency of GNRH secretion serves two purposes: suppression of
FSH secretion and promotion of LH production, causing a switch in the gonadotropin
output of the anterior pituitary. FSH levels then begin to fall, which has important
consequences for growing follicles. During the early stages of FSH-driven follicle
growth, survival of the follicle is dependent on elevated serum concentration of FSH.
Once the follicle reaches a threshold size, such elevated FSH levels are no longer
required for survival (63). Subordinate follicles still require elevated FSH levels for
survival, and the decline in FSH triggers atresia in these follicles. However, follicles that
were initially more mature and responsive to FSH, the dominant follicle(s), no longer
require such elevated FSH for survival. Therefore, as FSH levels fall, subordinate
follicles die, leaving the dominant follicle(s) to reach the preovulatory stage.
Furthermore, dominant follicles also produce large quantities of estradiol and inhibin. In
fact, production of inhibin-B peaks during the follicular phase in humans (64). These
endocrine messengers act together to suppress FSH secretion, and in this way the
dominant follicles hasten the demise of subordinates (65).
In some cases, none of the preantral follicles that were initially recruited for growth
by FSH become dominant, and all undergo atresia. In this case, another cohort of
preantral follicles is recruited for growth, constituting a second “wave” of follicle growth.
This process may repeat, with the recruitment of additional waves, until a dominant
follicle arises. Evidence for waves of follicle growth came from transvaginal ultrasound
data, which demonstrated that two thirds of women experience 2 waves per
interovulatory interval (IOI) and one-third experience 3 waves per IOI (66).
As growth of the dominant follicles continue, expression of LHR in mural GCs
increases and estradiol production continues to rise. Once a threshold concentration of
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serum estradiol is met, an acute release of LH is triggered from the anterior pituitary.
This “LH surge” acts on the preovulatory follicle to trigger resumption of meiosis,
cumulus expansion, ovulation and formation of the CL. The CL produces large quantities
of estradiol, progesterone, and inhibin A, which all suppress FSH secretion (67). This is
when the follicular phase ends, and the luteal phase, characterized by the dominating
influence of CL, begins. It should be noted that basal levels of FSH continue to recruit
cohorts of preantral follicles for growth during the luteal phase. However, until the
influence of the CL is diminished, FSH levels do not reach levels sufficient for a
dominant follicle to arise, and the likely outcome for these follicles is atresia.
If pregnancy is not initiated, the CL undergoes a process known as luteolysis,
which involves apoptosis of luteal cells, regression of the CL, and a corresponding
decline in steroid and inhibin A production. As serum levels of these endocrine
messengers decline, their suppressive effect on FSH production is relieved. As the CL
regresses further and is reabsorbed into the ovary, rising FSH levels once again initiate
growth of the next cohort of preantral follicles. Thus, the luteal phase gives way to the
follicular phase, and the ovarian cycle begins again.
On the other hand, if the ovulated oocyte is fertilized and pregnancy is initiated, the
CL is rescued from luteolysis by chorionic gonadotropin (CG) produced in the placenta,
and then maintained by other factors of placental origin (68). For the remainder of
pregnancy, the CL continues to produce endocrine messengers that suppress FSH
secretion.

1.3 Eph receptors and Ephrins
1.3.1 Overview
The first Eph receptor was discovered and characterized during a human genomic
library screen for novel receptor tyrosine kinases (RTKs). Probing for sequences
homologous to the tyrosine kinase domain of v-fps, a viral oncogene, revealed a novel,
highly-conserved gene that is highly expressed in the erythropoietin-producing human
hepatocellular carcinoma cell line ETL-1. The novel gene was termed eph, after the cell
type in which it was initially discovered (69). Since then, the family of identified Eph
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receptors has expanded and now comprises the largest known family of receptor tyrosine
kinases (RTKs) in vertebrates. In vertebrates, 16 receptors (encoded by Eph genes) and 9
ephrin ligands (encoded by Efn genes) have been identified. These can be further
classified into two classes each of receptor and ligand, designated A and B based on
sequence similarity and receptor-ligand affinity. In general, Eph receptors and ephrins
have higher binding affinity for partners of the same class, and bind within these classes
promiscuously.
Eph receptors and their ephrin ligands exhibit a number of features that distinguish
them from other RTK families and their ligands. For example, all Eph receptors and
ephrin ligands are associated with the cell membrane by either a transmembrane domain
or a glycosylphosphatidylinositol (GPI) linkage. As such, Eph-ephrin signaling is
initiated exclusively at points of cell-cell contact.
Another unique aspect of Eph-ephrin signaling is that it is bidirectional, allowing
signaling cascades to propagate into both receptor-bearing (forward signaling) and
ligand-bearing (reverse signaling) cells. Forward signaling is mediated by Eph tyrosine
kinase activity and adaptor proteins that enable crosstalk with downstream signaling
pathways. Reverse signaling via B-class ephrins occurs in a similar manner, where the
receptor-bound ligand can interact with intracellular signaling elements via adaptor
proteins. Much less is known about reverse signaling via A-class ephrins, which are
associated with the cell membrane but lack a transmembrane domain. It has been
proposed that clustering of A-class ephrins into higher-order signaling clusters favours
the recruitment of transmembrane proteins, which in turn interact with intracellular
signaling elements. To date, several such partners have been identified (70-72) .
Eph-ephrin signaling has been characterized primarily in the context of
developmental processes and other functions in complex animals. However, it is likely
that Eph-ephrin signaling played important roles in much more primitive organisms, as
suggested by the identification of an Eph receptor in the sponge (73). This suggests that
Eph receptors were present prior to the divergence of parazoans and eumetazoans (74),
which is estimated to have occurred roughly 940 million years ago (75). Evidence from a
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recent phylogenetic analysis of Eph receptors and ephrins indicates that ancient chordates
had one A-class ephrin, one B-class ephrin, and one Eph receptor that was capable of
binding both classes of ligand. Since then, duplication and diversification has likely
resulted in the large families of Eph receptors and ephrins that are expressed in modern
organisms (76).
1.3.2 Ephrins
Like Eph receptors, all ephrins are membrane-associated signaling elements and
can be classified into two subtypes, A and B, based on sequence similarity. However, the
inter-class structural differences are greater for ephrins than for Eph receptors. A-class
ephrins consist of one extracellular receptor-binding domain (RBD) that contains a
hydrophobic pocket, which serves as an acceptor site for a G-H loop present in the
ligand-binding domain (LBD) of cognate Eph receptors. This RBD is linked to the
plasma membrane via a glycosylphasphatidylinositol (GPI) linkage; A-class ephrins do
not possess transmembrane or cytoplasmic domains (). The lack of a cytoplasmic domain
means that cytoplasmic signaling partners could not be inferred based on known
interacting motifs. However, a growing body of evidence indicates that A-class ephrins
transmit downstream signals via cis interactions of A-class ephrins with partners that
contain transmembrane domains. This occurs during the formation of signaling clusters,
and such partners include NTRK2 (neurotrophic tyrosine kinase, receptor, type 2) (71),
NGFR (nerve growth factor receptor) (70), and RET (ret proto-oncogene) (72).
Like A-class ephrins, B-class ephrins also contain a RBD, which interacts with the
LBD of cognate Eph receptors in a manner similar to that of A-class ephrins. However, in
B-class ephrins the RBD is linked to a transmembrane helix, which is in turn linked to the
cytoplasmic region of the ligand. The intracellular region contains several conserved
tyrosine residues as well as a PDZ (postsynaptic density protein 95/disks large homolog
4/zona occludens protein 1) domain. Upon activation and formation of signaling clusters,
the ephrin-B PDZ domain is phosphorylated by SRC (v-src avian sarcoma (SchmidtRuppin A-2) viral oncogene homolog) kinases. The phosphorylated PDZ domain
recognizes and binds adaptor proteins that facilitate downstream signaling. Such adaptor
proteins include RGS3 (regulator of G-protein signaling 3) (77) and NCK2 (NCK adaptor
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protein 2) (78). Disruption of the ephrin-B PDZ domain in mice results in lymphatic
defects (79) and defective formation of the corpus callosum (80).
1.3.3 Eph receptors
Like classic RTKs, Eph receptors have an ectodomain (a region that extends into
the extracellular space), a transmembrane region spanning the cell membrane, and an
intracellular region involved in propagation of downstream signals. The ectodomain
contains residues that serve to interact with ephrin ligands as well as other Eph receptors.
The LBD of the Eph receptor contains a hydrophobic pocket that interacts with a
hydrophobic loop in the RBD of cognate ephrin ligands. This high-affinity interaction is
believed to be the primary thermodynamic driver for complex formation (81). The
cysteine-rich region is important for cis-interactions with other Eph receptors during the
formation of higher-order signaling clusters (82). To date, no functions have been
assigned to the two fibronectin type-III domains of the ectodomain.
The membrane-spanning region consists of a transmembrane helix that links the
ectodomain to the cytoplasmic region. The cytoplasmic region consists of a
juxtamembrane domain (JM) proximal to the interior of the cell membrane, a kinase
domain (KD), and two regions that bind downstream signaling proteins: a sterile-alpha
motif (SAM) and a PDZ domain. In the inactive Eph receptor monomer, the JM occludes
the KD, suppressing kinase activity. Activation of the Eph receptor by a cognate ligand
favours recruitment of another receptor-ligand pair, forming a heterotetramer.
Autophosphorylation of the JM results in phosphorylation at two conserved tyrosine
residues, which in turn initiates a conformational change that disrupts the JM-KD
interaction (83).
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Figure 1-3: Ephrin and Eph receptor domains.
Eph receptors and ephrins are classified into 2 subtypes, A and B, based on receptorligand affinity and sequence similarity. Eph receptors of both A and B subtypes consist of
a ligand-binding domain, a cysteine-rich domain, 2 fibronectin type III domains, a
transmembrane helix, a juxtamembrane region, a kinase domain, a sterile-alpha motif
(SAM), and a PDZ-binding domain. A-class ephrins consist of a receptor-binding domain
associated with the cell membrane via a GPI-linkage. B-class ephrins consist of a
receptor-binding domain, a transmembrane helix, an intracellular domain, and a PDZbinding domain.
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1.3.4 Initiation of Eph-Ephrin Signaling
All Eph receptors and ephrin ligands are membrane-associated, and as such,
signaling is initiated from points of cell-cell contact. Initiation of signaling begins with
the thermodynamically favourable insertion of the ephrin receptor-binding domain G-H
loop into a hydrophobic pocket present in the ligand-binding domain of the cognate Eph
receptor (84). The conformational flexibility of this hydrophobic pocket varies amongst
different Eph receptors, which contributes to the promiscuity and variable affinities of
Eph-ephrin pairs (85-88).
These heterodimers then combine resulting in the formation of heterotetramers.
Heterotetramer formation is facilitated by interactions between the LBDs of the Eph
receptor from each heterodimer. Interactions at this interface are mostly polar, consisting
of van der Waals contacts, hydrogen bonds, and ionic interactions (89). Heterotetramers
also comprise the fundamental unit of ephrin signaling, due to the nature of RTK
activation. The Eph receptor KD is autoinhibited by the receptor’s own activation loop.
This loop obstructs the KD active site, preventing access to ATP and tyrosine substrates.
Ligand-induced Eph receptor dimerization initiates autophosphorylation, and promotes
phosphorylation of conserved tyrosine residues in the JM and activation loop of one Eph
receptor by its partner (90). This results in relief of the autoinhibitory activation loop-KD
interaction, allowing the KD to enter an “active” conformation and to access ATP and
tyrosine substrates (91).
Oligomerization of active heterotetramers into higher-order signaling clusters is
facilitated by interactions in cis between the LBD and cysteine-rich domains of Eph
receptors. Interactions at the LBD-cysteine-rich domain interface are also mostly polar,
consisting of van der Waals contacts, hydrogen bonds, and ionic interactions (88).
Continued recruitment of heterotetramers enlarges the heterooligomer, resulting in the
formation of higher-order Eph-ephrin signaling clusters that also behave as adhesive
contacts between cells. The size of these signaling clusters is not currently known, and is
a subject of continued investigation (89).
1.3.5 Eph-ephrin Signal Transduction
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Transduction of Eph-ephrin signaling begins at points of cell-cell contact, and is
notable for its bidirectionality, with signaling cascades propagating via receptors as well
as ligands. Signal tranduction via Eph receptors is termed “forward signaling” while
transduction via ephrins is termed “reverse signaling”.
Forward signaling is mediated primarily by conserved tyrosine residues in the
intracellular regions of the activated Eph receptor. Upon activation by ephrin ligands and
formation of heterotetramers, autophosphorylation by the Eph kinase domain results in
phosphorylation of these tyrosine residues. In addition to triggering conformational
changes that enhance kinase domain activity, these residues also serve as docking sites
for intracellular proteins that facilitate further signal propagation. These include Src
family kinases, Abl family kinases, guanine-exchange factors, GTPase-activating
proteins, as well as adaptor proteins that facilitate recruitment of additional kinases and
GTPase-modulating proteins. Recruitment of these cytoplasmic signaling elements
permits the activated Eph receptor to impinge on intracellular signaling pathways that
control cytoskeletal remodeling, migration, adhesion, proliferation, and gene expression.
For example, stimulation of EPHA2 in MDA-MB-231 breast cancer cells with
recombinant ephrin-A1 results in recruitment of the adaptor proteins SHC (Src homology
2 domain containing) and GRB2 (Growth factor receptor-bound protein 2), which enables
phosphorylation of ERK (Extracellular regulated kinase) (92). In another example,
stimulation of EPHA3-expressing human epithelial kidney 293T cells with recombinant
ephrin-A5 promotes recruitment of the adaptor protein CRK (V-Crk Avian Sarcoma
Virus CT10 Oncogene Homolog) and activation of the GTPase RHOA (Ras homolog
family member A), which in turn induces membrane blebbing and retraction of cellular
protrusions (93). These examples illustrate how Eph receptors can sense physical contact
with another cell and trigger various cellular responses. Some are transient, such as
cytoskeletal rearrangement, while others, such as ERK activation, may have lasting
effects via phosphorylation of ERK substrate proteins that regulate gene expression.
In addition to kinase domain-dependent signaling, some evidence supports kinase
domain-independent signaling. These studies involved mice that express Eph receptors
which lack cytoplasmic domains (94,95) or possess KD-inactivating mutations (96), but
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are capable of rescuing the phenotype of the full-Eph receptor knockout. It has been
proposed that in such cases, the extracellular Eph domains may potentiate signaling
activity of other membrane-associated receptors (95), or that induction of reverse
signaling via ephrins in adjacent cells was sufficient for phenotype rescue (94,96).
Reverse signaling is less understood. Little is known about the mechanisms
underlying signal transduction via A-class ephrins, which are associated with the cell
membrane via a GPI-linkage. Since these ephrins lack transmembrane domains, it was
proposed that the formation of large signaling clusters resulted in recruitment of
transmembrane signaling proteins that facilitate signal transduction. This was confirmed
with the discovery that the transmembrane protein NGFR (p75 neurotrophin receptor) colocalizes and physically interacts with ephrin-A5 in mouse retinal axons. The same study
found that retinal axons from mice lacking NGFR did not exhibit a response to EphA7,
indicating that this transmembrane receptor is required for reverse signaling via ephrinA5 in mouse retinal axons (70).
Signaling via B-class ephrins is better understood. In contrast to A-class ephrins,
the B-class ephrin extracellular domain is associated with the cell membrane via a
transmembrane helix, which is in turn linked to a cytoplasmic region that contains a PDZ
domain. As is the case with Eph receptors, the intracellular domains of B-class ephrins
contain conserved tyrosine residues that are phosphorylated by SRC kinases upon
receptor binding. These residues serve as docking sites for adaptor proteins that facilitate
downstream signaling.
In addition to forward and reverse signaling, which are initiated by Eph receptors
and cognate ephrins interacting in trans, Eph-ephrin interactions in cis have also been
reported. It has been proposed that these interactions suppress activation of Eph receptors
that are co-expressed with ephrins, resulting in silencing of forward signaling (97).
Interaction of ephrin-B2 and EPHA3 in cis has also been reported in H226 and A549
lung cancer cells, resulting in attenuation of EPHA3 activation. This suggests that Ephephrin interactions in cis do not necessarily require a cognate ligand-receptor pair (98).
1.3.6 Termination of Eph-ephrin Signaling
19

In many biological systems in which Eph-ephrin signaling has been studied, the
main roles of Eph receptors and ephrins are to mediate adhesive and repulsive responses
in order to control cell positioning. Eph-ephrin signaling clusters are adhesive structures
that physically tether interacting cells, meaning that the initial interaction between cells
bearing cognate Eph receptors and ephrins is adhesive in nature. Depending on the cell
type, the outcome of this interaction may involve maintenance of adhesion or initiation of
a repulsive response. This is especially relevant in biological processes such as axon
guidance, tissue segmentation, and tissue remodeling, where repulsive responses are
crucial in guiding cells to the correct position or maintaining boundaries between
different populations of cells (99). In order for these repulsive responses to occur, the
initial adhesive Eph-ephrin interaction must be terminated so that Eph-ephrin tethered
cells can disengage and migration may proceed. So far, two disengagement mechanisms
have been identified: proteolytic cleavage of Eph receptor or ephrin ectodomains, and
endocytosis of the cell membrane region that contains the Eph-ephrin signaling cluster.
The first reported mechanism of disengagement involved proteolytic cleavage of
ephrin-A2 by the ADAM10 metalloprotease (100). Further studies revealed that
ADAM10 is constitutively associated with EphA3, interacting with this Eph receptor via
its LBD. Formation of the Eph-ephrin heterodimer positions the protease domain of
ADAM10 such that cleavage of the ephrin-A2 ectodomain occurs in trans, which severs
the Eph-ephrin tether between cells (101,102). More recently, proteolytic cleavage of Eph
receptor ectodomains has also been reported. In contrast to cleavage of ephrins, which is
mediated by ADAM-family metalloproteases, cleavage of Eph receptors is mediated by
gamma-secretase (103,104).
For B-class Eph-ephrin pairs, the current body of evidence suggests that the
predominant mechanism for disengagement is endocytosis. ADAM13 has been reported
to cleave the ephrin-B1 ectodomain in Xenopus embryos, although this may not be a
general mechanism that is conserved across species (105). Disengagement via
endocytosis has been reported for forebrain neurons expressing EphB2 and ephrin-B1,
where immunofluorescence studies demonstrated that vesicles containing both receptor
and ligand are transported into both cells (106). Another study published simultaneously
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reported that adjacent Swiss 3T3 fibroblasts expressing EphB4 and ephrin-B2 exhibit
endocytosis of vesicles containing both receptor and ligand into both cells. Smallmolecule blockade of the RAC1 (ras-related C3 botulinum toxin substrate 1) pathway
prevented endocytosis and retraction, indicating that endocytosis is RAC1-dependent in
this model (107). Neither of these studies investigated the fate of endocytosed signaling
elements. However, it was later reported that activation of EphB1 in Chinese hamster
ovary cells results in phosphorylation of CBL (Cbl proto-oncogene, E3 ubiquitin protein
ligase) and ubiquitination of EphB1, suggesting subsequent proteasomal degradation of
EphB1 (108).
Thus, the mechanisms underlying termination of signaling for Eph-ephrin
complexes is class-dependent. In general, A-class Eph-ephrin complexes are severed via
cleavage of the ephrin ectodomain, while B-class Eph-ephrin complexes are endocytosed
into adjacent cells and subsequently undergo ubiquitination and degradation. Future
studies may identify additional mechanisms for termination of Eph-ephrin signaling.

1.4 Rationale
Since the first Eph receptor was identified in 1987, several reports have provided
evidence that Eph-ephrin signaling occurs in the adult ovary. LacZ (beta-galactosidase)
staining of ovarian sections from mice expressing an ephrin-B2-beta-galactosidase fusion
protein revealed that ephrin-B2 is expressed by thecal cells of preovulatory ovarian
follicles and blood vessels in the CL, suggesting that Eph-ephrin signaling is involved in
ovarian angiogenesis (109). Subsequent RT-PCR studies detected transcripts for EPHB1,
EPHB2, EPHB3, EPHB4, EPHB6, EFNB1, EFNB2, and EFNB3 in the human CL,
suggesting that these Eph receptors and ephrins are involved in CL formation (110).
Lastly, transcripts for Efna4, Efnb1, Efnb2, Epha2, Epha4, and Epha7 were detected in
human GCs (111), suggesting a role for these Eph receptors and ephrins in the
preovulatory follicle.
These reports indicated that Eph receptors and ephrins are expressed in the ovarian
follicle and the CL. However, the first evidence suggesting their involvement in follicle
growth came from microarray data indicating that Efna5 expression is reduced in GCs
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from eCG-treated Esr2-/- mice (112). These mice lack estrogen receptor beta (ERβ) and
exhibit a severe reproductive phenotype, with females exhibiting impaired follicle growth
and subfertility (113) due to impaired FSH-induced differentiation of GCs and an
attenuated response to LH (114). Taken together, these reports indicate that Efna5
expression is reduced in GCs of a mouse model that is subfertile and exhibits an impaired
response to gonadotropins. Therefore, reduced expression of Efna5 in GCs may be
involved in the reproductive phenotype of this mouse.
Taken together, these reports suggest that Eph-ephrin signaling occurs in the ovary
during follicle growth and formation of the CL. However, there have been no published
investigations of Eph receptor and ephrin expression and/or function in a gonadotropinstimulated animal model of follicle growth and ovulation. Understanding how Eph-ephrin
signaling is involved in these critical events will define a novel role for Eph receptors and
ephrins in ovarian function, a system outside the current scope of ephrin biology.

1.5 Hypothesis
The work presented in this thesis aims to test the hypothesis that ephrin-A5 is required
for gonadotropin-dependent follicle growth and ovulation, as well as optimal fertility.

1.6 Objectives
In order to test this hypothesis, I pursued the following objectives:
1. Characterize expression of Efn and Eph genes in granulosa cells of an eCGstimulated mouse model and a granulosa cell line, and determine whether
cultured GCs respond to stimulation with Eph receptors and ephrins.
2. Perform a reproductive assessment of Efna5-/- female mice to determine
whether absence of ephrin-A5 alters fertility.
3. Characterize transcriptional regulation of Epha5 by FSH and downstream
cAMP-dependent pathways.
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2 Chapter 2: The ephrin signaling pathway regulates
morphology and adhesion of mouse granulosa cells in vitro
This chapter is based on a peer-reviewed journal article:
Buensuceso AV, Deroo BJ. The ephrin signaling pathway regulates morphology and
adhesion of mouse granulosa cells in vitro. Biol Reprod. 2013;88(1):25.

2.1 Introduction
The successful formation of a preovulatory follicle in response to folliclestimulating hormone (FSH) requires dramatic changes in the follicle, including an
increase in follicle size and granulosa cell (GC) number, GC differentiation, and
formation of an antrum. FSH also induces changes in GC morphology and adhesion that
are essential for preovulatory follicle development both in vivo and in vitro (1).
Interestingly, changes in GC morphology and adhesion can also be induced by proteins of
the extracellular matrix (ECM) during preovulatory follicle formation (1). Alterations in
GC morphology are largely attributed to modifications of the cytoskeleton resulting from
signals from the ECM or adherens junctions, whereas GC adhesion and contact are
primarily mediated by gap junctions, tight junctions, and adherens junctions (1).
However, few other mechanisms regulating GC morphology and contact have been
identified. Recently, the Eph-ephrin family of molecules, a family that consists of ephrin
ligands and their Ephrin (Eph) receptors, has been shown to regulate both cellular shape
and adhesion during development, cancer, and the normal function of many different
tissues (2,3). Although members of the Eph-ephrin family have been identified in the
ovary, Eph-ephrin signaling and the role it may play during folliculogenesis have not
been well-characterized.
Eph receptors comprise the largest known family of receptor tyrosine kinases
(RTKs), with 16 Eph receptors (encoded by Eph genes) and 9 ephrin ligands (encoded by
Efn genes) (Table 2-1) (2,4-6). Both Eph receptors and ligands are divided into either Aclass or B-class, based on receptor-ligand affinity and sequence similarity. Eph receptors
and their ephrin ligands are membrane-associated; thus, signaling is initiated exclusively
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from points of cell-to-cell contact upon binding of the ephrin ligand of one cell to the Eph
receptor of an adjacent cell. Ephrin signaling is bidirectional, with signals propagating
into both the receptor-bearing cells (forward signaling) and ligand-bearing cells (reverse
signaling) (2). Eph receptors and ephrins were initially implicated in cell positioning and
migration during development, particularly of the nervous system; however, ephrins have
since been shown to regulate cell positioning, migration, adhesion, and differentiation
during the development of many other tissues, including the retina (7), thyroid (8),
vasculature (9), and mammary gland (10,11). Eph-ephrin signaling also regulates
keratinocyte adhesion and differentiation (12) and hematopoietic stem cell adhesion (13).
Compelling evidence also suggests that Eph-ephrin signaling plays several important
roles in cancer development and progression (3). Expression of ephrin ligands and
receptors is often reduced in advanced-stage tumors, and Eph-ephrin signaling regulates
tumor growth, metastasis, and angiogenesis by altering cell proliferation, motility,
invasion, and migration (3). Given that FSH induces changes in GC morphology and
adhesion during formation of a preovulatory follicle, we speculated that FSH may
regulate Eph-ephrin gene expression, and that Eph-ephrin signaling may regulate GC
function.
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Table 2-1: The Ephrin receptors and their ephrin ligand specificities.
Ligands are listed in approximate order of decreasing affinity for each receptor.
Table adapted from (4) and updated (i (5), ii (6), and iii (6)).
Eph receptors

Ligands

EphA1

ephrin-A1

EphA2

ephrin-A3, ephrin-A1, ephrin-A5, ephrin-A4, ephrin-A2

EphA3

ephrin-A5, ephrin-A2, ephrin-A3, ephrin-A1, ephrin-A4, ephrin-B1

EphA4

ephrin-A5, ephrin-A1, ephrin-A3, ephrin-A2, ephrin-B2, ephrin-B3, ephrin-A4

EphA5

ephrin-A5, ephrin-A1, ephrin-A2, ephrin-A3, ephrin-A4

EphA6

ephrin-A2, ephrin-A1, ephrin-A3, ephrin-A4, ephrin-A5

EphA7

ephrin-A2, ephrin-A3, ephrin-A1, ephrin-A4, ephrin-A5

EphA8

ephrin-A5, ephrin-A3, ephrin-A2

EphB1

ephrin-B2, ephrin-B1, ephrin-A3

EphB2

ephrin-B1, ephrin-B2, ephrin-B3, ephrin-A5i

EphB3

ephrin-B1, ephrin-B2, ephrin-B3

EphB4

ephrin-B2, ephrin-B1

EphB6

ephrin-B2ii, ephrin-B3iii
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To date, a limited number of reports have described Eph-ephrin gene expression in
the mammalian ovary (14-16). Gale et al. (14) identified ephrin-B2 (EPHB2) in the
endothelium of vessels surrounding and invading the theca interna of mouse preovulatory
follicles and in the highly vascularized corpus luteum. Those authors suggested that
EPHB2 regulates angiogenesis during the formation of preovulatory follicles and the
corpus luteum. Egawa et al. (15) investigated the mRNA levels of all B-class ephrins in
the human ovary during formation of the corpus luteum. They also demonstrated that
EPHB1 localized to the theca interna and that EPHB2 bound to the surface of freshly
isolated human GCs. Xu et al. (16) characterized the mRNA levels of ephrin A and B
ligands and receptors in human GCs and detected expression of EPHA2, EPHA4,
EPHA7, EFNA4, EFNB1, and EFNB2. This expression was unaffected by treatment of
GCs with human chorionic gonadotropin (hCG) (16). Finally, expression of EPHA4 has
been detected in bovine theca cells (17).
None of these studies investigated whether FSH regulates the expression of Ephephrin genes in the ovary, nor did they demonstrate a functional or behavioral effect of
Eph-ephrin signaling on follicular cells, such as changes in cell shape and adhesion.
Therefore, given that changes in cell shape and contact occur during GC differentiation
both in vitro and in vivo in response to FSH signaling, and given that a subset of ephrins
has been identified in GCs, we hypothesized that Eph-ephrin signaling may be a novel
mechanism by which GC shape and adhesion are regulated and that expression of ephrin
family members may be regulated by gonadotropins.
To determine if FSH regulates Eph-ephrin gene expression in mouse GCs, we
examined the expression of the entire family of Eph-ephrin genes after FSH treatment of
primary mouse GCs and an immortalized, FSH-responsive rat GC line (GFSHR-17) (18).
Using these models and recombinant ephrin ligands and receptors, we also investigated
the functional effects of Eph-ephrin signaling on GC morphology and adhesion and
identified beta-catenin as a potential downstream target of EFNA5 signaling in GCs.
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2.2 Materials and Methods
2.2.1 Cell Culture
The GFSHR-17 cell line is an immortalized, gonadotropin-responsive rat GC line
(18) that we obtained from Dr. Abraham Amsterdam (Weizmann Institute of Science).
GFSHR-17 cells were maintained in Dulbecco modified Eagle medium/F12
(DMEM/F12; Wisent, Inc.) containing 5% fetal bovine serum (FBS; Wisent, Inc.) at
37°C in 5% CO2 before use in experiments.
2.2.2 Mice and Treatments
Experiments were performed in compliance with the guidelines set by the Canadian
Council for Animal Care and the policies and procedures approved by The University of
Western Ontario Council on Animal Care. Investigations were conducted in accordance
with the National Research Council's Guide for Care and Use of Laboratory Animals.
C57BL/6 female mice (Postnatal Day [PND] 23–28) were used in all experiments. For
quantitative RT-PCR (qRT-PCR) studies, mice were treated either with saline or with
3.25 or 5.0 IU of equine chorionic gonadotropin (eCG; Sigma Chemical Co.) for 48 h
before isolation of GCs. For immunofluorescence studies, immature females were treated
with either saline for 48 h, 5.0 IU of eCG for 48 h, or 5.0 IU of eCG for 48 h followed by
5.0 IU of hCG for 24 h (Sigma).
2.2.3 Isolation of GCs
Ovaries were removed and immediately transferred to a 100-mm cell-culture dish
containing 15 mL of ice-cold M199 medium supplemented with 1 mg/mL of bovine
serum albumin (BSA), 2.5 μg/mL of amphotericin B, and 50 μg/mL of gentamicin (all
reagents from Invitrogen). Ovaries were pooled, and the GCs from each pool were then
expressed by manual puncture with 25-gauge needles followed by pressure applied with a
sterile spatula. Follicular debris was removed manually, and the GC suspension was
filtered through a 150-μm Nitex nylon membrane (Sefar America, Inc.) mounted in a
Swinnex filter (Millipore). The GCs were then pelleted by centrifugation at 250 × g for 5
min at 4°C followed by two washes in DMEM/F12 medium containing 1%
penicillin/streptomycin solution (15070-063; Invitrogen). The final cell pellet was frozen
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at −80°C for qRT-PCR studies or cultured in DMEM/F12 supplemented with 10% FBS
for GC spreading and adhesion studies. For qRT-PCR studies, human recombinant FSH
was obtained from Dr. A.F. Parlow (National Hormone and Peptide Program, National
Institute of Diabetes and Digestive and Kidney Diseases). Forskolin was purchased from
Sigma Chemical Co.
2.2.4 RNA Isolation and qRT-PCR
Frozen pellets of GCs were solubilized in TRIzol (Invitrogen), and RNA was
isolated according to the manufacturer's protocol. RNA was further treated with DNase I,
then reverse-transcribed using Superscript II (Invitrogen). Complementary DNA (cDNA)
levels were detected using qRT-PCR with the ABI PRISM 7900 Sequence Detection
System (Applied Biosystems) and SYBR Green I dye (Applied Biosystems). Primers
were generated using Primer Express Software (Version 2.0; Applied Biosystems) ().
Fold-changes in gene expression were determined by quantitation of cDNA from target
(treated) samples relative to a calibrator sample (vehicle). The gene for ribosomal protein
L7 (Rpl7) was used as the endogenous control for normalization of initial RNA levels.
Expression ratios were calculated according to the mathematical model described by
Pfaffl (19), where ratio = (Etarget)ΔCt(target)/(Econtrol)ΔCt(control) and E = efficiency of the
primer set, calculated from the slope of a standard curve of log(ng of cDNA) versus cycle
threshold (Ct) for a sample that contains the target according to the formula E = 10−(1/slope)
and ΔCt = Ct(vehicle) − Ct(treated sample). Three independent experiments were carried out, and
the results were averaged for statistical analysis by a one-way ANOVA followed by a
Tukey multiple comparison post-hoc test (Figure 2-1) or by a two-tailed unpaired
Student t-test (Figure 2-2).
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Table 2-2: Primer sequences used for quantitative RT-PCR.
Gene

Forward Primer

Reverse Primer

Rpl7

5’ – AGCTGGCCTTTGTCATCAGAA – 3’

5’ – GACGAAGGAGCTGCAGAACCT – 3’

Epha1

5’ – CCTGGAGGGAATCTGAGCTATG – 3’

5’ – CCTGGGTTCCAACACCATCT – 3’

Epha2

5’ – CCAGGAAGGCTACGAGAAGG – 3’

5’ – TCAGATGCCTCAGACTTGAAG – 3’

Epha3

5’ – CCGCAGTCAGCATCACAACT – 3’

5’ – TTTCTGGAAGTCCGATCTTTCTTAA – 3’

Epha4

5’ – GACAACGATGCAGCCTCCAT – 3’

5’ – TCTCGTTGACATTAGAAATCAA – 3’

Epha5

5’ – GCTGGTTCCCATTGGGAAAT – 3’

5’ – CACATTGGTGACTGGAGAAGGA – 3’

Epha6

5’ – CTCCCAAGCCATTCACAGCTAT – 3’

5’ – GCCCAGTCCTTTCTCATCATACC – 3’

Epha7

5’ – TCTTCGCTGCTGTTAGCATCA – 3’

5’ – GCAGTACTCGCTCCTTCATGACT – 3’

Epha8

5’ – CTCGGATGAAGAGAAGATGCATT – 3’

5’ – TGGTTCAAGGGCAAGAAGACA – 3’

Ephb1

5’ – CAAGATGTGTTTCCAGACTCTGACA – 3’

5’ – TGCCGAGCCAGCAATCA – 3’

Ephb2

5’ – ACCTCAGTTCGCCTCTGTGAA – 3’

5’ – GGCTCACCTGGTGCATGAT – 3’

Ephb3

5’ – AGCGGGTTACGGACAGTATAGC – 3’

5’ – AGCTGCTGGGCACCTGAA – 3’

Ephb4

5’ – GATCCTCACGGAATTCATGGA – 3’

5’ – ACTGTGAACTGCCCGTCGTT – 3’

Ephb6

5’ – GGCAGCAGCCATCAATGTC – 3’

5’ – GGCTCACCTGGTGCATCAC – 3’

Efna1

5’ –AGTGCTTGAAGCTGAAGGTGA– 3’

5’ –TCTTCTCCTGTGGGTTGACAT– 3’

Efna2

5’ – TTTTCCCTGGGCTTTGAGTTC – 3’

5’ – GGGTCGGTCCACGAGGTT – 3’

Efna3

5’ – TGCCGGCCAAGAATACTACTACA – 3’

5’ – ACCTTCATCCTCAGACACTTCCA – 3’

Efna4

5’ – GGCCGGTGCCTGAGACT – 3’

5’ – CCCGGACGTACCGCTTT – 3’

Efna5

5’ – TCTGCAATCCCAGACAACGGAAGA – 3’

5’ – TCATGTACGGTGTCATCTGCTGGT – 3’

Efnb1

5’ – TCGCACCCGCACTATGAA – 3’

5’ – TCAACTGCTCGGGTGTCACA – 3’

Efnb2

5’ – CAGACAAGAGCCATGAAGATCCT – 3’

5’ – GACCGTGATTCCTGGCTGAT – 3’

Efnb3

5’ – CAGAGGCATGAAGGTGCTTCT – 3’

5’ – GCATTTCAGACACAGGTTTTCG – 3’

MOUSE
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RAT
Rpl7

5’ – CGCTGCGCCAGGAACCCTTA – 3’

5’ – GCCTTTCGCAGTGTCTTCAGGGC – 3’

Epha5

5’ – TCCTTGCTCACACAAACTATACCT – 3’

5’ – TACATTTACAGACACATACTGCCG – 3’

Efna5

5’ – TGGAAGAAGATCCTGCCTAAAGC – 3’

5’ – CGATCACGAACACCTATAGTTTTCA – 3’

40

2.2.5 Immunofluorescence
Dissected ovaries were immediately embedded in Cryomatrix (Fisher Scientific,
Inc.) and frozen using liquid nitrogen. Tissues were cut into sections (section thickness, 6
μm), mounted onto slides (Fisher), and stored at −20°C until use. Sections were fixed
with 4% formaldehyde for 10 min, rinsed three times with PBS, then permeabilized with
0.1% Triton X-100 for 15 min. Sections were again rinsed three times with PBS, blocked
for 30 min with blocking solution (5% BSA in 0.1% Triton X-100), then rinsed three
times with blocking solution. The tissue was then incubated for 1 h with primary
antibody specific to each target—namely, rabbit anti-EFNA5 (1:50; sc-20722; Santa Cruz
Biotechnology, Inc.), rabbit anti-EPHA5 (1:50; ab5397-100; Abcam), and rabbit antipan-cadherin (1:100; ab6529; Abcam). Sections were then rinsed three times in blocking
solution and incubated in secondary antibody (fluorescein isothiocyanate-conjugated goat
anti-rabbit secondary antibody, 1:250; F9887; Sigma). The tissue was then rinsed twice in
PBS followed by a 5 min incubation in 4′,6-diamidino-2-phenylindole (1:1000; Sigma),
and slides were mounted with VECTASHIELD (Vector Laboratories). Slides were stored
at 4°C and visualized the following day with an AX70 Provis upright microscope
(Olympus). Images were captured using Image-Pro 6.2 software (Media Cybernetics).
2.2.6 Cell Spreading and Adhesion Assays
Cell spreading and adhesion assays were based on similar assays used by others
(20-23) to study the effects of Eph-ephrin interactions on cell rounding, spreading, and
adhesion. In these assays, recombinant ephrin ligand or Eph receptor protein is spotted
onto tissue-culture plastic, after which cells are seeded onto the plates and allowed to
attach. Rounding or adhesion is then quantified within the spotted area. In the present
experiments, both primary mouse GCs and GFSHR-17 cells were used.
In these assays, recombinant human EFNA5/human Fc (immunoglobulin [Ig] G)
chimera (374-EA; R&D Systems), rat EPHA5/human Fc chimera (541-A5; R&D
Systems), or human Fc (IgG; 009-000-008; Jackson ImmunoResearch) was used. (Ephephrin recombinant proteins are commercially available only as Fc-fusion proteins, which
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interact with the preclustering antibodies.) Each of these recombinant proteins was first
preclustered before application to tissue-culture surfaces by combining Fc with F(ab′)2
fragment rabbit anti-human IgG antibody (Fcγ fragment specific; 309-006-008; Jackson
ImmunoResearch) at a 5:1 molar ratio followed by gentle agitation at room temperature
for 2 h. Preclustering of recombinant Eph receptor and ephrin fusion proteins is necessary
to activate either the ephrin ligands or the Eph receptors, because this mimics the
membrane Eph receptor or ephrin ligand clustering that occurs in vivo upon activation
(24-26). Serial dilutions in PBS were then prepared as follows: EFNA5/Fc at 74, 37,
18.5, and 9.25 μg/mL for the cell rounding/spreading assay and EPHA5/Fc at 83, 42, 21,
and 10 μg/mL for the cell adhesion assay. These concentrations were chosen based on
those used by Yin et al. (23) in similar experiments and resulted in equimolar amounts of
EFNA5 and EPHA5 in each dilution. Droplets (3.5 μl) of preclustered Fc or EFNA5/Fc
or EPHA5/Fc were placed onto a 60-mm tissue-culture dish (Sarstedt) and incubated at
37°C for 1.5 h to allow the protein to adsorb to the tissue-culture surface. For both assays,
serial dilutions of the Fc (IgG) fragment were also spotted to correspond to each
concentration of EFNA5/Fc or EPHA5/Fc to control for differences in the number of
micrograms of protein spotted at each concentration; however, only the highest Fc
concentration is reported as the control in Figure 2-4, Figure 2-5, Figure 2-6, and
Figure 2-7 because no differences in either cell shape (see Figure 2-4 and Figure 2-5) or
cell adhesion (Figure 2-6 and Figure 2-7) were observed between the different Fc (IgG)
dilutions. Droplets were outlined using fine permanent marker on the underside of the
dish to distinguish between treated and untreated areas, and the dish was rinsed twice
with 4 mL of ice-cold PBS to remove nonadsorbed EFNA5/Fc or EPHA5/Fc. The dish
was then seeded with 1.4 million cells in a 4-mL volume of DMEM/F12 containing 10%
FBS. Cells were incubated at 37°C with 5% CO2 for 2 h to allow the cells to adhere and
spread. (The minimum time required to observe maximal cell spreading [i.e., 2 h] had
been previously determined experimentally). Cells were then rinsed twice with PBS to
remove media and nonadhered cells and fixed in 4% paraformaldehyde in PBS for 10
min at room temperature.
Quantitation of the effects of recombinant EFNA5/Fc on cell spreading. One 100×
image (1020 × 768 μm) was taken from the center of each spotted region using an IX70
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microscope attached to an DP71 camera (both from Olympus). All cells within one 100×
field were visually scored as being “spread” (characterized by the presence of
lamellipodia) or “round” (characterized by round morphology and complete absence of
lamellipodia). The fraction of spread cells was determined by dividing the number of
spread cells in each image of the EFNA5/Fc surface by the number of spread cells in the
image from the control Fc (IgG) surface. Three independent experiments were carried
out, and the results (Figure 2-4 and Figure 2-5) were analyzed for statistical significance
by a one-way ANOVA followed by a Tukey multiple comparison post-hoc test.
Quantitation was based, as described, on an image taken from the center of the spotted
region (Figure 2-6A, asterisk).
Quantitation of the effects of recombinant EPHA5/Fc on cell adhesion.The total
number of cells within one 100× field image obtained from the EPHA5/Fc surface was
divided by the number of cells on the control Fc (IgG) surface, resulting in a value of one
for the Fc-coated plates and fractions of one for the EPHA5/Fc surfaces. Note that the
exact images in Figure 2-6 were not used for quantitation; they are presented to show the
dramatic difference in adhesion between EPHA5-coated and noncoated regions. Three
independent experiments were carried out, and the results (see Figure 2-6 and Figure
2-7) were analyzed for statistical significance by a one-way ANOVA followed by a
Tukey multiple comparison post-hoc test.
2.2.7 Human Phospho-Kinase Array
To screen for potential downstream targets of EFNA5-induced signaling in GCs,
such as the phosphorylation of kinases and their protein substrates, we used the Human
Phospho-Kinase Array Kit (ARY003B; R&D Systems), which simultaneously detects the
relative site-specific phosphorylation of 46 phosphorylated proteins or their targets
(Supplemental Table 6-1). GFSHR-17 cells were seeded onto tissue-culture surfaces
coated with EFNA5/Fc or Fc alone, and lysates were harvested at 15 and 20 min after
seeding. We chose 15- and 20-min time points based on a search of the literature, which
indicated that many of the signaling elements captured by the array exhibit maximum
phosphorylation within 15 min of stimulation. These lysates were applied to the Human
Phospho-Kinase Arrays, which were then developed according to the manufacturer's
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instructions. Spot intensities were also quantified using ImageJ software (National
Institutes of Health, http://rsb.info.nih.gov/ij/) according to the manufacturer's directions.
2.2.8 Immunoblot Analysis: Beta-Catenin
The EFNA5/Fc or Fc (IgG) were preclustered before application to tissue-culture
surfaces by combining with F(ab′)2 fragment rabbit anti-human IgG antibody (Fcγ
fragment specific) at a 5:1 molar ratio followed by gentle agitation at room temperature
for 2 h. The preclustered recombinant protein was then used to coat 60-mm tissue-culture
dishes and incubated at 37°C for 1.5 h, then rinsed twice with 4 mL of ice-cold PBS. The
dish was then seeded with 2.1 million GFSHR-17 cells in a 4-mL volume of DMEM/F12
containing 5% FBS. Cells were incubated at 37°C with 5% CO2 for 15 and 20 min. At
each time point, lysates were generated by placing the dishes on ice, gently rinsing the
cells twice with ice-cold PBS, and scraping the cells in 100 μl of ice-cold RIPA buffer
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor cocktail (1:100;
P8340; Sigma) and a phosphatase inhibitor cocktail (1:100; P2850; Sigma). Lysates were
then transferred to a 1.5-mL microcentrifuge tube, incubated on ice for 20 min with mild
agitation, and then centrifuged at 15 000 × g for 20 min at 4°C. The supernatant was
boiled in Laemmli buffer for 5 min and then analyzed using SDS-PAGE. The separated
proteins were transferred to a polyvinylidene fluoride membrane at 100 V (constant
voltage) for 2 h at 4°C. After blocking for 1 h in Tris-buffered saline and Tween 20
(TBST)/5% nonfat milk, the membrane was probed with rabbit IgG specific to betacatenin (1:1000 in TBST/5% nonfat milk; D10A8; Cell Signaling). The membrane was
then probed with horseradish peroxidase-conjugated donkey IgG against rabbit IgG
(1:10 000 in TBST/5% nonfat milk) and visualized using ECL Plus (Amersham
Biosciences) and Hyperfilm (Amersham). To assess equal protein loading, the membrane
was subsequently probed using a rabbit monoclonal IgG against histone deacetylase 4
(HDAC4, sc-11418; Santa Cruz Biotechnology, Inc.). Densitometric analysis of
immunoblot data (ImageLab 4.1; Bio-Rad) was then carried out to quantitate the ratio of
beta-catenin:HDAC4.
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2.3 Results
2.3.1 Identification of FSH-Regulated Ephrin Ligands and Eph Receptors in Mouse
GCs
To determine if FSH regulates Eph-ephrin expression in GCs of immature PND
23–28 female mice, we initially screened the mRNA levels of all known mouse ephrin
(Efn) and Eph receptor (Eph) genes in GCs isolated from immature female mice treated
for 48 h with either saline or 5.0 IU of eCG (Supplemental Figure 6-1 and
Supplemental Figure 6-2). Eph-ephrin gene expression was determined by qRT-PCR.
Based on this screening, we chose a subset of Efn and Eph genes that appeared to be
regulated by eCG to further verify and to investigate the possibility of a dose-dependent
response to eCG. To do this, we purified mRNA from GCs isolated from immature
female mice treated for 48 h with either saline, 3.25 IU of eCG, or 5.0 IU of eCG. Ephephrin gene expression was again determined by qRT-PCR. We verified that the mRNA
levels of one Efn gene and three Eph genes were significantly increased by eCG (Figure
2-1). At 3.25 IU of eCG, significant increases in the ephrin ligand Efna5 and the Eph
receptors Epha5 and Epha3 (Figure 2-1, A, B, and D) were observed. At 5.0 IU of eCG,
significant increases in Efna5, Epha5, Ephb2, and Epha3 (Figure 2-1, A–D) were
observed, along with an apparent increase in Epha8, though the effect was not significant
(P = 0.08 by Student t-test). To demonstrate that these eCG-dependent increases in Efna5,
Epha5, Ephb2, and Epha3 were specific to this subset of Eph-ephrin family members—
that is, that eCG did not affect the expression of all Eph-ephrin family members—we also
examined the mRNA levels of the ligand Efna1 and the Eph receptor Epha2 (Figure
2-1F) in response to eCG. Efna1 mRNA levels did not increase in response to 5.0 IU of
eCG; in fact, a significant decrease was observed (P < 0.01). In addition, expression of
Epha2 was not significantly changed in response to eCG treatment (Figure 2-1F). These
results indicate that FSH increases the expression of a subset of ephrin ligands and Eph
receptors in GCs of immature mice.
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Figure 2-1: Expression of a subset of ephrin ligands and Eph receptors is stimulated
by FSH in mouse GCs.
Wild-type PND 23–28 C57Bl/6 mice were treated with saline or eCG (3.25 or 5.0
IU/mouse) for 48 h. GCs were isolated by ovarian puncture and pooled, and then mRNA
was isolated. The mRNA levels of Efna5 (A), Epha5 (B), Ephb2 (C), Epha3 (D), and
Epha8 (E) as determined by qRT-PCR were compared to an Rpl7 control. Efna1 and
Epha2 were similarly analyzed (F) to indicate that not all Eph-ephrin ligand and receptor
mRNA levels are increased by eCG. Data represent the gene expression compared with
the Rpl7 control and are presented as the average ± SEM of three independent
experiments. Differences in average mRNA levels between vehicle treatment and 3.25 or
5.0 IU of eCG were analyzed by a one-way ANOVA followed by a Tukey multiple
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comparison post-hoc test (Tukey test). A) Efna5. A statistically significant difference was
found between the three treatments as determined by one-way ANOVA (F2,6 = 18, P =
0.003). Tukey test revealed that statistically significant differences between vehicle and
3.25 IU of eCG (a: P < 0.05), between vehicle and 5.0 IU of eCG (a: P < 0.05), and
between 3.25 and 5.0 IU of eCG (a: P < 0.05). B) Epha5. A statistically significant
difference was found between the three treatments as determined by one-way ANOVA
(F2,6 = 14, P = 0.006). Tukey test revealed statistically significant differences between
vehicle and 3.25 IU of eCG (a: P < 0.05), between vehicle and 5.0 IU of eCG (a: P <
0.05), but not between 3.25 and 5.0 IU of eCG. C) Ephb2. No statistically significant
difference was found between the three treatments as determined by one-way ANOVA,
but comparison of means between vehicle and 3.25 or 5.0 IU of eCG by a two-tailed
unpaired Student t-test revealed a statistically significant difference between vehicle and
5.0 IU of eCG (b: P < 0.02). D) Epha3. A statistically significant difference was found
between the three treatments as determined by one-way ANOVA (F2,6 = 14, P = 0.005).
Tukey test revealed statistically significant differences between vehicle and 3.25 IU of
eCG (P < 0.05), between vehicle and 5.0 IU of eCG (P < 0.05), but not between 3.25 and
5.0 IU of eCG. E) Epha8. No statistically significant difference was found between the
three treatments as determined by one-way ANOVA. F) Efna1 and Epha2. Not all Ephephrin ligand and receptor mRNA levels are increased by eCG. Data represent the gene
expression compared with the Rpl7 control and are presented as the average ± SEM of
three independent experiments. Differences in average mRNA levels between vehicle
treatment and 5.0 IU of eCG were analyzed by a two-tailed unpaired Student t-test (d: P
< 0.01).
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2.3.2 FSH and cAMP Regulate Efna5 and Epha5 Expression in a Rat GC Line
To determine if FSH increased the expression of Efna5, Epha3, Epha5, Epha8, and
Ephb2 in a species other than mouse, we treated GFSHR-17 cells (an immortalized, FSHresponsive cell line derived from primary rat GCs (18)) with human recombinant FSH
(50 ng/mL) for 24 or 48 h and determined mRNA levels by qRT-PCR (Figure 2-2). Of
the five Eph-ephrin family members increased by eCG in primary GCs (Figure 2-1), we
found that expression of two of these genes, Efna5 and Epha5, increased in response to
FSH in GFSHR-17 cells (Figure 2-2, A and B). Indeed, Efna5 mRNA levels were
increased after 24 and 48 h of FSH treatment (Figure 2-2A), whereas Epha5 mRNA
levels (Figure 2-2B) increased only after 24 h of FSH treatment. Because FSH regulates
many of its target genes in GCs via the cAMP-dependent protein kinase A (PKA)
pathway (27), we next wanted to determine if forskolin, a direct activator of adenylate
cyclase, would increase Efna5 and Epha5 mRNA levels in GFSHR-17 cells. Again,
Efna5 mRNA levels were increased after 24 and 48 h of forskolin treatment (Figure
2-2C), whereas Epha5 mRNA levels (Figure 2-2D) increased only after 24 h of forskolin
treatment. We also investigated whether any of the other eCG-responsive Eph-ephrin
family members identified in Figure 2-1 responded to forskolin in GFSHR-17 cells, but
only Efna5 and Epha5 mRNA levels were affected. These results indicate that Efna5 and
Epha5 are increased by FSH in both mouse and rat GCs and that this increase is
mediated, at least in part, through a cAMP-dependent pathway. Because Efna5 and
Epha5 were the two Eph-ephrin family members from our screen that were both
expressed in both mouse and rat GCs and were regulated by FSH and cAMP in both
model systems, we chose to further investigate the localization and function of these
genes during the rest of the present study.
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Figure 2-2: FSH and forskolin increase Efna5 and Epha5 mRNA levels in the
immortalized rat GC line GFSHR-17.
GFSHR-17 cells were treated for 24 and 48 h with recombinant FSH (50 ng/mL; A and
B) or forskolin (fsk; 10 μM; C and D), and mRNA levels of Efna5 and Epha5 were
determined by qRT-PCR and compared to an Rpl7 control. Data are presented as the
mean ± SEM of three independent experiments. Differences in average mRNA levels
between vehicle treatment (veh) and fsk or FSH were analyzed by a two-tailed unpaired
Student t-test (a: P < 0.01; b: P < 0.05).
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2.3.3 Localization of EFNA5 and EPHA5 in the Mouse Ovary
Quantitative RT-PCR experiments indicated that Efna5 and Epha5 mRNA was
present within mouse primary GCs. Therefore, we wanted to investigate EFNA5 and
EPHA5 protein localization within the whole mouse ovary using immunofluorescence
(Figure 2-3). To investigate EFNA5 and EPHA5 localization in follicles of various sizes
and in the corpus luteum, immature mice were exposed to one of the following three
treatments: saline for 48 h, 5.0 IU of eCG for 48 h, or 5.0 IU of eCG for 48 h followed by
5.0 IU of hCG for 24 h.
EFNA5 (Figure 2-3, A, C, E, G, and I) localized to the periphery (Figure 2-3, G
and I) of GCs in a punctate pattern (Figure 2-3I) in follicles ranging in size from primary
to preovulatory. Small preantral follicles generally expressed less EFNA5 (Figure 2-3A,
arrowhead) than larger preantral or antral follicles. In both preantral and antral follicles,
we frequently observed that EFNA5 immunoreactivity was higher in mural GCs than in
cumulus cells (Figure 2-3, A and G), and this difference often appeared as a gradient,
with EFNA5 density being highest near the basement membrane and lowest near the
antrum (Figure 2-3G, arrow). Interestingly, EFNA5 immunoreactivity was lower in
corpora lutea (Figure 2-3E) than in preantral and antral follicles. Weak EFNA5 staining
was also observed in the theca and interstitial cells (Figure 2-3C).
Localization of EPHA5 was similar to that of EFNA5, with immunoreactivity
localized to the periphery of GCs in follicles ranging in size from primary to preovulatory
(Figure 2-3 B, D, F, H, and I), again with weaker staining in smaller follicles (Figure
2-3B, arrowhead). However, staining appeared to be uniform around the GC periphery,
without the punctate appearance that characterized EFNA5 (compare Figure 2-3, I vs. J).
Finally, EPHA5 immunoreactivity appeared to be weaker in corpora lutea than in
preantral or antral follicles (Figure 2-3F). Weak EPHA5 staining was also observed in
the theca and interstitial cells (Figure 2-3D).
To verify that EFNA5 and EPHA5 localized to the GC membrane, we stained
ovarian sections with a pan-cadherin antibody (Figure 2-3, K and L) to detect the
transmembrane cadherin proteins that form adherens junctions between GCs. We
51

observed similar localization of both EFNA5 and EPHA5 and pan-cadherin (compare
Figure 2-3, A and B vs. K, and G and H vs. L), indicating that both EFNA5 and EPHA5
are membrane-localized in GCs.
Note that for each primary antibody, no signal was observed in sections stained
with secondary antibody alone, indicating the signal we observed was not due to
nonspecific binding of the secondary antibody (data not shown).
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Figure 2-3: Localization of EFNA5 and EPHA5 in the mouse ovary.
Immature mice were treated either with saline for 48 h (A and B), eCG for 48 h (C, D, G,
H, K, L, M, N, O, and P), or eCG for 48 h followed by hCG for 24 h (E and F). Ovaries
were isolated and frozen, and EFNA5 and EPHA5 localization was determined by
immunofluorescence with anti-EFNA5 and anti-EPHA5 antibodies. A pan-cadherin
antibody was also used to detect membrane localization within the ovary (I and J).
EFNA5 was found in the periphery of GCs of small primary to large antral follicles (A,
C, E, G, and I) and often took on a punctate appearance (arrowhead in I). Expression was
lower in small preantral follicles (arrowhead in A) than in larger preantral or antral
follicles. EFNA5 expression was reduced in corpora lutea (E). We observed similar
localization of both EFNA5 (A and B) and pan-cadherin (K and L). Weak EFNA5
staining was also observed in the theca and interstitial cells (see, e.g., A and C). No

53

EFNA5 signal was observed in sections stained with secondary antibody alone, indicating
the EFNA5 signal observed was not due to nonspecific binding of the secondary antibody
(FITC: M and O) and (FITC + DAPI merge: N and P). EPHA5 was localized to the
periphery of GCs in follicles from primary to preovulatory (B, D, F, H, and J), with
weaker staining in small follicles (arrowhead in B). EPHA5 expression was weaker in
corpora lutea than in larger preantral or preovulatory follicles (F). Weak EPHA5 staining
was also observed in the theca and interstitial cells. EFNA5 and EPHA5
immunoreactivity was stronger in mural GCs than in cumulus cells of antral follicles
(arrowhead in D and G). We observed similar localization of both EPHA5 (B and H) and
pan-cadherin (K and L). No EPHA5 signal was observed in sections stained with
secondary antibody alone (M, N, O, P), indicating the EPHA5 signal observed was not
due to nonspecific binding of the secondary antibody. Original magnification ×100 (A, B,
M, and N), ×200 (C–H and L, O, and P), and ×400 (I and J).
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2.3.4 Inhibition of GC Spreading by EFNA5/Fc
Although ephrins have been previously identified in the ovary, no functional role
for ephrins in GCs has been shown. Therefore, we investigated what roles Eph-ephrin
signaling may play in GC morphology or function. Because Eph-ephrin signaling inhibits
spreading and causes cell rounding in vitro in other cell types (20,28), and because FSH
induces GC rounding in both cultured primary cells (1) and GFSHR-17 cells (18), we
investigated the effect of EFNA5 on GC morphology using both GFSHR-17 and primary
mouse GCs. To do this, we used a cell spreading assay used previously by others (20-23)
to study the effects of Eph-ephrin interactions on cell rounding, spreading, and adhesion
in other cell types. Specifically, we seeded GFSHR-17 cells onto tissue-culture surfaces
spotted with serial dilutions of a recombinant human EFNA5/Fc chimera (74, 37, 18.5,
and 9.25 μg/mL) or onto surfaces spotted with Fc alone as a negative control (Figure 2-4,
A and B). GFSHR-17 cells plated onto the EFNA5/Fc surface were notably rounder and
less spread (having fewer lamellipodia) than those on the Fc-coated surface (Figure 2-4,
A and B). To quantitate the extent of cell spreading, we visually scored each cell as
exhibiting either a rounded or a spread morphology (see Materials and Methods for
details). We then calculated the ratio of rounded (nonspread) cells to the total number of
cells scored (Figure 2-4A, bar graph). Spreading was significantly inhibited on
EFNA5/Fc-coated surfaces but not on Fc-coated surfaces. The number of rounded cells
increased approximately 3-fold on the 74 and 37 μg/mL of EFNA5/Fc-coated surfaces
compared to Fc alone (Figure 2-4A, bar graph). To determine if this EFNA5-induced cell
rounding could be observed in primary GCs, we conducted an identical experiment with
primary GCs isolated from untreated immature mice. Again, EFNA5/Fc significantly
inhibited cell spreading and increased cell rounding, although to a lesser extent than
GFSHR-17 cells (Figure 2-5A, bar graph; compare to Figure 2-5A to Figure 2-4A). At
an EFNA5/Fc concentration of 74 μg/mL, the number of rounded primary GCs was
approximately 2-fold higher than when plated onto Fc alone (Figure 2-5). Thus, EFNA5
reduces cell spreading of both a rat GC line and primary mouse GCs.
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2.3.5 Inhibition of GC-Substrate Adhesion by EPHA5
Given that GCs express both ephrin ligands and Eph receptors, and given that Ephephrin signaling regulates cellular adhesion (29), we wanted to determine the effect of
EPHA5 signaling on GFSHR-17 and primary mouse GC adhesion (Figure 2-6 and
Figure 2-7). The coating/spotting technique in this experiment was similar to that used
for the EFNA5/Fc cell spreading experiments (Figure 2-4 and Figure 2-5), with serial
dilutions of EPHA5/Fc (83, 42, 21, and 10 μg/mL). GFSHR-17 cells were seeded onto
tissue-culture surfaces spotted with dilutions of EPHA5/Fc or Fc alone. We noticed a
dramatic and significant reduction in cells adhering to the EPHA5/Fc-coated surface
compared to those coated with Fc alone (Figure 2-6A) that occurred in an EPHA5/Fc
dose-dependent manner (Figure 2-6B). We quantified the extent of this reduced adhesion
by counting the number of cells in the center of the EPHA5/Fc-coated surface (Figure
2-6B) and comparing this to the total number of adherent cells on the Fc-coated surface
(EPHA5-Fc:Fc ratio). As the coating density of EPHA5/Fc was reduced, the number of
cells adhering to the coated surface increased (Figure 2-6B). We were then curious to
know if EPHA5 would also inhibit adhesion of primary mouse GCs. Using a similar
procedure, primary mouse GCs were plated onto EPHA5/Fc-coated surfaces, and the
number of adherent cells was again counted (Figure 2-7). As observed for the GFSHR17 cell line, cell adhesion was significantly reduced by approximately 70% at the highest
concentration of EPHA5/Fc (83 μg/mL), resulting in an inverse relationship between cell
adhesion and EPHA5/Fc concentration (Figure 2-7B). These results suggest that EPHA5,
acting through ephrin ligands present on GC membranes, can alter the adhesive
properties of both mouse and rat GCs.
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Figure 2-4: EFNA5 inhibits spreading and induces rounding of immortalized rat
GCs.
GFSHR-17 cells were seeded onto tissue-culture plates that had been previously spotted
with serial dilutions of a recombinant human EFNA5/Fc chimera or the Fc fragment
alone (top left) as a negative control. GFSHR-17 cells displayed significantly less
spreading and a more rounded morphology when plated onto EFNA5/Fc-coated surfaces
compared to Fc-coated surfaces, as determined by the absence of lamellipodia (A: 9.25–
74 μg/mL; B: 74 μg/mL only). The fraction of rounded cells was quantified by dividing
the number of rounded cells by the total number of cells in the field of vision at ×100 (see
Materials and Methods for further quantification details). Three independent experiments
were conducted, and the difference in the ratio of rounded cells to total cells between Fcalone and each concentration of EFNA5/Fc was plotted (A; bar graph shows average ±
SEM). Differences in the average ratio of rounded cells to total cells were analyzed for all
conditions by a one-way ANOVA followed by a Tukey test. A statistically significant
difference was found between the five conditions as determined by one-way ANOVA
(F4,5 = 64, P = 0.0002). Tukey test revealed numerous statistically significant (P < 0.05)
differences between many of the conditions. The following comparisons were statistically
significant (P < 0.05) but are not shown on the bar graph for clarity: Fc versus 74 μg/mL,
Fc versus 37 μg/mL, Fc versus 18.5 μg/mL, 74 μg/mL versus 18.5 μg/mL, 74 μg/mL
versus 9.25 μg/mL, 37 μg/mL versus 18.5 μg/mL, and 37 μg/mL versus 9.25 μg/mL.
Original magnification ×100 (A) and ×200 (B).
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Figure 2-5: EFNA5 inhibits spreading and increases rounding of primary mouse
GCs.
GCs isolated from the ovaries of immature mice were seeded onto tissue-culture plates
that had been previously spotted with serial dilutions of a recombinant human EFNA5/Fc
chimera or the Fc fragment alone (top left) as a negative control. Primary mouse GCs
displayed significantly less spreading and a more rounded morphology when plated onto
EFNA5/Fc-coated surfaces compared to Fc-coated surfaces, as determined by the
absence of lamellipodia (A: 9.25–74 μg/mL; B: 74 μg/mL only). The fraction of rounded
cells was quantified by dividing the number of rounded cells by the total number of cells
counted in the field of vision at ×100 (see Materials and Methods for further
quantification details). Three independent experiments were conducted, and the
difference in the ratio of rounded cells to total cells between Fc-alone and each
concentration of EFNA5/Fc was plotted (A; bar graph shows average ± SEM).
Differences in the average ratio of rounded cells to total cells were analyzed for all
conditions by a one-way ANOVA followed by a Tukey post-test. A statistically
significant difference was found between the five conditions as determined by one-way
ANOVA (F4,10 = 6, P = 0.01). Tukey post-test revealed several statistically significant (P
< 0.05) differences between many of the conditions. The following comparisons were
statistically significant (P < 0.05) but are not shown on the bar graph for clarity: Fc
versus 74 μg/mL, 74 μg/mL versus 18.5 μg/mL, and 74 μg/mL versus 9.25 μg/mL.
Original magnification ×100 (A) and ×200 (B).
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Figure 2-6: EPHA5 receptor inhibits adhesion of immortalized rat GCs to cell
culture surfaces.
A) GFSHR-17 cells were plated onto tissue-culture plates previously spotted with serial
dilutions of a recombinant rat EPHA5/human Fc chimera or the Fc fragment alone (top
left) as a negative control. The spotted region is marked by an asterisk and outlined by a
dotted line; the uncoated region outside the spotted area is marked by a circle. B) The
total number of cells within a single ×100 field image obtained from the EPHA5/Fc
surface was divided by the number of cells on the control Fc (IgG) surface, resulting in a
value of one for the Fc-coated plates, and fractions of one for the EPHA5/Fc surfaces.
Three independent experiments were carried out, with the results presented as the average
± SEM for statistical analysis by a one-way ANOVA followed by a Tukey test. A
statistically significant difference was found between the five conditions as determined
by one-way ANOVA (F4,10 = 13, P = 0.0005). Tukey test revealed numerous statistically
significant (P < 0.05) differences between many of the conditions. The following
comparisons were statistically significant (P < 0.05) but are not shown on the bar graph
for clarity: Fc versus 83 μg/mL, Fc versus 42 μg/mL, 83 μg/mL versus 10 μg/mL, and 42
μg/mL versus 10 μg/mL.
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Figure 2-7: EPHA5 inhibits substrate adhesion of mouse primary GCs.
A) Primary GCs were plated onto tissue-culture plates previously spotted with serial
dilutions of a recombinant rat EPHA5/human Fc chimera. Mouse primary GCs adhered
less to EPHA5/Fc-coated surfaces than Fc-coated surfaces. The total number of cells
attached to the EPHA5/Fc surface was divided by the number of cells on the control Fc
surface, resulting in a value of one for the Fc-coated plates and fractions of one for the
EPHA5/Fc surfaces. B) Three independent experiments were carried out, with the results
presented as the average ± SEM for statistical analysis by a one-way ANOVA followed
by a Tukey test. A statistically significant difference was found between the five
conditions as determined by one-way ANOVA (F4,10 = 20, P < 0.0001). Tukey test
revealed numerous statistically significant (P < 0.05) differences between many of the
conditions. The following comparisons were statistically significant (P < 0.05) but are
not shown on the bar graph for clarity: Fc versus 83 μg/mL, Fc versus 42 μg/mL, Fc
versus 21 μg/mL, 83 μg/mL versus 21 μg/mL, 83 μg/mL versus 10 μg/mL, and 42 μg/mL
versus 10 μg/mL.
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2.3.6 Beta-Catenin Is a Downstream Target of EFNA5-Induced Signaling in GCs
To screen for potential intracellular targets of EFNA5-induced forward signaling in
GCs, we used the Human Phospho-Kinase Array Kit, which simultaneously detects the
relative site-specific phosphorylation of 46 phosphorylated proteins and/or their targets.
GFSHR-17 cells were seeded onto tissue-culture surfaces coated with EFNA5/Fc (37
μg/mL) or Fc alone, and lysates were harvested at 15 and 20 min after seeding. These
lysates were applied to the arrays, and the blots were processed and the spot intensities
quantified according to the manufacturer's directions (Supplemental Figure 6-3,
Supplemental Table 6-2, and Supplemental Table 6-3). Only two proteins, beta-catenin
and phospho-STAT5, were observed at both 15- and 20-min time points at different
levels when comparing the blots for Fc (IgG) alone versus EFNA5/Fc. Beta-catenin
protein levels were reduced to 0.16 and 0.51 of control values at 15 and 20 min,
respectively. Similarly, phospho-STAT5 protein levels were reduced to 0.30 and 0.58 of
control values at 15 and 20 min, respectively.
We decided to focus on the observation of reduced beta-catenin levels after
exposure to EFNA5 based on beta-catenin's known association with adherens junctions
and the actin cytoskeleton (30), which would be relevant to the changes in cell
morphology that we observe when GFSHR-17 cells are exposed to EFNA5. Therefore,
we verified the reduced beta-catenin levels observed in the array by immunoblot analysis
to detect beta-catenin under the same culture conditions used in the array. This analysis
revealed that GFSHR-17 cells seeded onto EFNA5/Fc contained lower beta-catenin
protein levels at 20 min after seeding (Figure 2-8) than cells seeded onto Fc alone,
confirming the reduction observed using the Human Phospho-Kinase Array. No
differences were observed between EFNA5/Fc and Fc at 15 min after seeding. These
results suggest that beta-catenin may be a downstream target of EFNA5 signaling.
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Figure 2-8: Beta-catenin protein levels in GFSHR-17 cells are reduced in response to
EFNA5.
A) GFSHR-17 cells were seeded onto 60-mm tissue-culture dishes coated with
preclustered ephrinA5-Fc or Fc (37 μg/mL). Lysates were collected 15 min (lanes 1 and
2) and 20 min (lanes 3 and 4) after seeding. Lysate from non-treated HeLa cells (lane 5)
was used as a positive control for the beta-catenin antibody. Fifty micrograms of each
lysate were separated by SDS-PAGE, and beta-catenin protein levels were assessed by
immunoblot analysis. To assess equal protein loading, the membrane was subsequently
probed using a rabbit monoclonal IgG against HDAC4. B) Densitometric analysis of
immunoblot data (ImageLab 4.1) showing the ratio of beta-catenin to HDAC4.
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2.4 Discussion
In the present study, we have shown that FSH increases the expression of a subset
of ephrin ligands and Eph receptors in primary mouse and immortalized rat (GFSHR-17)
GCs and that exposure of GCs to EFNA5 and EPHA5 alters GC morphology and
adhesion, respectively. These results suggest that Eph-ephrin signaling may play a role in
the changes in GC contact and organization that occur within the follicle during
folliculogenesis.
2.4.1 Eph-Ephrin Gene Expression Is Regulated by FSH via the cAMP/PKA Pathway in
GCs
We have observed that eCG increases the expression of Efna5 and several of its
receptors (Epha3, Epha5, Epha8, and Ephb2) in mouse GCs. Interestingly, all Eph
receptors that we observed to be increased in response to eCG bind preferentially to
EFNA5 (4) (Table 2-1 and Figure 2-1), the sole ligand increased in response to FSH in
our mouse GC model. This coordinate increase of an ephrin and several of its cognate
receptors suggests an attractive model in which the expression of an ephrin ligand and its
receptors are coordinately increased during the response to FSH, resulting in increased
Eph-ephrin signaling that contributes to the formation of the developing follicle.
Coordinated increases in Eph receptors and ephrin ligands have been previously observed
in mouse skin cells under conditions of hypoxia (31). In theory, this coordinated
regulation by FSH would increase Eph-ephrin signaling when cell movement occurs,
such as during antrum formation.
We found that treating rat GCs with FSH and forskolin resulted in increased
expression of Efna5 and Epha5, suggesting that these genes are activated via the
cAMP/PKA pathway (27), as are many FSH target genes. Why only Efna5 and Epha5,
but not Ephb2, Epha3, and Epha8, expression increased in response to FSH in GFSHR17 cells is likely due to differences in species (mouse vs. rat) and in primary GCs
compared to an immortalized GC line. To date, little is known about what signaling
molecules regulate the expression of ephrin ligand and Eph receptor genes, and to our
knowledge, this is the first demonstration that cAMP regulates Eph-ephrin family
63

members in GCs. Our data indicate that in GCs, cAMP increases Eph and Efn expression,
suggesting that cAMP may similarly regulate Eph and Efn expression in other model
systems.

2.4.2 EFNA5 and EPHA5 Localization During Folliculogenesis
In general, both EFNA5 and EPHA5 were more highly expressed in larger follicles,
such as preantral follicles with many layers of GCs or antral follicles, than in smaller
ones, such as primary follicles with one or two layers of GCs (Figure 2-3). This suggests
that expression of EFNA5 and EPHA5 may be driven, at least in part, by FSH. Although
primordial and primary follicle development is commonly accepted to be independent of
FSH, recent evidence indicates that in immature mice (the model in the present study),
primordial follicles respond to FSH (32), suggesting that FSH may regulate GC
differentiation and development in small preantral follicles as well, because the FSH
receptor is expressed in mouse primary follicles (33). Thus, FSH may be one factor
increasing the expression of EFNA5 and EPHA5 in both small preantral and larger antral
follicles, which would be consistent with our data that Efna5 and Epha5 mRNA levels
increase in GCs of mice treated with eCG (Figure 2-1) and in GFSHR-17 cells treated
with FSH. In addition, the punctate pattern of staining that we observe for EFNA5
(Figure 2-3, G and I) has also been observed for other ephrins, notably EFNA3 in glial
cells of the hippocampus (34).
An interesting observation was that EFNA5 and EPHA5 immunoreactivity was
stronger in mural GCs than in cumulus cells of antral follicles (Figure 2-3G), with a
gradient of staining between the two. A similar graded pattern of expression has been
reported for mRNA of the luteinizing hormone receptor (Lhcgr); cytochrome P450,
family 11, subfamily A, polypeptide 1 (Cyp11a1); and Cd34 mRNA and is hypothesized
to result from an oocyte-stimulated MAD homolog 2/3 (Smad2/3) signaling gradient that
is strongest in cumulus GCs (35). A mural-to-antral gradient of expression has also been
reported for connective tissue growth factor (Ctgf) mRNA in rat follicles (36). Therefore,
we hypothesize that EFNA5 and EPHA5 expression may also be regulated by an oocyte64

derived factor, such as bone morphogenetic protein 15 (BMP15) or growth differentiation
factor 9 (GDF9) (35). Although little is known about what factors regulate EFNA5 or
EPHA5 expression, evidence indicates that EFNA5 expression is regulated by antiMüllerian hormone (AMH) and glial cell-derived neurotrophic factor (GDNF) (37), both
of which affect the transition from primordial to primary follicles.
Based on our immunofluorescence data, we cannot identify whether individual
mouse GCs express EFNA5 alone, EPHA5 alone, or EFNA5 and EPHA5 simultaneously.
Whereas activation of an Eph receptor on one cell by an ephrin ligand on a nearby cell is
the most commonly reported interaction, overlapping coexpression of cognate Eph
receptor-ligand pairs within the same cell has been frequently observed. For example,
EFNA5 and EPHA5 are coexpressed in pancreatic beta-cells (38), and EFNA5 and
EFNA4 are coexpressed in motor neurons of embryonic chick spinal cord (39).
Therefore, it is possible that GCs express both EFNA5 and EPHA5 and, therefore, that
neighboring GCs could activate each other through forward signaling, reverse signaling,
or both.

2.4.3 EFNA5 Inhibits Spreading and Increases Rounding of GCs
Our observation that exposure of primary GCs and rat GFSHR-17 cells to EFNA5
induces cell rounding is consistent with the ability of EFNA5 to induce cell rounding in a
number of other model systems. This cell rounding, often referred to as reduced cell
spreading, has been associated with both increased and decreased cell migration,
depending on the cell type. For example, spreading of rat primary vascular smooth
muscle cells is inhibited on tissue-culture surfaces coated with EFNA1, resulting in a
rounded cell morphology (20). Similarly, addition of EFNA5 to cell-culture medium
induces rounding of both immortalized human melanoma cells and EPHA3-expressing
293T cells (28), which correlates with reduced adhesion. Those authors suggest this
reduced adhesion would lead to increased cell motility. Similarly, Foo et al. (40) show
that smooth muscle cells lacking EPHB2 are defective in spreading and show increased
motility (40). On the other hand, many reports suggest that reduced spreading (cell
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rounding) leads to reduced migration, such as the EPHA1-induced rounding and reduced
migration observed in Human Embryonic Kidney 293 (HEK293) cells stably transfected
with EPHA1 (41). Thus, in the ovary, changes in GC shape and spreading may regulate
migration during folliculogenesis.
In addition to changes in cell shape, “[e]xtensive and intricate changes in the
physical arrangement of cells” (p. 6 (42)) occur within a developing follicle during
folliculogenesis, and for these rearrangements to occur, GCs must migrate within the
follicle. Several stages occur during folliculogenesis when GCs (both mural and cumulus)
are thought to migrate within the follicle. GCs migrate to surround the oocyte during the
formation of primordial follicles (to form multiple GC layers during proliferation and
formation of preantral follicles) and also during the formation of the antrum, which
requires a significant creation of space within the follicle. Both older and more recent
studies of cultured follicles indicate that on a two-dimensional surface in the absence of
FSH, GCs disperse and migrate across tissue-culture plastic away from the oocyte but
reorganize to form an antrum when exposed to FSH (43). Three-dimensional culture in
hydrogels minimizes the extent of GC migration, yet GC outgrowth still occurs, allowing
antrum formation (43). In either model, GC movement clearly is critical to the formation
of the antrum. Treatment with hCG enhances cumulus cell migration as determined by in
vitro migration assays (44). Finally, during formation of the corpus luteum, luteinizing
GCs migrate toward the center of the luteinizing follicle (45) and can be shown to
migrate using in vitro migration assays (46). Numerous studies have shown that Ephephrin signaling simultaneously induces cell rounding, reduces cell spreading, and
enhances cell migration and motility of a number of diverse cell types (22,28,41,47,48).
Therefore, the GC rounding we observe in response to EPHA5 could potentially regulate
GC migration in vivo.
2.4.4 EPHA5 Inhibits Adhesion of GCs
Granulosa cell movement and differentiation during folliculogenesis are thought to
require changes in cell-cell adhesion and cellular junctions during this time (49). Not
surprisingly, the type of junctions connecting GCs within the follicle change in both
number and type during follicle growth (50). Four types of cell-cell junctions have been
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identified in the ovary of various species: adherens junctions, gap junctions, desmosomes,
and tight junctions (50-52), with adherens and gap junctions being the best characterized.
In smaller follicles, gap junctions exist, but adherens junctions and desmosomes
predominate (50,53). As the follicle grows under the influence of FSH and other factors,
the number of gap junctions increases, whereas the number of desmosomes and adherens
junctions decreases (50,53). Gap junction number and size increase dramatically to their
maximum frequency in the preovulatory follicle (1), concomitant with a decrease in
adherens junctions, and it is believed that this change leads to reduced cell-cell adhesion,
allowing the formation of the antrum (54).
In the present study, we observe that primary GCs resist binding when reverse
signaling (i.e., signaling into the cell containing the ephrin ligand) is activated through
the Eph receptor coated onto tissue-culture surfaces. This suggests that reverse signaling
through an EPHA5-compatible ephrin ligand on the GC surface results in reduced
adhesion and repulsion. Several recent reports support a role for ephrin ligand-mediated
reverse signaling in reducing cell adhesion. In mice lacking EFNA5, midline fusion
occurs in the developing neural tube (55), and those authors propose that this fusion
results from loss of Eph-ephrin reverse signaling that would normally promote cell
repulsion. In that same study, “an inverse correlation” (p. 203 (55)) was observed
“between Efna5 gene dosage and [cell] adhesion” (p. 203 (55)), and cells from Efna5-null
mice displayed decreased adhesion compared to wild-type cells. In another study, ephrinA-expressing retinal neurons avoid EPHA7-Fc surfaces during axonal outgrowth,
suggesting that reverse signaling via A-class ephrin ligands promotes repulsion and/or
reduced adhesion (56). We speculate that in vivo, this reverse signaling through EFNA5
on GCs could lead to reduced cell-cell contact during, for example, formation of the
antrum, when reduced cell-cell adhesion is required for GC migration. This would be
similar to the role that Eph-ephrin signaling plays in the repulsive guidance of migrating
neurons (29).
Interestingly, Eph-ephrin signaling has been shown to cross-talk with adherens
junctions, tight junctions, and gap junctions in other model systems (2). In various
tissues, gap junctions are critical for Eph-ephrin function in processes as diverse as cell
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sorting, insulin secretion, and osteogenic differentiation (38,57,58). Thus, cross-talk
between these junctions and Eph-ephrin signaling may also be occurring in GCs.
Although several published reports have described Eph receptor and ephrin
expression in the mouse and human ovaries, none of these demonstrated an effect of
ephrin signaling on GC characteristics or function. Gale et al. (14) found that EFNB2 is
expressed in the neovasculature of corpora lutea and the theca cell layer of preluteinized
follicles. Egawa et al. (15) showed that EFNB1 is expressed in luteal cells of the human
corpus luteum. These reports suggest roles for ephrin ligands in the vascularization of the
theca and corpora lutea as well as in luteal cells. Xu et al. (16) demonstrated that EPHA2,
EPHA4, EPHA7, EFNA4, EFNB1, and EFNB2 mRNA are present in cultured human
luteinized GCs. In line with the findings of Xu et al., we detected expression of several
Eph receptors and ephrins in mouse GCs.
2.4.5 EFNA5 Reduces Beta-Catenin Protein Levels in GCs
We observed a reduction in beta-catenin protein levels in GFSHR-17 cells seeded
onto EFNA5/Fc concomitant with rounding/reduced spreading. Beta-catenin has two
primary functions in cells. First, in conjunction with alpha-catenin and E-cadherin, it
forms a link between adherens junctions and the actin cytoskeleton. Second, it serves as a
transcription factor in conjunction with proteins of the T-cell factor (TCF)/lymphoid
enhancer-binding factor (LEF) family of transcription factors in the nucleus (59,60). In
the cytoplasm, beta-catenin undergoes constant turnover, with phosphorylation,
ubiquitination, and then proteasomal degradation (61). We speculate that activation of
Eph receptors cognate to EFNA5 in GFSHR-17 cells may regulate adherens junction
assembly and/or degradation or lead to transcriptional effects through interactions of
beta-catenin with TCF/LEF family members. In the context of the growing follicle, betacatenin degradation may affect remodeling of adherens junctions, leading to changes in
the cytoskeleton, which occur during changes in cell shape (62). In turn, changes in cell
shape have been associated with changes in cell migration (28,40,41). Reduced levels of
beta-catenin may also influence expression of TCF/LEF target genes in GCs that may
influence cellular morphology. Further experiments will be required to fully delineate the
relationship between EFNA5 and beta-catenin.
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In summary, we have shown that EFNA5 and EPHA5 are expressed in mouse GCs,
that forward signaling induced by EFNA5 regulates GC morphology by inhibiting cell
spreading, and that reverse signaling induced by EPHA5 inhibits cell adhesion. The
expression of EPHA5 and EPHA5 in follicles of various sizes suggests that they may
play multiple roles during different stages of folliculogenesis. We speculate that further
studies will indicate that these and other members of the Eph-ephrin signaling system
play important roles in the development of healthy preovulatory follicles and corpora
lutea throughout folliculogenesis.
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3 Chapter 3: Ephrin-A5 is required for optimal fertility and a
complete ovulatory response to gonadotropins in the mouse
This chapter is based on a manuscript submitted to Endocrinology:
Buensuceso AV, Son A, Paquet M, Withers BM, Zhou R, and Deroo BJ. (2015) EphrinA5 is required for optimal fertility and a complete ovulatory response to gonadotropins in
the female mouse. Manuscript ID# EN-15-1216.

3.1 Introduction
Folliculogenesis is a dynamic and carefully-timed process during which a
primordial follicle develops into a fully mature preovulatory follicle capable of expelling
a fertilizable oocyte. This process requires a tremendous amount of cell proliferation,
migration, directional cell growth, extracellular (ECM) synthesis, and changes in cell
adhesion and morphology. These dramatic changes are not surprising given that the
diameter of a human preovulatory follicle is approximately 600 times larger than a
primordial follicle (1). Although changes in cell morphology and migration during
folliculogenesis are critical to the production of a healthy preovulatory follicle, the
factors regulating these two processes are not well understood.
The Eph-ephrin family of molecules consists of ephrin ligands and their cognate
tyrosine kinase receptors, Eph receptors. Eph-ephrin family members regulate both
cellular shape and adhesion during development, cancer, and the normal function of
many different tissues (2). Since Eph receptors and ephrins are membrane-associated,
signaling is initiated exclusively from points of cell-to-cell contact. Eph-ephrin signaling
is bidirectional, with signal transduction occurring in both receptor-bearing cells (forward
signaling) and in ligand-bearing cells (reverse signaling). Eph receptors and ephrin
ligands are both classified into two types, designated A or B, based on receptor-ligand
specificity. Receptors and ligands of the same class bind preferentially. In forward
signaling, ligand-bound Eph receptors interact with signaling elements via adapter
proteins, and may also phosphorylate targets directly. Reverse signaling via B-class
ephrins occurs in a similar manner, where the receptor-bound ligand can interact with
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intracellular signaling elements via adapter proteins. As well-established regulators of
cell positioning, ephrins and Eph receptors are likely candidates for involvement in
follicle growth and ovulation. Although members of the Eph-ephrin family have been
identified in the ovary, Eph-ephrin signaling and the role it may play during
folliculogenesis have not been well-characterized.
We previously reported that FSH increases the expression of a subset of ephrin
ligands and Eph receptors in primary mouse and immortalized rat granulosa cells (GCs),
and that exposure of GCs to the ligand ephrin-A5 (EFNA5) and its receptor EPHA5 alters
GC morphology and adhesion, respectively (3). Expression of ephrins and Eph receptors
has also been described in mouse (4), human (5,6), and bovine ovaries (7). Furthermore,
in bovine ovaries Efna5 expression is higher in large antral follicles, ie. with a mean
diameter five times higher than small follicles (8). These studies suggest that Eph-ephrin
signaling may be required for normal folliculogenesis.
To test the hypothesis that Eph-ephrin signaling regulates folliculogenesis, we
characterized the reproductive capacity and characteristics of female mice lacking ephrinA5. Previous studies of these mice revealed axon guidance defects (9) and disrupted
organization of lens cells in the eye (10-12), but have not been previously characterized
with respect to reproductive function. We report compromised fertility in adult Efna5null (Efna5-/-) females, indicating a novel role for Eph-ephrin signaling in female
reproductive function.

3.2 Materials and Methods
3.2.1 Mice and treatments
All mouse experiments described in this study were conducted in accordance with
the accepted standards of humane animal care, as outlined in the journal’s Ethical
Guidelines. Experiments were performed in compliance with the guidelines set by the
Canadian Council for Animal Care, and the policies and procedures approved by the
University of Western Ontario Council on Animal Care (Protocol Number: 2007-042).
The generation of Efna5-null (Efna5-/-) mice has been described previously (9). Immature
Efna5-/- female mice and their wildtype (WT) littermates were generated by breeding
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heterozygous (Efna5+/-) males with heterozygous (Efna5+/-) females. All females were
weaned at post-natal day (PND) 21 and genotyped as previously described (9).
For studies examining ovulation capacity, serum steroid levels, ovarian gene
expression, and histology, mice were treated with: a) 100 µL saline, b) 5.0 IU equine
chorionic gonadotropin (eCG) (Sigma Chemical Co., St. Louis, MO) for 48 hours, or c)
5.0 IU equine chorionic gonadotropin (eCG) for 48 hours followed by 5.0 IU human
chorionic gonadotropin (hCG) (Sigma). Whole ovaries were harvested 4, 14, or 24 hours
post-hCG treatment.
3.2.2 Continuous breeding study
PND 60 Efna5+/+ and Efna5-/- females were paired with PND 60 Efna5+/+ males for
6 months. Cages were checked twice weekly for pregnant females, daily thereafter for
newborn pups, and the dates of birth and number of pups were recorded. After 6 months,
the average litter size and the average number of days between litters was calculated for
each female.
3.2.3 Assessment of ovulatory potential in response to gonadotropin treatment
Reproductively immature female mice were subjected to a standard superovulation
protocol and counted the number of ovulated oocytes. PND 21 Efna5+/+ and Efna5-/females were injected subcutaneously (sc) with 5 IU eCG, followed 48 h later by 5 IU
hCG. Oviducts were harvested 14 h post-hCG and placed in a 25 µL drop of saline on a
60 mm tissue culture dish. After harvest was completed, oviducts were transferred to a 25
µL droplet of M2 medium containing hyaluronidase. Oviducts were then ruptured using a
0.5 inch 30-gauge needle, releasing the ovulated cumulus-oocyte-complexes (COCs) into
the surrounding medium. Presence of hyaluronidase resulted in dissociation of oocytes
and associated granulosa cells, yielding easily discernible individual oocytes. Upon
dissociation, oocytes were counted using a dissecting microscope and a click-counter.
3.2.4 Assessment of serum steroid levels
To determine serum 17β-estradiol (estradiol) levels, PND 21-22 females were
injected sc with 5 IU eCG alone or 5 IU eCG followed by 5.0 IU hCG 48 h later. Blood
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was collected from the vena cava 48 h post-eCG for estradiol quantitation and 14 or 24 h
post-hCG for progesterone quantitation. Serum was analyzed by the University of
Virginia Center for Research in Reproduction Ligand Assay and Analysis Core
(Charlottesville, VA) for estradiol (ELISA) and progesterone (RIA) concentrations.
3.2.5 RNA isolation and quantitative RT-PCR
Frozen whole ovaries were homogenized in Trizol (Invitrogen, Carlsbad, CA) and
RNA was isolated according to the manufacturer's protocol. RNA was further treated
with DNaseI, then reverse-transcribed using Superscript II (Life Technologies, Carlsbad,
CA). Complementary DNA (cDNA) levels were detected using quantitative RT-PCR
with the ViiA™ 7 Real-Time PCR System (Life Technologies) and SYBR Green I dye or
Taqman Gene Expression Analysis probe sets. Primers were generated using Applied
Biosystems Primer Express Software version 3.0 or obtained from published literature
(Table 3-1) and Taqman probe sets were purchased from Life Technologies (Table
3-2).Fold changes in gene expression were determined as previously described (3).
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Gene

GenBank
accession no.

Forward (5' to 3')

Reverse (5' to 3')

Referenc
e

Rpl7

NM_011291

AGCTGGCCTTTGTCATCAGAA

GACGAAGGAGCTGCAGAACCT

Adamts
1

NM_009621

CACATGCAAGAAGATGTCAGG

CCCTTTGATTCCGATGTTTC

(13)

Adamts
4

NM_172845

TCAACACCCCTAACGACTCA

TGCATGGCTTGGAGTTATCA

(14)

Cyp11a
1

NM_019779

CCAGTGTCCCCATGCTCAAC

TGCATGGTCCTTCCAGGTCT

(15)

Cyp17a
1

NM_007809

GATCTAAGAAGCGCTCAGGCA

GGGCACTGCATCACGATAAA

(16)

Hsd17b
1

NM_010475

TGTTCGCCTAGCTTCTGACC

AGCAGCCACAGATTTGGAGT

(15)

Hsd17b
7

NM_010476

AATGTGGCTCCTTCGCTTTT

GAGACTCCGGTTTTTGGTGG

Hsd3b1

NM_008293,

CTCAGTTCTTAGGCTTCAGCAATTA
C

CCAAAGGCAAGATATGATTTAGG
A

(17)

NM_00130480
0
Fshr

NM_013523

ATGTGTTCTCCAACCTACCCA

GCTGGCAAGTGTTTAATGCCTG

(15)

Star

NM_011485

CCGGAGCAGAGTGGTGTCA

CAGTGGATGAAGCACCATGC

(15)

Table 3-1: Primer sequences used for quantitative RT-PCR.
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Gene

Genbank accession no.

Taqman probe set

Rpl7

NM_011291.5

Mm02342562_gH

Pgr

NM_008829.2

Mm00435628_m1

Ptgs2

NM_011198.3

Mm00478374_m1

Cyp19a1 NM_007810.3

Mm00484049_m1

NM_013582.2

Mm00442931_m1

Lhcgr

Table 3-2: Taqman probe sets used for quantitative RT-PCR in Figure 3-4.
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3.2.6 Fixation, sectioning, and preparation of ovaries for histological examination
Immediately after harvest, ovaries were placed into previously weighed 1.5 mL
microcentrifuge tubes on ice, and weighed again. The microcentrifuge tubes were filled
with 1.4 mL cold fixative solution (paraformaldehyde, 4% v/v in PBS). Microcentrifuge
tubes were placed into a 50 mL conical tube which was then placed into a rotisserie
rotator for 24 h at 4°C. The fixative solution was aspirated and replaced with 1.4 mL 4°C
PBS. The microcentrifuge tubes were rotated for 24 h at 4°C, PBS was aspirated,
replaced with 1.4 mL 4°C PBS, and rotated for 24 h at 4°C. The PBS was aspirated and
replaced with 1.4 mL ethanol (70% v/v in MilliQ water). Fixed ovaries were then sent to
the Molecular Pathology Core Facility (Robarts Research Institute, London, ON, Canada)
for paraffin embedding, sectioning, and staining with hematoxylin/eosin (H&E).
3.2.7 Histological quantitation of COCs, corpora lutea, and multi-oocyte follicles
H&E-stained ovary sections were scanned using an Aperio ScanScope slide
scanner (Leica Biosystems) at 200x. COCs and corpora lutea (CLs) were counted in
every fifth section and multi-oocyte follicles (MOFs) in every third section throughout
the entire ovary. When necessary, additional sections were reviewed to ensure that the
same COCs, CLs, or MOFs were not counted twice.

3.3 Results
3.3.1 Ephrin-A5 is required for normal female fertility
In order to assess the fertility of female Efna5-/- mice, we conducted a continuous
breeding study (Figure 3-1A). Eight-week old Efna5+/+ or Efna5-/- females were housed
individually with 8-week old Efna5+/+ males for 6 months, and the litter sizes and dates of
birth were recorded. Efna5-/- females produced 40% smaller litters (P < 0.001) than
Efna5+/+ control females (Figure 3-1A). Average litter sizes for Efna5+/+ females were
13.1 (± 0.6, n=9) pups/litter compared to 8.0 (± 0.9, n=9) pups/litter for Efna5-/- females
(Figure 3-1A). No difference in litter frequency was observed between genotypes
(Figure 3-1B). These results indicate that fertility is compromised in female mice lacking
ephrin-A5. Therefore, to begin to understand the basis of this decreased fertility, we
assessed the ovarian response to gonadotropin stimulation.
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3.3.2 Efna5-/- females ovulate fewer oocytes than controls
In order to determine the ovulatory potential of Efna5-/- females, PND 23-25
Efna5+/+ and Efna5-/- females were hormonally stimulated (superovulated) by treatment
with eCG for 48 h, followed by hCG for 14 h, after which the oocyte yield per animal
was determined. The oocyte yield for Efna5-/- females was 38% lower than for Efna5+/+
females (P < 0.01, Figure 3-1C). An average of 49.3 (± 3.4, n=11) COCs/animal was
retrieved from Efna5+/+ females, compared to 30.7 (± 4.3, n=12) oocytes/animal from
Efna5-/- females (Figure 3-1C).
3.3.3 Serum estradiol and progesterone levels are unaffected by loss of ephrin-A5
The circulating levels of 17β-estradiol (estradiol) and progesterone can be used as
parameters for evaluating the ovarian response to gonadotropin stimulation, and can
provide insight into the reason for decreased fertility. Therefore, we assessed serum
estradiol and progesterone levels in gonadotropin-stimulated, PND 23-28 Efna5+/+ and
Efna5-/- females. No significant difference in serum estradiol levels was detected between
Efna5+/+ and Efna5-/- females 48 h post-eCG (Figure 3-2A). Similarly, no significant
difference in serum progesterone levels was detected between Efna5+/+ and Efna5-/females after either 14 h or 24 h hCG (Figure 3-2B).
3.3.4 Ovary to body weight ratio is unaffected by loss of ephrin-A5
In order to determine whether loss of ephrin-A5 alters the ovary-to-body weight
ratio in immature or adult mice, ovarian weights from Efna5+/+ and Efna5-/- females were
measured at 21, 60, and 120 days of age and normalized to body weight. No differences
were detected in the ovary-to-body weight ratio between Efna5+/+ and Efna5-/- females at
any of these ages (Figure 3-3, A-C).
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A

B

C

Figure 3-1: Reproductive assessment of Efna5-/- females.
Efna5+/+ or Efna5-/- PND 60 females were paired with an Efna5+/+ PND 60 male for a 6
month continuous breeding study to determine litter size (mean ±SEM) (A) and time
between births (mean ±SEM) (B). Released oocytes from superovulated Efna5+/+ or
Efna5-/- PND 21-23 females were counted to determine ovulatory capacity (mean ±SEM)
(C). A) “Litter size” and “time between litters” for Efna5+/+ and Efna5-/- genotypes were
compared using the Student two-tailed unpaired t-test. A statistically significant
difference was found between genotypes for both litter size and time between litters as
determined by Student’s unpaired t-test; t(16)=4.849. ***, p=0.0002. B) “Time between
births” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed
unpaired t-test. No statistically significant difference was found between genotypes as
determined by Student’s unpaired t-test; t(15)=0.1008, p=0.9211. C) “Ovulation
capacity” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed
unpaired t-test. A statistically significant difference was found between genotypes as
determined by Student’s unpaired t-test; t(21)=3.356. **, p=0.0030.
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Figure 3-2: Serum estradiol and progesterone concentrations are unaffected by loss
of ephrin-A5.
Serum estradiol (mean ±SEM) (A) was measured for eCG-treated Efna5+/+ and Efna5-/females and serum progesterone (mean ±SEM) (B) for superovulated females. A) “Serum
estradiol” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed
unpaired t-test. No statistically significant difference was found between genotypes as
determined by Student’s unpaired t-test; t(9)=1.142, p=0.2830. B) “Serum progesterone”
for Efna5+/+ and Efna5-/- genotypes was compared at 14 h and then at 24 h post-hCG
using the Student two-tailed unpaired t-test. At 14 h post-hCG, no statistically significant
difference was found between genotypes as determined by Student’s unpaired t-test;
t(19)=0.5520, p=0.5874. At 24 h post-hCG, no statistically significant difference was
found between genotypes as determined by Student’s unpaired t-test; t(6)=0.9392,
p=0.3839.
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Figure 3-3: Ovary/body weight ratio is normal in Efna5-/- females at PND 23, 60,
and 120.
Ovaries from Efna5+/+ and Efna5-/- females were harvested, weighed, and normalized to
body weight (mean ±SEM) at PND 23 (A), 60 (B) and 120 (C). “Ovary/body weight
ratio” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed
unpaired t-test. A) At PND 23, no statistically significant difference was found between
genotypes as determined by Student’s unpaired t-test; t(5)=1.212, p=0.2795. B) At PND
60, no statistically significant difference was found between genotypes as determined by
Student’s unpaired t-test; t(5)=0.04437, p=0.9663. C) At PND 120, no statistically
significant difference was found between genotypes as determined by Student’s unpaired
t-test; t(6)=1.460, p=0.1946.
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3.3.5 Ovarian gene expression is altered in Efna5-/- females after gonadotropin
stimulation
Because ovulatory capacity in response to gonadotropin stimulation was impaired
in Efna5-/- females (Figure 3-1C), we determined whether expression of gonadotropinresponsive genes known to be involved in follicle growth and ovulation was altered in
Efna5-/- ovaries. Immature Efna5-/- and Efna5+/+ females were treated with eCG for 48h
+/- hCG for 4, 14, or 24 h, and whole-ovary mRNA levels of known FSH and LHresponsive genes were determined by RT-qPCR. Specifically, we investigated the levels
of prostaglandin-endoperoxide synthase 2 (Ptgs2), progesterone receptor (Pgr), and
ADAM metallopeptidase with thrombospondin type 1 motif, 4 (Adamts4) (18) to assess
the LH response (48h eCG + 4, 14, or 24 h hCG). We quantified the mRNA levels of
cytochrome P450, family 19, subfamily A, polypeptide 1 (Cyp19a1) and luteinizing
hormone/choriogonadotropin receptor (Lhcgr) to assess the FSH response (48h eCG).
As expected, hCG treatment increased Pgr, Ptgs2, and Adamts4 mRNA levels in
Efna5+/+ ovaries (Figure 3-4, A-C). However, in response to the same treatment, Pgr,
Ptgs2, and Adamts4 mRNA levels in Efna5-/- females were 58%, 54%, and 80% lower,
respectively, than in Efna5+/+ controls (P < 0.0001, Figure 3-4, A-C). To determine if
this reduced response to hCG was due to a reduction in LH receptor (Lhcgr) gene
expression, the mRNA levels of Lhcgr were determined after 48h eCG (Figure 3-4F).
There was no significant difference in Lhcgr mRNA levels between genotypes,
suggesting that loss of Lhcgr in Efna5-/- females was not responsible for the attenuated
response to hCG.
Since Lhcgr is a well-known FSH-responsive gene, this result also suggested that
the response to FSH was intact in Efna5-/- females. To test this, we investigated the
mRNA levels of another well-known FSH-responsive gene, Cyp19a1, after 48h eCG
treatment. No significant difference in Cyp19a1 mRNA levels was observed between
genotypes (Figure 3-4D), which is consistent with the lack of a difference in circulating
estradiol levels between genotypes (Figure 3-2A). No differences were observed in Fshr
mRNA levels (Figure 3-4E). In total, the results of these gene expression studies suggest
that the ovarian response to LH, but not FSH, is disrupted in Efna5-/- females.
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In order to understand why superovulated Efna5-/- females produced fewer oocytes
than wildtype controls, we examined the histology of ovaries from superovulated
wildtype and Efna5-/- females.
3.3.6 Efna5-/- ovaries exhibit increased numbers of expanded COCs after
gonadotropin stimulation
Since cumulus expansion is necessary for ovulation to occur, we assessed the
number of follicles containing expanded COCs in ovaries of superovulated Efna5+/+ and
Efna5-/- females. Examination of ovaries from Efna5-/- and wildtype control females
treated with eCG (48 h) followed by hCG (10 h) revealed a 2.6-fold increase in the
number of follicles that had undergone cumulus expansion in Efna5-/- females than in
controls, with an average of 26 per mouse in Efna5-/- females compared to 10 per mouse
in Efna5+/+ females (Figure 3-5A). Based on this observation, we wondered if there
would be a difference in the number of CLs/mouse between genotypes. However, ovaries
from Efna5+/+ and Efna5-/- females treated with eCG (48 h) followed by hCG (14 h)
exhibited no significant difference in the total number of corpora lutea/mouse (Figure
3-5B). However, Efna5-/- females contained a significantly higher number of oocytes
aberrantly retained in CLs (1.5 fold) than control females (Figure 3-5C).
3.3.7 Abnormal follicle rupture, hemorrhaging, and fibrin thrombus formation in
Efna5-/- ovaries after gonadotropin stimulation
In ovaries of Efna5-/- mice, follicles at all stages of growth were observed (Figure
3-6, A-J). However, Efna5-/- ovaries exhibited a number of abnormal and fascinating
histological features (Figure 3-6, A-J) that were not observed or were less pronounced in
Efna5+/+ controls (Figure 3-6K). These features included the presence of GCs and COCs
in the ovarian interstitium (Figure 3-6E, black arrow and Figure 3-6G, black arrow) and
the presence of GCs in blood vessel lumina (Figure 3-6C, black arrow, and Figure 3-6F,
open arrow). The presence of fibrin thrombi (Figure 3-6D, black arrow and Figure 3-6G,
open pentagon) and hemorrhaging (Figure 3-6, A-B, open stars) were also observed.
Efna5-/- ovaries also exhibited instances of follicles rupturing in abnormal locations,
specifically the non-apical rupture of follicles directed towards/into the interstitium as
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opposed to the exterior of the ovary (Figure 3-6D, open arrow and Figure 3-6G, black
arrow) and at least one occurrence of possibly premature rupture (Figure 3-6A, black
arrow). In some cases, follicles exhibiting non-apical rupture contained luteinizing GCs
(Figure 3-6G, open star). Finally, Efna5-/- ovaries also exhibited a significant, 50%
increase in oocytes trapped within luteinized follicles compared to Efna5+/+ controls
(Figure 3-6, H-J, and Figure 3-5C).
3.3.8 Increased number of multi-oocyte follicles in adult Efna5-/- mice
Interestingly, we observed that ovaries from 2 month-old Efna5-/- females contain
over four times more multi-oocyte follicles (MOFs) per ovary than wildtype controls (P <
0.05), with an average of 8.8 MOFs (± 2.8, n=5) per Efna5-/- female compared to 2.0
MOFs (± 0.70, n=5) per Efna5+/+ female (Figure 3-7B). Having observed this significant
increase in MOFs in adult Efna5-/- ovaries, we wanted to determine if this increase would
also be observed in immature Efna5-/- mice, to help understand when and how during
folliculogenesis this increase in MOFs might be occurring. In contrast to adult mice, no
difference in MOF number was observed between genotypes at PND 21, with an average
of 1.5 MOFs (± 1.5, n=2) per Efna5+/+ female and 2.3 MOFs (± 0.95, n=4) per Efna5-/female (Figure 3-7A).
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Figure 3-4: hCG-stimulated ovarian expression of Pgr, Ptgs2, and Adamts4 is
attenuated in Efna5-/- mice.
Relative transcript abundance compared to Rpl7 (mean ±SEM) was determined by qRTPCR in whole ovaries of superovulated females for Pgr (A), Ptgs2 (B), Adamts4 (C),
Cyp19a1 (D), Fshr (E), and Lhcgr (F). A) Pgr. A two-way ANOVA found a significant
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effect for treatment, F (2, 32) = 148.7, P < 0.0001; a significant effect for genotype, F (1,
32) = 10.09, P = 0.0033; and a significant interaction F (2, 32) = 11.13, P = 0.0002.
Tukey's multiple comparisons test revealed a significant difference between genotypes in
mice treated with 5.0 IU eCG (48 h) + 5.0 IU hCG (4 h), ****, P < 0.0001. B) Ptgs2. A
two-way ANOVA found a significant effect for treatment, F (2, 32) = 132.7, P < 0.0001;
a significant effect for genotype, F (1, 32) = 11.18, P = 0.0021; and a significant
interaction F (2, 32) = 12.09, P = 0.0001. Tukey's multiple comparisons test revealed a
significant difference between genotypes in mice treated with 5.0 IU eCG (48 h) + 5.0 IU
hCG (4 h), ****, P < 0.0001. C) Adamts4. A two-way ANOVA found a significant effect
for treatment, F (3, 32) = 12.44, P < 0.0001; a significant effect for genotype, F (1, 32) =
15.26, P = 0.0005; and a significant interaction F (3, 32) = 11.18, P = 0.0001. Tukey's
multiple comparisons test revealed a significant difference between genotypes in mice
treated with 5.0 IU eCG (48 h) + 5.0 IU hCG (14 h), ****, P < 0.0001. D) Cyp19a1. A
two-way ANOVA found a significant effect for treatment, F (2, 32) = 32.83, P < 0.0001;
no significant effect for genotype, F (1, 32) = 1.731, P = 0.1976; and no significant
interaction F (2, 32) = 2.303, P = 0.1163. Tukey's multiple comparisons test revealed a
significant difference between Efna5+/+ mice treated with saline (48 h) or 5.0 IU eCG (48
h), ****, P < 0.0001; and a significant difference between Efna5-/- mice treated with
saline (48 h) or 5.0 IU eCG (48 h), *, P = 0.0116. E) Fshr. A two-way ANOVA found a
significant effect for treatment, F (2, 32) = 22.57, P < 0.0001; no significant effect for
genotype, F (1, 32) = 0.8305, P = 0.3689; and no significant interaction, F (2, 32) =
0.2067, P = 0.8143. Tukey's multiple comparisons test revealed a significant difference
between Efna5+/+ mice treated with saline (48 h) or 5.0 IU eCG (48 h), *, P = 0.0210; and
a significant difference between Efna5-/- mice treated with saline (48 h) or 5.0 IU eCG
(48 h), *, P = 0.0135. F) Lhcgr. A two-way ANOVA found a significant effect for
treatment, F (2, 32) = 45.02, P < 0.0001; no significant effect for genotype, F (1, 32) =
2.482, P = 0.1250; and no significant interaction, F (2, 32) = 0.8808, P = 0.4243. Tukey's
multiple comparisons test revealed a significant difference between Efna5+/+ mice treated
with saline (48 h) or 5.0 IU eCG (48 h), ****, P < 0.0001; and a significant difference
between Efna5-/- mice treated with saline (48 h) or 5.0 IU eCG (48 h), ****, P < 0.0001.
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Figure 3-5: Follicles containing expanded COCs and retained oocytes are more
numerous in superovulated Efna5-/- mice.
Sectioned ovaries from superovulated Efna5+/+ and Efna5-/- mice were stained with
hematoxylin/eosin and scanned using an Aperio ScanScope (Leica Biosystems) at a
magnification of 200x. Follicles containing expanded COCs (A) and corpora lutea (CLs)
(mean ±SEM) (B) were counted in every fifth section throughout the entire ovary, noting
the fraction of CLs that contained oocytes (mean ±SEM) (C). Additional sections were
reviewed when necessary to ensure that CLs were not counted twice. A) “Number of
follicles containing expanded COCs per mouse” was compared between Efna5+/+ and
Efna5-/- genotypes using the Student two-tailed unpaired t-test. A statistically significant
difference was found between genotypes as determined by Student’s unpaired t-test;
t(10)=8.597. ****, p<0.0001. B) The number of corpora lutea per mouse was compared
between Efna5+/+ and Efna5-/- genotypes using the Student two-tailed unpaired t-test. No
statistically significant difference was found between genotypes as determined by
Student’s unpaired t-test; t(4)=2.104, p=0.1031. C) “Fraction of CLs containing oocytes”
was compared between Efna5+/+ and Efna5-/- genotypes using the Student two-tailed
unpaired t-test. A statistically significant difference was found between genotypes as
determined by Student’s unpaired t-test; t(4)=4.623. **, p=0.0099.
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Figure 3-6: Superovulated Efna5-/- mice exhibit non-apical follicle rupture and an
increased incidence of oocytes trapped within luteinized follicles.
Sectioned ovaries from superovulated Efna5+/+ and Efna5-/- mice were stained with
hematoxylin/eosin and scanned using an Aperio ScanScope (Leica Biosystems) at a
magnification of 200x. Black bars represent 100 µm. A) Non-apical follicle rupture in the
ovarian interstitium (black arrow) associated with hemorrhage near the site of rupture
(white star). B) Hemorrhaging in the interstitium (open star). C) Blood vessel with fibrin
thrombus and intraluminal granulosa cells (black arrow). D) Fibrin thrombus (black
arrow) with the presence of an oocyte in the interstitium (open arrow). E) Presence of
granulosa cells in the interstitium (black arrow). F) Non-apical follicle rupture in
interstitium (black arrow) and blood vessel containing fibrin thrombus with granulosa
cells. G) Fibrin thrombus (open pentagon) with the presence of an oocyte in the
interstitium (black arrow), non-basal ovulatory cone indicating follicle rupture (open
arrow), and luteinizing granulosa cells (open star).
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Figure 3-6. Superovulated Efna5-/- mice exhibit non-apical follicle rupture and an
increased incidence of oocytes trapped within luteinized follicles.
H, I, J) Oocytes trapped within luteinizing follicles (black arrows). K) Representative
Efna5+/+ ovary.

93

Figure 3-7: Efna5-/- adult females exhibit more multi-oocyte follicles than juveniles.
Sectioned ovaries from superovulated Efna5+/+ and Efna5-/- mice were stained with
hematoxylin/eosin and scanned using an Aperio ScanScope (Leica Biosystems) at a
magnification of 200x. Multi-oocyte follicles (MOFs) were counted in every third section
throughout both ovaries of PND 23 (A) and PND 60 (B) mice. Additional sections were
reviewed when necessary to ensure that MOFs were not counted twice. MOF counts were
compared between Efna5+/+ and Efna5-/- genotypes using the Student two-tailed unpaired
t-test. A) At PND 23, no statistically significant difference was found between genotypes
as determined by Student’s unpaired t-test; t(4)=0.4435, p=0.6803. B) At PND 60 a
statistically significant difference was found between genotypes as determined by
Student’s unpaired t-test; t(8)=2.313. *, p=0.0494.
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3.4 Discussion
To our knowledge, no reproductive assessment has been carried out using the
Efna5-/- mouse or any other ephrin or Eph receptor knockout animal model. We now
report that female mice lacking ephrin-A5 are subfertile and possess a number of ovarian
defects that may underlie this reduced fertility.
3.4.1 Efna5-/- females produce smaller litters and release fewer oocytes than
controls
In a continuous breeding study, Efna5-/- females produced litters that were 40%
smaller than Efna5+/+ controls, indicating that ephrin-A5 is important for optimal fertility
in female mice. Consistent with this observation, superovulated reproductively immature
Efna5-/- female mice ovulated 40% fewer COCs than controls, suggesting that ephrin-A5
is required for a maximal response to gonadotropins. This blunted response was not likely
due to differences in gonadotropin receptor levels, as both Lhcgr and Fshr mRNA levels
were similar in both genotypes. To further explore the basis of this attenuated ovarian
response, we measured the ovarian expression of known FSH and LH responsive genes in
Efna5-/- females stimulated with eCG and hCG.
3.4.2 Efna5-/- females exhibit an attenuated response to hCG but not eCG
After eCG treatment, no differences in the mRNA levels of the FSH-responsive
genes Cyp19a1 and Lhcgr were observed between Efna5+/+ and Efna5-/- ovaries,
suggesting that Efna5-/- ovaries respond normally to FSH. However, we observed
attenuated hCG-stimulated expression of the LH-responsive genes Pgr, Ptgs2, and
Adamts4 in Efna5-/- females compared to controls, suggesting that the ovarian response to
LH is compromised in Efna5-/- females, and may contribute to their reduced ovulatory
capacity.
3.4.3 Efna5-/- ovaries exhibit numerous histological abnormalities
Ovulation requires extensive tissue remodeling, which involves the dynamic
regulation of cell migration and adhesion, and the deposition and degradation of
extracellular matrix components. Like all members of the ephrin family, ephrin-A5 is
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best known as a regulator of cell positioning and is thus well-suited to be involved in
these processes, and ephrin-A5-Fc and EphA5-Fc influence morphology and reduce
adhesion, respectively, of mouse GCs in culture (3).
Gonadotropin-stimulated Efna5-/- mice possessed ovaries with an increased number of: a)
luteinized follicles containing trapped oocytes, b) follicle rupture within the ovary
resulting in oocyte release into the interstitium and/or blood vessel lumina, c) GCs
present in blood vessel lumina, d) the presence of fibrin thrombi in blood vessels, and e)
the presence of extravasated blood near sites of non-apical rupture. These histological
features bear a striking resemblance to those observed in several loss-of-function rodent
models, specifically for the LH-responsive genes Pgr, Ptgs2, and Adamts4, for which we
detected reduced mRNA levels in Efna5-/- ovaries.
3.4.4 Progesterone receptor (Pgr)
We observed a 58% reduction in ovarian Pgr mRNA levels in superovulated Efna5/-

mice. While follicle growth and cumulus expansion proceed normally in mice lacking

Pgr, ovulation fails due to impaired follicle rupture (19). This results in the formation of
luteinized follicles containing trapped COCs, suggesting that the primary physiological
role of Pgr in the ovary is promoting follicle rupture (20). Similar to the Pgr-/- ovary (19),
Efna5-/- ovaries exhibit an increased incidence of oocytes trapped within luteinized
follicles. Within the ovary, the PR is expressed primarily in GCs in response to
stimulation by LH, and mediates the expression of many genes involved in ovulation.
Therefore, attenuated expression of Pgr may be responsible, at least in part, for the
increased incidence of luteinized follicles containing trapped oocytes that we observed in
Efna5-/- females.
3.4.5 Prostaglandin-endoperoxide synthase 2 (Ptgs2)
We observed a 54% reduction in ovarian Ptgs2 mRNA levels in superovulated
Efna5-/- mice. Ptgs2 is involved in the post-LH rise in prostaglandin synthesis within the
preovulatory follicle (21). Ptgs2-/- females are infertile, exhibit oocyte retention in CLs,
and defective cumulus expansion (22). Rats treated with indomethacin, a PTGS2
inhibitor, are also anovulatory and exhibit follicle rupture defects including oocyte
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retention within luteinized follicles and non-apical follicle rupture (23). Similar to Ptgs2-/females, Efna5-/- females exhibited COCs trapped within CLs, non-apical follicle rupture
resulting in interstitial and intraluminal COC release, and formation of structures
reminiscent of follicular fluid emboli reported in ovaries of indomethacin-treated rats
(23). Therefore, reduced Ptgs2 expression may contribute to the reproductive phenotype
of Efna5-/- females.
3.4.6 ADAM metallopeptidase with thrombospondin type 1 motif, 4 (Adamts4)
We observed an 80% reduction in ovarian Adamts4 mRNA levels in superovulated
Efna5-/- mice. Adamts4 encodes a member of the a disintegrin and metalloproteinase with
thrombospondin-like repeats family. Adamts4 is expressed in the ovary along with
Adamts1 and Adamts5 in distinct spatiotemporal patterns, and is thought to be involved in
tissue remodeling that occurs prior to, during, and after ovulation (18). However, the
specific roles of these proteases in the context of ovulation are not currently known.
Interestingly, expression of Adamts4 is enriched in ovulation cones/stigma, which are
highly vascularized. Adamts4 is also enriched in endothelial cells of the forming CL of
superovulated mice 16 h post-hCG (18), suggesting that Adamts4 plays a role in follicle
rupture and neovascularization of the CL. Consistent with these proposed roles for
Adamts4, Efna5-/- females exhibit abnormal follicle rupture and vascular defects such as
fibrin thrombi. Although Adamts4-/- mice are reported as phenotypically normal (24),
suggesting that other proteases may compensate for its loss in the ovary, given the
dramatic reduction in Adamts4 mRNA levels we observe in Efna5-/- mice, we speculate
that loss of Adamts4 expression may contribute to the abnormal follicle rupture in Efna5-/females.
3.4.7 Relating LH, Pgr, Ptgs2, and Adamts4 to Efna5-/- reproductive and ovarian
defects
In the Efna5-/- ovary, we observed follicles ruptured within the ovary resulting in
intraovarian oocyte release, and a higher incidence of CLs containing trapped oocytes.
We postulate that in Efna5-/- mice, these follicles fail to ovulate normally because they
are, to varying degrees, unable to fully respond to LH.
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LH triggers a stepwise cascade of events, with cumulus expansion occurring early,
leading to ovulation and formation of the CL at a later stage. Therefore, it seems
plausible that different follicles may exhibit a range of partial responsiveness to LH.
Thus, we might expect to observe an ovulatory defect at any of the LH-triggered stages,
with LH able to “push” some preovulatory follicles further along the “ovulation” pathway
than others. This idea is supported by the attenuated expression of Pgr, Ptgs2, and
Adamts4 in Efna5-/- females, all of which are proposed to be involved in follicle rupture.
Cumulus expansion is normal in Pgr-/- mice, and although Ptgs2-/- mice exhibit reduced
cumulus expansion, Ptgs2 is reduced by ~50% in Efna5-/- females, which may be
sufficient for cumulus expansion to occur. Therefore, reduced expression of Pgr and
Ptgs2 following hCG treatment could specifically impair follicle rupture, while still
allowing cumulus expansion to occur.
Abnormal follicle rupture may also help explain the reduced ovulatory potential of
Efna5-/- females. A necessary condition of successful ovulation is that follicular rupture
occurs on the apical surface of the follicle to facilitate COC release into the oviduct. In
Efna5-/- mice, COCs released into the interstitium, blood vessel lumina, and retained in
corpora lutea, fail to reach the oviduct. Thus, the increased frequency of abnormal
follicular rupture, combined with the increased incidence of unruptured follicles, may
contribute to the decreased ovulation potential that we observed in Efna5-/- females.
3.4.8 Hemorrhaging, fibrin thrombi, and GCs in blood vessel lumina
We observed hemorrhaging and formation of fibrin thrombi in ovaries of
superovulated Efna5-/- females. These events likely result from non-apically released GCs
and follicular fluid, whose proteolytic/invasive properties damage the surrounding tissue,
including the vasculature. This vascular damage has been observed in other murine
models. In indomethacin-treated rats, release of follicular fluid and GCs into the
interstitium results in invasion of the stroma, rupture of blood and lymphatic vessels,
hemorrhagia, and the formation of emboli composed of follicular fluid (25). Furthermore,
cumulus cells from expanded COCs exhibit transiently increased invasive properties,
with increasing migratory and adhesive capacity 4 to 12 h post-hCG (26). Under normal
circumstances, these properties may contribute to successful fertilization by promoting
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migration of the apically ovulated COC. However, when directed toward the ovarian
interstitium during non-apical follicle rupture, these properties may contribute to the
ovarian hemorrhaging and formation of fibrin thrombi observed in Efna5-/- females.
3.4.9 How does loss of ephrin-A5 result in reduced expression of Pgr, Ptgs2, and
Adamts4?
We show that ephrin-A5 is necessary for optimal ovarian expression of Pgr, Ptgs2,
and Adamts4 in response to gonadotropin stimulation. Since Pgr and Ptgs2 are known
LH-responsive genes, and in our study, Adamts4 is also LH-responsive, it is logical that
the reduced mRNA levels of Pgr, Ptgs2, and Adamts4 in Efna5-/- ovaries are due, at least
in part, to an attenuated transcriptional response of GCs to LH. Reduced transcript
stabilization is another possible mechanism. How ephrin-A5 might regulate either
transcript production or stabilization in the ovary is currently unknown.
Nevertheless, Eph-ephrin signaling has been linked to changes in gene expression
in various model systems, although the mechanism(s) by which this occurs are not well
understood. Stimulation with A-class ephrins increases expression of epidermal
differentiation markers and suppresses expression of genes associated with cell adhesion
in human epidermal keratinocytes (27). Furthermore, EphB4-/- embryonic stem cells
(ESCs) exhibit impaired differentiation, with many genes dysregulated compared to
EphB4+/+ ESCs (28). Finally, stimulation of rat epithelial small intestine IEC-6 cells with
EphB1 results in upregulation of wound-healing genes via the ERK1/2 pathways (29).
Currently, the mechanism by which Eph-ephrin signaling influences ovarian gene
expression in GCs is not known. However, several reports indicate that the ERK, betacatenin, and PKA pathways, which are activated by LH, are influenced by Eph-ephrin
signaling, and therefore may be disrupted by loss of ephrin-A5 in the ovary, resulting in
reduced expression of LH-responsive genes such as Pgr and Ptgs2.
In the mouse, extracellular regulated kinases 1 and 2 (ERK1/2) are essential for
female fertility. Mice lacking ERK1/2 in GCs exhibit a compromised response to LH,
including impaired cumulus expansion, ovulation, luteinization, and induction of many
LH-responsive genes, including Pgr and Ptgs2 (30). Several reports in other model
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systems indicate that Eph-ephrin signaling regulates phosphorylation of ERK1/2,
inhibiting activation in most model systems (31-33) and promoting activation in some
(34-37). EPHB4 can inhibit or enhance ERK1/2 activation depending on cell type, due to
differences in coupling with downstream signaling elements (38). Therefore, given that
ERK1/2 are necessary for LH-stimulated activation of Ptgs2 and Pgr in mouse GCs (30),
and that ERK1/2 phosphorylation is elevated for at least 4 h post-LH in cultured rat
follicles (39), GCs lacking ephrin-A5 in our model may insufficiently activate ERK1/2
signaling to optimally induce Ptgs2 and Pgr upon stimulation with LH. Determining the
molecular mechanism by which loss of ephrin-A5 may attenuate ERK1/2 activation,
resulting in suboptimal LH gene activation, requires further investigation.
Second, ephrin-A5 may also influence Ptgs2 expression by altering beta-catenin
levels. We previously reported that stimulation of rat granulosa cells with ephrin-A5
results in decreased beta-catenin levels (3). Beta-catenin serves as both a component of
adherens junctions (40) and as a transcriptional activator (41,42). In the ovary,
appropriate beta-catenin levels in GCs is critical for fertility, since mice expressing a
granulosa cell-specific, dominant-stable form of beta-catenin exhibit impaired ovulation
and luteinization, and attenuated hCG-stimulated expression of Ptgs2 (43). Therefore,
FSH-induced expression of ephrin-A5 (3) may promote degradation of beta-catenin in
mouse GCs in preparation for the LH surge. In GCs of Efna5-/- mice, loss of ephrin-A5
may result in increased beta-catenin levels, contributing to the reduced expression of
Ptgs2.
Third, Eph-ephrin signaling may cross-talk with the cAMP/PKA pathway. Indirect
crosstalk between the Eph-ephrin and cAMP/PKA pathways has been previously
described in two model systems. In mouse cortical progenitor cells, stimulation with
recombinant ephrin-B1 potentiates activation of the PKA target, cAMP-responsive
element binding protein (CREB), by glutamate in an EphB2-dependent manner (44).
Furthermore, ephrin-A5 stimulation of cultured mouse hippocampal slices promotes
activation of PKA and CREB in an EphA5-dependent manner (45). Therefore, Ephephrin signaling may indirectly activate or potentiate PKA in GCs, and loss of ephrin-A5
may result in insufficient PKA activation for optimal induction of Pgr and Ptgs2.
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Finally, it is possible that in Efna5-/- females, reduced Adamts4 expression is a
consequence of attenuated induction of Pgr by LH. In Pgr-/- mice, LH-induced ovarian
expression of Adamts4 is attenuated 12 h post-hCG , suggesting that PR regulates
Adamts4 expression. In Efna5-/- ovaries, hCG-induced Pgr expression is reduced 4 h
post-hCG, and Adamts4 expression is attenuated 14 h post-hCG, suggesting that the
reduction of PR at 4 h may reduce Adamts4 expression by 14h.
3.4.10 Efna5 is one of many neuronal guidance genes expressed in the mouse ovary
This study has shown that Efna5 plays an important role in the mouse ovary, and
that its absence has negative consequences for female fertility. However, ephrin-A5 has
been characterized primarily in the context of axon guidance during embryonic
development; thus, its role in female reproduction and in the mouse ovary are novel. In
support of a role for a neuronal guidance gene such as ephrin-A5 in the ovary, it is
interesting to note that expression of neuronal cell guidance genes in the ovary is not
without precedent. In addition to Efna5, expression of several genes associated with
neuronal cell guidance is higher in large bovine follicles than in small antral follicles (8).
The authors speculate that these genes mediate ovarian tissue remodeling and cell
migration in the follicle, resulting in oocyte release facing the ovarian surface (8). In line
with this reasoning, we also observed non-apical follicle rupture of follicles in Efna5-/females. Thus, ephrin-A5 may be one of many genes with roles in both neuronal cells and
in the ovary.
3.4.11 Experimental Considerations
One limitation of our Efna5-/- model is that it is a global knockout, and thus it is
possible that abnormal development of the hypothalamus, pituitary, and/or uterus may
occur. However, our results suggest that the hypothalamic-pituitary-gonadal (HPG) axis
is likely not largely disrupted in Efna5-/- females. First, litter frequency was unaffected,
suggesting that estrous cyclicity is normal in Efna5-/- females, and therefore, as far as its
capacity to coordinate the proper timing of follicle growth and ovulation, the HPG axis is
intact. An intact HPG axis is also consistent with our observation that gonadotropinstimulated estradiol and progesterone levels were similar in Efna5-/- females and controls.
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However, we cannot completely rule out the possibility that the lack of ephrin-A5 in the
hypothalamus or pituitary may be in part responsible for the phenotype we observed. To
do this, a granulosa cell type-specific, conditional Efna5 knockout mice would be
required.
3.4.12 Unexpected findings
We observed an increased number of multi-oocyte follicles (MOFs) in ovaries of
normally-cycling adult Efna5-/- females compared to controls. However, we did not detect
a difference in MOF numbers in immature mice at 3 weeks of age, suggesting that in
Efna5-/- females MOF formation is not a result of impaired oocyte nest break-down;
otherwise, differences in MOF levels would be expected in immature mice. Instead, our
results suggest that the increase in MOF numbers is gonadotropin-dependent, and may
occur by gonadotropin-dependent merging of single follicles. Follicle merging has been
proposed to increase the incidence of MOFs in mice harboring an oocyte-specific
deletion of core-1-β1,3-galactosyl-transferase (C1galt1) (46,47), due to degradation of
the basal lamina and initiation of aberrant granulosa cell invasion. In Efna5-/- females, we
speculate that MOF formation may be linked to abnormal follicle rupture. Premature
rupture of follicles prior to cumulus expansion may result in breaching of the follicle wall
and permit joining of adjacent follicles, resulting in MOF formation, as in the oocytespecific C1galt1 knockout mice (46).

3.5 Conclusion
In conclusion, our data indicate that ephrin-A5 is required for optimal reproductive
function in female mice. Its absence results in reduced fertility and a partially impaired
response to hCG, which includes attenuated ovarian expression of Pgr, Ptgs2, and
Adamts4, follicle rupture defects, and reduced ovulatory capacity. Ephrin-A5 plays an
important and previously-unidentified role in the normal function of the mouse ovary,
and we speculate that defective ovarian ephrin-A5 signaling accounts for some
incidences of idiopathic infertility in women.
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4 Chapter 4: Cyclic AMP stimulates PKA-dependent
transcriptional activation of the mouse Epha5 upstream
genomic region in the KGN granulosa cell line
4.1 Introduction
Eph receptors, encoded by Eph genes, comprise the largest known family of
receptor tyrosine kinases (RTKs) and interact with ligands known as ephrins, which are
encoded by Efn genes. The entire family of Eph receptors and ephrins is classified into
two subclasses, A or B, based on receptor-ligand affinity and amino acid sequence
similarity (1). In general, A-class receptors have greater affinity for A-class ephrins than
for B-class ephrins, and B-class receptors have greater affinity for B-class ephrins than
for A-class ephrins. Receptor-ligand interaction is promiscuous within classes, although
inter-class promiscuity has been reported (2). All Eph receptors and ephrins are
membrane-associated, and therefore Eph-ephrin signaling is initiated at points of cell-cell
contact. Furthermore, as membrane-associated signaling elements, both Eph receptors
and ephrins may transmit signals via their cytoplasmic domains and/or by association
with other transmembrane signaling proteins. Eph-ephrin signaling has been studied
primarily in the context of embryonic development, particularly in axon guidance and
tissue segmentation (3,4).
Despite progress in understanding Eph receptor and ephrin function, relatively little
is known about regulation of the genes encoding them. Much of the knowledge of Eph
and Efn transcriptional regulation emerged from efforts to understand patterns of
expression during embryonic development. As a result, many transcriptional regulators of
Eph and Efn expression identified thus far are well-known regulators in embryonic
development. For example, homeobox (Hox) genes have been implicated in controlling
Eph and Efn expression during embryonic morphogenesis (5). Chick brain factor 1,
encoded by Cbf1, regulates expression of Efna2, Efna5, and Epha3 during axon guidance
in the chick (6), while NFYA (nuclear transcription factor Y, alpha), MEIS1 (myeloid
ecotropic viral integration site), and MAZ (Myc-associated zinc finger protein) regulate
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Efnb2 expression during prenatal angiogenesis in mice (7). NF-Y has also been
implicated in regulating EFNA4 expression in human lymphocytes (8).
Furthermore, the expression of numerous Eph and Efn genes is dysregulated in cancer,
where this dysregulation has been associated with tumour-promoting and suppressing
activity (9). For example, Epha2 is upregulated in some human cancers, and its
downregulation has been associated with decreased tumour growth and prolonged
survival in some animal models (10). Expression of EFNA1 and EFNA5 in ovarian
tumors negatively correlates with patient survival (11). In contrast, Ephb4 behaves as a
tumor suppressor during intestinal tumorigenesis in a mouse model (12). Moreover, it
was recently reported that the Eph receptor complement expressed by a cancer cell can,
depending on ephrin expression in the surrounding tissue, determine its invasiveness
(13). Therefore, an improved understanding of the mechanisms underlying Eph and Efn
transcriptional regulation has implications for both developmental and cancer biology.
While our knowledge of Eph and Efn expression in adult ovarian function is sparse,
several reports have indicated that expression of Eph and Efn genes in the adult ovary
changes during follicle growth. Esr2-/- females, which lack estrogen receptor beta (ERβ),
exhibit impaired expression of multiple FSH-responsive genes in granulosa cells (GCs),
including Efna5 (14). We previously reported that several genes that encode members of
the Eph-ephrin family are upregulated in GCs of female mice treated with equine
chorionic gonadotropin (eCG) (15) a horse-derived gonadotropin with FSH receptor
(FSHR)-stimulating activity in rodents. Furthermore, expression of EFNA5 and EPHB6 is
higher in large antral follicles than in small follicles in the cow, suggesting that FSH may
also regulate expression of Eph and Efn genes in other species (16). In addition to
suggesting a role for Eph-ephrin signaling in FSH-dependent follicle growth and/or
ovulation, these data also provide insight into the transcriptional regulation of Eph and
Efn genes.
We previously reported that Efna5, Epha3, Epha5, Epha8, and Ephb2 are
upregulated in mouse GCs following treatment with eCG (15). The FSHR is an integral
Gs protein-coupled receptor composed of a FSH-binding extracellular domain, a
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membrane-spanning domain composed of 7 transmembrane helices, and a cytoplasmic
domain (17). Expressed in GCs of secondary and larger follicles (18), it is one of two
gonadotropin receptors in mammals, the other being the luteinizing hormone receptor
(LHR). Binding of FSH to the FSHR extracellular domain results in Gs protein activation,
which in turn activates adenylate cyclase and catalyzes the hydrolysis of adenosine
triphosphate (ATP) to generate the second messenger cyclic adenosine monophosphate
(cAMP) (19). In GCs of many species, elevation of cytoplasmic cAMP concentration
favours activation of protein kinase A (PKA) and its downstream pathways, including
those that modulate gene expression (20). Therefore, activation of many genes
downstream of FSHR activation is dependent on cAMP-associated pathways. The
promoters of some cAMP-responsive genes are activated by cis-regulatory sequences
known as cAMP-responsive elements (CREs), which have a consensus sequence of 5’TGACGTCA-3’ (full CRE) or 5’-CGTCA-3’ or 5’-TGACG-3’ (half CRE) (21).
Estrogen receptors are nuclear hormone receptors, of which there are two forms.
Within the ovary in mice, ERα localizes primarily to thecal and interstitial cells and is
encoded by the Esr1 gene. ERβ is localized primarily to GCs and is encoded by the Esr2
gene. That action of estrogens is mediated predominantly by ERα and ERβ, which bind
estrogens and effect changes in the transcriptional activity of target genes. Esr2-/- females
exhibit a severe reproductive phenotype that includes subfertility and impaired formation
of antral follicles (22). GCs from Esr2-/- mice also exhibit suboptimal production of
cAMP, a defect thought to contribute to dysregulation of FSH-responsive genes
following treatment with FSH (14). Therefore, there is evidence suggesting that Eph and
Efn expression in GCs changes during FSH-dependent follicle growth and is regulated by
cAMP. Transcriptional regulation of any Eph or Efn genes by cAMP-dependent pathways
has not been previously described in GCs or in any other model system. Therefore, we
investigated the role of cAMP-dependent regulation in regulating Epha5 transcription in
GCs. In particular, we focused on cAMP-dependent regulation of Epha5 transcription in
GCs.
In order to investigate regulation of Eph and Efn genes by cAMP, we assessed
expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 in GCs of Esr2-/- mice. In order to
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evaluate responsiveness of the Epha5 putative promoter region to cAMP, we then
generated a luciferase reporter construct (Epha5-Luc) containing the mouse genomic
sequence from -1589 to +23 relative to the start of the Epha5 5’ UTR (+1). Using this
construct with dibutyryl-cAMP and a PKA inhibitor, we investigated activation of the
Epha5 promoter region in a human tumour-derived GC line. Furthermore, we used sitedirected mutagenesis to generate a function-disrupting point mutation in a putative CRE
half-site within Epha5-Luc.

4.2 Materials and Methods
4.2.1 Cell culture and transfections
The KGN cell line was derived from a human stage 3 GC carcinoma (23,24). KGN
cells were maintained in Dulbecco modified Eagle medium/F-12 (DMEM/F12; Wisent)
containing 10% fetal bovine serum (FBS; Wisent) at 37°C in 5% CO2.
Twenty-four hours prior to transfection, KGN cells were seeded into 24-well plates
at a density of 9.5 × 104 cells/well. Eight hours later, the culture medium was replaced
with DMEM/F12 containing 10% charcoal-stripped fetal bovine serum (CS-FBS;
Wisent). Sixteen hours later, transfections were performed using FuGENE HD (Promega)
with a reagent:plasmid ratio of 5:2 (µL FuGENE HD:µg DNA) at 0.5 µg total plasmid
per well (490 ng firefly luciferase reporter plasmid and 10 ng Renilla luciferase control
plasmid). Transfection mix was prepared according to the manufacturer’s instructions
(Promega). In all luciferase reporter studies, controls included KGN cells transfected with
pGL3-basic (promoter-less vector) to establish that increases in luciferase activity were
specific to the Epha5-Luc plasmid (pGL3-basic plasmid containing the mouse genomic
sequence -1589 to +23 bp relative to the start of the Epha5 5’ UTR). Furthermore,
controls also included KGN cells transfected with a known cAMP-responsive luciferase
plasmid (CRE-Luc) obtained as a gift from Dr. Nathalie di Clemente (Institut National de
la Santé et de la Recherche Médicale, Clamart, France).
For qRT-PCR studies with KGN cells, human recombinant FSH was obtained from
Dr. A.F. Parlow (National Hormone and Peptide Program, National Institute of Diabetes
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and Digestive and Kidney Diseases, USA). Recombinant FSH was reconstituted in sterile
water to a concentration of 50 ng/mL and stored at -80°C.
For experiments involving the PKA inhibitor H-89 (Cell Signaling), H-89 was
reconstituted in dimethyl sulfoxide (DMSO) to a concentration of 20 mM and stored at 20°C. Cells were pre-treated with H-89 at a final concentration of 20 µM, 1:1000 v/v
DMSO, or with an equal volume of DMSO (1:1000 v/v) for 30 minutes. Both H-89- and
DMSO-treated KGN cells were treated with dbcAMP at a final concentration of 1.0 mM
for 24 hours.
4.2.2 Mice
Experiments were performed in compliance with the guidelines set by the Canadian
Council for Animal Care and the policies and procedures approved by The University of
Western Ontario Council on Animal Care. Investigations were conducted in accordance
with the National Research Council's Guide for Care and Use of Laboratory Animals
(Protocol # 2008-047-02). C57BL/6 female mice (Postnatal Day [PND] 23–28) were
used in all experiments. For quantitative RT-PCR (qRT-PCR) studies, mice were treated
either with saline or with 5.0 IU eCG (Sigma Chemical Co.) for 48 h before isolation of
GCs.
4.2.3 Isolation of GCs
48 h after treatment with saline or eCG, mice were euthanized by CO2 asphyxiation
and whole ovaries were harvested into a 100 mm cell culture dish containing cold M199
medium supplemented with 1 mg/mL of bovine serum albumin (BSA), 2.5 µg/mL of
amphotericin B, and 50 µg/mL of gentamicin (all reagents from Invitrogen). Ovaries
were pooled, and the GCs from each pool were then expressed by manual puncture with
25-gauge needles followed by pressure applied with a sterile spatula. The GC suspension
was filtered through a 150-µm Nitex nylon membrane (Sefar America, Inc.) mounted in a
Swinnex filter (Millipore). The GCs were then pelleted by centrifugation at 250 × g for 5
min at 4°C followed by two washes in DMEM/F12 medium containing 1%
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penicillin/streptomycin solution (Invitrogen). The final cell pellet was frozen at −80°C
for qRT-PCR studies.
4.2.4 RNA isolation and qRT-PCR
Frozen pellets of GCs were solubilized in TRIzol (Invitrogen), and RNA was
isolated according to the manufacturer's protocol. RNA was further treated with DNase I,
then reverse-transcribed using Superscript II (Invitrogen). Complementary DNA (cDNA)
levels were detected using qRT-PCR with the ABI PRISM 7900 Sequence Detection
System (Applied Biosystems) and SYBR Green I dye (Applied Biosystems). Primers
were generated using Primer Express Software (Version 2.0; Applied Biosystems) (Table
4-1). Fold-changes in gene expression were determined by quantitation of cDNA from
target (treated) samples relative to a calibrator sample (vehicle). The gene for ribosomal
protein L7 (Rpl7 in mouse GCs or RPL7 in KGN cells) was used as the endogenous
control for normalization of RNA levels. Expression ratios were calculated according to
the mathematical model described by Pfaffl (25), where ratio =
(Etarget)ΔCt(target)/(Econtrol)ΔCt(control) and E = efficiency of the primer set, calculated from the
slope of a standard curve of log(ng of cDNA) versus cycle threshold (Ct) for a sample
that contains the target according to the formula E = 10−(1/slope) and ΔCt = Ct(vehicle) −
Ct(treated sample). Three independent experiments were carried out for studies using mouse
GCs, and the results were averaged for statistical analysis by a two-way ANOVA
followed by a Tukey multiple comparison post-hoc test (Tukey test) (Figure 4-1). Two
independent experiments were carried out for studies using KGN cells, and the results
were averaged for statistical analysis by a two-tailed unpaired Student t-test (Figure
4-4A).
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Table 4-1: Primers used for qRT-PCR in Figure 4-1 and Figure 4-4.

GenBank
accession no.

Forward (5' to 3')

Reverse (5' to 3')

Rpl7

NM_011291

AGCTGGCCTTTGTCATCAGAA

GACGAAGGAGCTGCAGAACCT

Efna5

NM_207654

TCTGCAATCCCAGACAACGGAAGA

TCATGTACGGTGTCATCTGCTGGT

Epha3

NM_010140

CCGCAGTCAGCATCACAACT

TTTCTGGAAGTCCGATCTTTCTTAA

Epha5

NM_007937

GCTGGTTCCCATTGGGAAAT

CACATTGGTGACTGGAGAAGGA

Epha8

NM_007939

CTCGGATGAAGAGAAGATGCATT

TGGTTCAAGGGCAAGAAGACA

Ephb2

NM_010142

ACCTCAGTTCGCCTCTGTGAA

GGCTCACCTGGTGCATGAT

RPL7

NM_000971

AAATTGGCGTTTGTCATCAGAA

AAGAAGCTGCAACACCTTTCG

EPHA5

NM_004439

AGGCAGGATATGAAGAGAAAAATGG

ATTTGCCGCAGCTCTGGAT

Gene
Mouse

Human

NM_182472
NM_001281765
NM_001281766
NM_001281767
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4.2.5 Immunoblotting
Protein lysates were generated in a 1.5 mL microcentrifuge tube by homogenizing a
GC pellet in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl
[pH 8.0], 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS)
supplemented with a protease inhibitor cocktail (1:100; P8340; Sigma). Lysates were
then centrifuged at 15 000 × g for 20 min at 4°C. The supernatant was boiled in Laemmli
buffer for 5 min and then analyzed using SDS-PAGE. The separated proteins were
transferred to a polyvinylidene fluoride membrane at 100 V (constant voltage) for 2 h at
4°C. After blocking for 1 h in Tris-buffered saline and Tween 20 (TBST)/5% nonfat milk,
the membrane was probed with a monoclonal IgG specific to ephrin-A5 (1:200 in
TBST/5% nonfat milk; ab60705; Abcam). The membrane was then probed with an antimouse horseradish peroxidase-conjugated IgG generated in donkey (1:10 000 in
TBST/5% nonfat milk) and visualized using ECL Plus (Amersham Biosciences) and
Hyperfilm (Amersham). To assess equal protein loading, the membrane was subsequently
probed using a rabbit monoclonal IgG to detect alpha-tubulin (TUBA1A, T5168; Sigma).
4.2.6 Generation of the Epha5-Luc luciferase reporter plasmid
The genomic sequence upstream of Epha5 was amplified by PCR using Phusion
High-Fidelity DNA Polymerase (New England Biolabs), using the following primer
sequences (5’

3’): Forward: AGAGGCCACCGAACTGCCCA, Reverse:

GCTCGCTCGCTCCTGCTGTG. Amplification was performed using a bacterial artificial
chromosome template containing the mouse genomic region of interest (NCBI clone
RP23-331O22, Clone ID # 705829) obtained from The Centre for Applied Genomics,
The Hospital for Sick Children, Toronto, Canada. This yielded a 1589 bp amplification
product that was digested using the KpnI and XhoI restriction enzymes, yielding a 1571
bp digestion product. The pGL3-basic plasmid was also digested using KpnI and XhoI.
Both digestion fragments were purified by agarose gel extraction and then ligated,
yielding the 6362 bp Epha5-Luc luciferase reporter plasmid. Plasmid minipreps were
prepared using 5 mL bacterial cultures grown from transformed colonies, and sent for
sequencing (Robarts Research Institute, The University of Western Ontario).
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4.2.7 Generation of the mutEpha5-Luc luciferase reporter plasmid by site-directed
mutagenesis
In order to assess whether a conserved CRE half-site located at -389 bp relative to
the start of the mouse Epha5 5’ UTR (Figure 4-2 and Figure 4-3) was required for
transcriptional activation of Epha5-Luc by cAMP, the QuikChange XL site-directed
mutagenesis kit (Agilent) was used to substitute two nucleotides in the CRE half-site to
disrupt function (TGACG

TGATC). This strategy has been previously used to disrupt

CRE half-site function in a construct containing part of the Tcl1 mouse promoter (26).
QuikChange primers were designed using the QuikChange Primer Design Tool
(http://www.genomics.agilent.com/primerDesignProgram.jsp).
Forward (5’

3’): agagcctgtgaatgtgctgttatatgatcacaaggttgttggt.

Reverse: (5’

3’): accaacaaccttgtgatcatataacagcacattcacaggctct.

4.2.8 Dual-luciferase assays
KGN cells that had been cultured, transfected, and treated in 24-well plates were
washed twice with PBS and then lysed by adding 105 µL Passive Lysis Buffer (Promega)
to each well followed by rocking at room temperature for 15 min. 100 µL of each lysate
was transferred to 1.5 mL microcentrifuge tubes and centrifuged at 12 000 g for 15
seconds to pellet loose debris. 20 µL of each lysate was transferred to a white, opaque 96well plate (82050-726; VWR) and assessed for firefly and Renilla luciferase activity
using the Dual-Luciferase Assay (E1960; Promega). Fluorescence was measured using a
Synergy H4 Microplate Reader (Biotek).

4.3 Results
4.3.1 Induction of FSH-responsive Efn and Eph genes is reduced in GCs of Esr2-/- mice
We previously reported that eCG enhances expression of Efna5, Epha3, Epha5,
Epha8, and Ephb2 in mouse GCs (15). In order to determine whether eCG-stimulated
expression of FSH-responsive Efn and Eph genes is altered in mice that exhibit impaired
production of cAMP, we assessed mRNA transcript levels for these genes in GCs of
eCG-treated, reproductively immature Esr2-/- mice. PND 23-28 Esr2+/+ and Esr2-/-
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females were treated with saline or 5.0 IU eCG (48 h) and GCs were harvested. Relative
mRNA transcript abundance was determined by qRT-PCR for Efna5, Epha3, Epha5,
Epha8, and Ephb2. In GCs of eCG-treated Esr2+/+ females, we observed 3-, 2.5-, 5.2-,
3.7-, and 2.7-fold increases in mRNA levels, respectively, for these genes compared to
saline-treated controls. In GCs of eCG-treated Esr2-/- females, we did not detect changes
in mRNA levels for any of these genes (Figure 4-1). Protein levels for ephrin-A5 were
lower in GCs from Esr2-/- compared to Esr2+/+ females (Supplemental Figure 6-4).
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Figure 4-1: Induction of FSH-responsive Efn and Eph genes by eCG is significantly
reduced in Esr2-/- GCs.
Relative transcript abundance compared to Rpl7 (mean ±SEM) was determined by qRTPCR in GCs of eCG-treated females for Efna5 (A), Epha3 (B), Epha5 (C), Epha8 (D),
and Ephb2 (E). A) Efna5. A two-way ANOVA found a significant effect for treatment, F
(1, 8) = 35.09, P = 0.0004; a significant effect for genotype, F (1, 8) = 79.47, P < 0.0001;
and a significant interaction, F (1, 8) = 28.92, P = 0.0007. A Tukey test revealed a
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, ***, P = 0.0002. B)
Epha3. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 16.78, P =
0.0035; a significant effect for genotype, F (1, 8) = 24.03, P = 0.0012; and a significant
interaction, F (1, 8) = 25.43, P = 0.0010. Tukey's multiple comparisons test revealed a
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, ***, P = 0.0009. C)
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Epha5. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 22.85, P =
0.0014; a significant effect for genotype, F (1, 8) = 21.82, P = 0.0016; and a significant
interaction, F (1, 8) = 10.57, P = 0.0117. Tukey's multiple comparisons test revealed a
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, **, P = 0.0021. D)
Epha8. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 26.25, P =
0.0009; a significant effect for genotype, F (1, 8) = 53.72, P < 0.0001; and a significant
interaction, F (1, 8) = 22.95, P = 0.0014. Tukey's multiple comparisons test revealed a
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, ***, P = 0.0005. E)
Ephb2. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 11.00, P =
0.0106; a significant effect for genotype, F (1, 8) = 24.87, P = 0.0011; and a significant
interaction, F (1, 8) = 21.11, P = 0.0018. Tukey's multiple comparisons test revealed a
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, **, P = 0.0023.
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4.3.2 Epha5-Luc is transcriptionally activated by cAMP in KGN cells
In order to determine whether the proximal genomic region upstream of Epha5 is
responsive to cAMP, we carried out a promoter-reporter (luciferase) assay. We generated
a luciferase reporter construct (Epha5-Luc) containing the mouse genomic sequence from
-1589 to +23 bp relative to the start of the Epha5 5’ UTR, inserted upstream of the
luciferase gene (Figure 4-2). This plasmid was then transfected into KGN cells, a cell
line derived from a human GC tumor (23). In KGN cells treated with FSH, we observed a
significant 2.5-fold increase in endogenous EPHA5 mRNA levels compared to vehicletreated cells (p=0.0099) (Figure 4-4A). KGN cells transfected with Epha5-Luc reporter
plasmid were co-transfected with the pRL-SV40 Renilla luciferase control plasmid, and
were treated with 1.0 mM dibutyryl-cAMP (dbcAMP), a cell membrane-permeable form
of cAMP, for 24 hours. Cells were then lysed and luciferase activity was measured. In
KGN cells treated with dbcAMP, we observed a 56% increase in normalized luciferase
activity compared to vehicle-treated cells (p=0.0461) (Figure 4-4B).
4.3.3 cAMP-stimulated activation of Epha5-Luc is reduced by co-treatment with H-89
Elevated intracellular concentration of cAMP is known to activate several PKAindependent pathways, such as RAPGEF3 (Rap guanine nucleotide exchange factor 3)
and RAPGEF4 (Rap guanine nucleotide exchange factor 4) (27,28), as well as PKB
(protein kinase B) (29). In order to determine whether activation of Epha5-Luc by
dbcAMP in KGN cells was PKA-dependent or PKA-independent, we used the PKA
inhibitor H-89. KGN cells transfected with Epha5-Luc were co-treated with 1.0 mM
dbcAMP (24 h) and either DMSO (vehicle control, 1:1000 v/v) or 20 µM H-89 (in
DMSO, 1:1000 v/v). In DMSO-treated cells, we observed a 2.3-fold cAMP-induced
enhancement of normalized luciferase activity (p=0.0143) (Figure 4-5A). In the presence
of 20 µM H-89, this enhancement was reduced (Figure 4-5B).
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Figure 4-2: A putative consensus CRE half-site upstream of Epha5 is conserved
across several species.
The genomic sequence from -5000 to +1 bp relative to the start of the Epha5 5’ UTR
from several species was aligned using Multiple Alignment using Fast Fourier Transform
(http://mafft.cbrc.jp/alignment/software) (A) and T-Coffee (http://www.tcoffee.org) (B).
The putative CRE half-site at -389 bp is highlighted in yellow. “cons” = conserved
nucleotides.
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Figure 4-3: Generation of the Epha5-Luc luciferase reporter construct.
The 1589 bp genomic region upstream of the mouse Epha5 5’ UTR (+1) was amplified,
digested with KpnI and XhoI restriction enzymes, and then ligated into the pGL3-basic
luciferase reporter plasmid to assess capacity to drive transcription of luc+ (luciferase). A
putative consensus CRE half-site is present (-389). The Epha5-Luc plasmid map was
generated using Geneious Pro Trial.
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Figure 4-4: Endogenous EPHA5 is induced by FSH, and Epha5-Luc is activated by
dbcAMP in KGN cells
Relative transcript abundance for EPHA5 compared to RPL7 (mean ±SEM) was
determined by qRT-PCR in FSH-treated (24 h) KGN cells (A). Firefly luciferase activity
normalized to Renilla luciferase activity (mean ±SEM) was determined for water- and
dbcAMP-treated KGN cells transfected with the Epha5-Luc luciferase reporter construct
(B). A) A statistically significant difference was found between water- and FSH-treated
KGN cells as determined by an unpaired, two-tailed Student’s t-test; t(2)=9.967. **,
p=0.0099. B) A statistically significant difference was found between water- and
dbcAMP-treated KGN cells as determined by an unpaired, two-tailed Student’s t-test;
t(4)=2.857. **, p=0.0461.
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Figure 4-5: Activation of Epha5-Luc by dibutyryl-cAMP is reduced by co-treatment
with the PKA inhibitor H-89.
Stimulation of Renilla-normalized firefly luciferase activity (mean ±SEM) was
determined for dbcAMP-treated (1.0 mM) KGN cells transfected with Epha5-Luc, in the
absence (A) and presence (B) of H-89 (20 µM). A) A statistically significant difference
was found between dbcAMP-treated KGN cells transfected with Epha5-Luc in the
absence of H-89 as determined by an unpaired, two-tailed Student’s t-test; t(4)=4.147. *,
p=0.0143. B) No statistically significant difference was found between dbcAMP-treated
KGN cells transfected with Epha5-Luc in the presence of H-89 as determined by an
unpaired, two-tailed Student’s t-test; t(4)=0.8134. *, p=0.0.4616.
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4.4 Discussion
We previously reported that expression of Efna5, Epha3, Epha5, Epha8, and Ephb2
is increased in GCs isolated from mice treated with eCG (15). Furthermore, microarray
studies indicate that eCG-stimulated expression of Efna5 is attenuated in GCs of Esr2-/females, which exhibit impaired cAMP production (14). Since eCG stimulates the FSHR,
which in turn activates responsive genes via cAMP-dependent pathways, we investigated
the transcriptional regulation of Eph and Efn genes by cAMP in GCs. Transcriptional
regulation of Eph and Efn genes by cAMP-dependent pathways has not been previously
described. Here, we present evidence that stimulation of Efna5, Epha3, Epha5, Epha8,
and Ephb2 by eCG is attenuated in GCs of mice with impaired cAMP production.
Furthermore, the proximal genomic region upstream of the mouse Epha5 gene is
responsive to dbcAMP in a PKA-dependent manner.
4.4.1 hCG-stimulated induction of Efna5, Epha3, Epha5, and Ephb2 is significantly
reduced in GCs of Esr2-/- mice
During our investigation into the roles of Eph receptors and ephrins in the mouse
ovary, we assessed expression of Eph and Efn genes in GCs from eCG-stimulated,
reproductively immature Esr2+/+ and Esr2-/- females. Esr2 encodes estrogen receptor beta
(ERβ), the predominant form of estrogen receptor in GCs (22). In addition to subfertility
and impaired antral follicle formation, eCG-stimulated Esr2-/- mice exhibit attenuated
expression of Efna5 in GCs compared to Esr2+/- controls. The same study revealed that
GCs from these mice also exhibit impaired cAMP production (14).
Since a common mechanism by which FSH enhances expression of its responsive
genes occurs via cAMP-dependent pathways (20), we first confirmed that Efna5 was
dysregulated in GCs of eCG-stimulated Esr2-/- females, and determine whether other Efn
and Eph genes were similarly dysregulated. We found that eCG enhanced expression of
Efna5, Epha3, Epha5, Epha8, and Ephb2 in Esr2+/+ but not Esr2-/- females. This is
consistent with the report that GCs from Esr2-/- females exhibit attenuated activation of
many FSH-responsive genes including Inhba (inhibin beta-A) (Inhba), Hsd3b1 (3-betahydroxysteroiddehydrogenase 1), and Comp (cartilage oligomeric matrix protein) in Esr2124

/-

GCs. The same study proposed that a deficiency in cAMP production underlies the

reduced induction of FSH-responsive genes. In addition, GCs of Esr2-/- females produce
50% less cAMP in response to the adenylate cyclase activator forskolin, and exhibit
attenuated phosphorylation of CREB following treatment with FSH, compared to GCs
from Esr2+/+ mice (14). Therefore, impaired production of cAMP is associated with loss
of eCG-stimulated Efna5, Epha3, Epha5, Epha8, and Ephb2 expression in mouse GCs.
4.4.2 The 1589 bp region upstream of Epha5 is transcriptionally activated by cAMP in
a PKA-dependent manner in KGN cells
Since FSHR is a Gs protein coupled receptor, its activation results in stimulation of
adenylate cyclase and an associated elevation of intracellular cAMP concentration (20).
In GCs, the major downstream target of cAMP seems to be PKA, although PKAindependent targets including cAMP-dependent guanine exchange factors (27,28) and
protein kinase B (PKB) (29) may also mediate the response to FSH.
PKA is a serine-threonine protein kinase that is composed of two catalytic and two
regulatory subunits. In the inactive state, kinase activity of the catalytic subunits is
suppressed by the presence of the regulatory subunits. Elevated levels of cAMP favour
disengagement of the regulatory subunits, permitting translocation of the catalytic
subunits into the nucleus (30) where PKA alters the activity of target proteins by
phosphorylation. One target of PKA in the nucleus is cAMP response element binding
protein (CREB), a member of the basic region leucine zipper (bZIP) family of DNAbinding proteins. Upon stimulation with cAMP, CREB is activated by phosphorylation at
serine 133 (30). Activated CREB then binds to cis-regulatory elements that are associated
with cAMP-responsive genes and recruits CREB-binding protein (CBP), a transcriptional
coactivator. These cis-regulatory sequences are known as cAMP-responsive elements
(CREs), and have a consensus sequence of 5’-TGACGTCA-3’ (full CRE) or 5’-CGTCA3’ or 5’-TGACG-3’ (half CRE) (21). These sequences are typically found near the
transcriptional start site, with ~60% of consensus CREs and variants found within 500 bp
of the 5’ UTR (31). Other transcriptional regulators known to bind CREs include the
transcriptional activator activating transcription factor 1 (ATF1) and the transcriptional
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repressor cAMP responsive element modulator (CREM). However, the current body of
evidence suggests that CREB is the primary CRE-binding protein in most cell types (32).
Among the FSH-responsive genes transcriptionally regulated via CREB in GCs is
Cyp19a1, which encodes the enzyme CYP19A1 (cytochrome P450, family 19, subfamily
A, polypeptide 1), commonly referred to as aromatase. CYP19A1 catalyzes the
aromatization of testosterone and androstenedione, and is the rate-limiting step in the
synthesis of estradiol in biological systems. Furthermore, increased Cyp19a1 expression
and elevated estradiol production are hallmarks of FSH-induced GC differentiation (33).
CREB directly binds the rat promoter region of the rat Cyp19a1 gene (34). Furthermore,
binding of CREB to a CRE in the human CYP19A1 promoter region is required for
cAMP-dependent activation of this region (35). We examined the genomic region
upstream of the mouse Epha5 gene and identified a putative consensus CRE half-site
located 389 bp upstream of the 5’ UTR that was conserved in multiple species (Figure
4-2).
We postulated that this CRE half-site is required for activation of Epha5 by cAMP
via the PKA pathway. In order to test this idea, we cloned 1589 bp of the mouse genomic
region upstream of the Epha5 5’-UTR into the pGL3-basic luciferase reporter plasmid,
generating the Epha5-Luc luciferase reporter construct. We then assessed the capacity of
this construct to respond to cAMP in KGN cells, a cell line derived from a human GC
tumor (23). KGN cells have been previously used as a model system to study the
regulation of CYP19A1 by FSH and cAMP (36). We observed that treatment with FSH
increased endogenous expression of EPHA5 in KGN cells (Figure 4-4A), which is
consistent with our previous finding that Epha5 is a FSH-responsive gene in mouse GCs
(15). We then found that treatment with dbcAMP increased luciferase activity in KGN
cells transfected with Epha5-Luc (Figure 4-4B), indicating that the 1589 bp genomic
region upstream of Epha5 is responsive to cAMP.
Since cAMP is known to activate several targets other than PKA (27-29), we then
determined whether activation of Epha5-Luc by dbcAMP was PKA-dependent or PKAindependent. In order to make this distinction, we co-treated KGN cells transfected with
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Epha5-Luc with dbcAMP and the PKA inhibitor H-89. Co-treatment with H-89
attenuated activation of Epha5-Luc by dbcAMP (Figure 4-5), indicating that activation
was PKA-dependent. It should be noted that while H-89 is a widely-used PKA inhibitor,
it is known to effectively inhibit at least 7 other kinases (37). Therefore, the possibility
that H-89 inhibits other targets should be considered. Future studies investigating
regulation of Eph and Efn genes by cAMP-dependent pathways should include other H89 specific inhibitors that exhibit reduced cross-inhibition, such as the commercially
available molecule Rp-cAMPS (38).
In order to test whether stimulation of the Epha5-Luc construct by dbcAMP was
dependent on the CRE half-site 389 bp upstream of the Epha5 5’ UTR, we used sitedirected mutagenesis to introduce two CRE-disrupting base pair substitutions into the
site, generating the mutEpha5-Luc luciferase reporter construct, which we will use in
future studies of Epha5 regulation. Current studies (Supplemental Figure 6-5) using the
mutEpha5-Luc construct have been unsuccessful due to difficulties with transfections that
occurred after a change in reagent suppliers. Re-optimization of transfection conditions
are ongoing.
Our findings indicate that in GCs, cAMP transcriptionally activates the proximal
upstream genomic region of Epha5 in a PKA-dependent manner. Given the observation
that induction of FSH-responsive Efn and Eph genes by eCG is reduced in GCs of mice
that exhibit impaired cAMP production, it is reasonable to speculate that Efna5, Epha3,
Epha5, Epha8, and Ephb2 are regulated in a similar manner in GCs. In other tissues,
hormones such as thyroid-stimulating hormone (TSH) in the thyroid gland and
adrenocorticotrophic hormone (ACTH) in the adrenal cortex stimulate their respective
GPCRs, resulting in elevated cAMP concentrations. Activation of these and other Gs
protein-associated signaling pathways may stimulate Efn and Eph expression, and their
associated physiological processes may involve Eph-ephrin signaling.
Regulation of Eph and Efn genes by FSH may also be important in cancer. FSHR
mRNA has been detected in a large percentage of ovarian epithelial inclusions and
ovarian epithelial tumors (OETs) (39), while FSHR protein is detected in endothelial

127

cells from a wide range of tumors, and may be involved in tumour angiogenesis (40).
Furthermore, overexpression of FSHR in cultured MCV152 OET cells increases cell
proliferation and invasiveness (41). These reports suggest that cAMP-dependent
enhancement of Eph and Efn expression may be involved in the formation, invasiveness,
and growth of such FSHR-expressing tumors, particularly in light of the evidence
indicating that Eph and Efn dysregulation is common in cancer (9).
4.4.3 Conclusion
Taken together, our findings indicate that in GCs, Epha5 expression is induced by
FSH via the cAMP-dependent PKA pathway. Our findings in Esr2-/- mice suggest the
possibility that Efna5, Epha3, Epha8, and Ephb2 are similarly regulated. Thus, PKA
represents a novel upstream regulator of Epha5, and potentially other members of the
Eph-ephrin family, in GCs.
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5 Chapter 5: Discussion
5.1 Summary
Previous studies have reported detection of numerous Eph and Efn mRNA
transcripts (1-4) and protein (5) in the ovary, suggesting that Eph-ephrin signaling plays a
role in ovarian function. The first evidence indicating a functional role in fertility was a
microarray screen of genes dysregulated in granulosa cells (GCs) of Esr2-/- mice, which
are subfertile and exhibit impaired antral follicle growth and ovulation (6). Among the
FSH-responsive genes dysregulated in GCs of these mice is Efna5 (4), suggesting that
altered expression of this gene contributes to their ovarian phenotype. Based on these
reports, we hypothesized that Efna5 is required for optimal gonadotropin-dependent
follicle growth and ovulation in the mouse.
This thesis presents findings gathered over the course of this investigation,
beginning with a characterization of Eph and Efn expression in mouse GCs and
confirmation that these cells are competent to respond to stimulation with recombinant
ephrin-A5 and EphA5 in culture, which induce altered morphology and reduced
adhesion, respectively. Based on study of a mouse model that lacks ephrin-A5, we
present evidence that this ephrin is required for optimal fertility and a complete ovarian
response to human chorionic gonadotropin (hCG). Specifically, loss of ephrin-A5 impairs
follicle rupture and alters expression of several genes thought to be involved in oocyte
release. Furthermore, we use a luciferase reporter system in a GC line to demonstrate that
the cAMP-dependent PKA pathway regulates transcription of the mouse Epha5 gene. We
also present evidence indicating that stimulation of FSH-responsive Eph and Efn genes is
attenuated in GCs of Esr2-/- mice, which exhibit impaired cAMP production. This
suggests that Efna5, Epha3, Epha8, and Ephb2 are regulated in a similar manner.
Therefore, our findings indicate that in the mouse, FSH enhances expression of Efna5,
Epha3, Epha5, Epha8, and Ephb2. Efna5 is required for a complete response to LH, and
its loss results in reduced expression of several genes involved in ovulation and is
associated with impaired follicle rupture. The evidence presented in this thesis establishes
a place for Eph receptors and ephrins within the current model of gonadotropin-
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dependent follicle growth and ovulation in the mouse, and identifies the cAMPdependent PKA pathway as a novel regulator of Epha5 transcription.

5.2 Expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 is enhanced in GCs
of mice stimulated with equine chorionic gonadotropin (FSH)
Prior to our investigation, several studies reported Eph and Efn expression in the
ovary. EPHB1, EPHB2, EPHB4, EFNB1, and EFNB2 mRNA transcripts were detected in
the human corpus luteum by RT-PCR (1) and beta-galactosidase-linked EFNB2 protein
was localized to blood vessels of the mouse thecal layer and corpus luteum by X-gal (5bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) staining (5). Moreover, mRNA
transcripts for Epha1, Epha2, Ephb1, and Ephb3 were reported to be more abundant in
dominant follicles compared to subordinate follicles in the cow (3). However, these
studies did not investigate Efn and Eph expression in the context of a fertilitycompromised or FSH-stimulated animal model. The report that Efna5 is dysregulated in
GCs isolated from FSH-stimulated (and subfertile) Esr2-/- mice (4) suggested that Ephephrin signaling contributes to optimal fertility.
Since ephrins initiate signaling upon interaction with cognate Eph receptors, we
surmised that GCs are likely to express Eph genes, which encode Eph receptors. In
Chapter 2, we detected mRNA transcripts for numerous Eph and Efn genes in GCs of
saline-treated mice. Of these genes, expression of a subset of Eph and Efn genes is
enhanced when mice are stimulated with equine chorionic gonadotropin (eCG), a horsederived gonadotropin that activates the FSH receptor. In GCs, FSH enhances expression
of genes that are required for the generation of a preovulatory follicle that is competent to
respond to the surge in luteinizing hormone (LH) that triggers ovulation. Chapters 2 and
4 identify Efna5, Epha3, Epha5, Epha8, and Ephb2 as FSH-responsive genes in mouse
GCs, and represents the first evidence for gonadotropin-regulated Efn and Eph expression
in GCs. Consistent with our findings, a recently published microarray comparison of gene
expression in small and large follicles in the cow ovary found that expression of Efna5
and Ephb6 is enhanced 8.6- and 3.8-fold, respectively, in large compared to small
follicles (7). Since follicle growth is driven primarily by FSH, this supports the idea that
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Eph and Efn expression increases under the influence of FSH. Furthermore, it was
recently reported that expression of EFNB2 is enhanced in human luteal cells in response
to human chorionic gonadotropin (hCG) (8), a placenta-derived gonadotropin with the
capacity to activate the LH receptor. Complemented by our own findings, these studies
are adding to a growing body of evidence indicating that Eph receptors and ephrins are
part of the ovarian response to gonadotropins, encompassing follicle growth, ovulation,
and formation of the corpus luteum.

5.3 Efna5 is required for a complete response to human chorionic
gonadotropin (LH)
To date, no Eph receptor or ephrin knockout mouse has been reported to exhibit
altered ovarian function. A partially-penetrant reproductive phenotype has been reported
in Epha7-/- females, but this was attributed to a developmental uterovaginal defect
resulting in complete vaginal obstruction (9). Chapters 2 and 4 of this thesis demonstrate
that eCG enhances expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 in mouse
GCs. Of these genes, only Efna5 encodes an ephrin ligand, while the remainder encode
Eph receptors that bind ephrin-A5. Therefore, we chose to investigate gonadotropindependent follicle growth and ovulation in the Efna5-/- mouse, based on the observation
that eCG does not enhance expression of other Efn genes in GCs that might compensate
for the loss of Efna5.
In Chapter 3, we present evidence that Efna5-/- females are subfertile and exhibit an
incomplete response to hCG. The impaired response to hCG included reduced ovulatory
potential, attenuated ovarian expression of the LH-responsive genes Pgr, Ptgs2, and
Adamts4, as well as impaired follicle rupture. Furthermore, adult Efna5-/- females
exhibited an increased incidence of multi-oocyte follicles (MOFs).
5.3.1 Morphological and adhesive responses in the context of the Efna5-/- phenotype
In Chapter 2, we demonstrated that in a two-dimensional cell culture model system,
GCs respond to recombinant ephrin-A5 and EphA5, exhibiting altered morphology and
cell-substrate adhesion, respectively. Specifically, seeding primary mouse GCs or rat
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GFSHR-17 cells onto an ephrin-A5-coated surface impedes cell spreading, while a
surface coated with recombinant EphA5 reduces cell-substrate adhesion. These responses
are indicative of repulsion, and it is reasonable to speculate that Eph-ephrin signaling
contributes to cell repulsion during ovulation, but whether loss of these morphological
and adhesive responses contributes to the ovarian phenotype we observed in Efna5-/- mice
is unknown. Nevertheless, these findings may provide insight into the way Eph-ephrinstimulated changes in morphology and adhesion are involved in follicle growth and
ovulation.
In the context of the growing follicle, such repulsive responses may contribute to
formation of the antrum, which occurs during FSH-dependent follicle growth and
requires movement of GCs relative to each other (10). Furthermore, cumulus cells exhibit
transiently increased migratory and adhesive properties at the time of ovulation. This is
proposed to facilitate adhesion of the COC to follicle wall extracellular matrix (ECM)
exposed by thinning of the granulosa layer at the site of rupture (11). Given our
observation that stimulation with ephrin-A5 and EphA5 induces a repulsive response in
cultured GCs (12), Eph-ephrin signaling may reduce granulosa cell adhesion at the time
of ovulation. In Efna5-/- mice, GC adhesion may remain sufficiently high as to impede
oocyte release. Interestingly, expression of other genes associated with cell repulsion
during axon guidance is increased in large compared to small follicles in the cow, such as
Slit (Slitrk1), roundabout (Robo1, Robo2), and semaphorin (Sema6a) (7). This suggests
that multiple pathways may be involved in regulating cell adhesion during follicle growth
and/or ovulation.
Given that ephrinA5 and Eph receptor A5 trigger morphological and adhesive
changes in granulosa cells in culture, Eph-ephrin signaling may contribute to cell
migration during release of the COC from the rupturing follicle. In Chapter 2, our data
indicate that in antral follicles of eCG-stimulated mice, immunoreactivity corresponding
to both ephrinA5 and Eph receptor A5 protein is stronger in mural granulosa cells than in
cumulus cells. This observation is consistent with the idea that FSH and oocytestimulated SMAD2/3 signaling establish opposing gradients of gene expression in the
follicle, such that expression of FSH-responsive genes is stronger in mural granulosa
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cells than in cumulus cells (13). Differential Eph receptor and ephrin expression that
gives rise to differences in adhesive affinity has been implicated in the segregation of
human colorectal cancer cells (14). In the follicle, differential Eph receptor and ephrin
expression in mural granulosa cells and cumulus cells may facilitate COC release through
differences in adhesive affinity that contribute to guiding the COC towards the site of
follicle rupture. In Efna5-/- females, FSH-stimulated expression of ephrinA5 and the
resulting gradient would be abolished, potentially altering the capacity of the follicle to
facilitate COC release and resulting in an increased likelihood of oocyte retention. Such a
scenario would complement the observation that the COC exhibits transiently increased
invasive migration at the time of ovulation (11) as well as the idea that in large antral
follicles, increased expression of ephrins and other signaling elements with roles in axon
guidance promote migration of the oocyte to the site of follicle rupture (7).
5.3.2 A possible role for Efna5 in follicle atresia
Our investigation yielded the unexpected finding that follicles containing expanded
COCs were more numerous in gonadotropin-stimulated (48 h eCG + 10 h hCG) Efna5-/females than in Efna5+/+ controls. Since the majority of follicles that are recruited for
FSH-dependent growth are destined for atresia (15), an increased number of follicles
containing expanded COCs may indicate disruption of atresia in Efna5-/- mice. The
possibility that ephrin-A5 is required for follicular atresia is supported by the observation
that expression of Efna4 and Efna5 is enhanced 4.2- and 3.3-fold, respectively, in small
atretic follicles compared to small healthy follicles in the cow (16). Given our
observation that Efna5 expression in GCs is enhanced by eCG, this is seemingly at odds
with the generally accepted idea that FSH serves as a survival signal that rescues follicles
from atresia (17). Therefore, enhancement of Efna5 expression in atretic follicles may
occur independently of FSH.
Cell death during atresia occurs by several biological mechanisms, including
apoptosis, autophagy, cornification, and necrosis (18). However, apoptosis is thought to
be the primary mechanism by which cell death occurs in atretic follicles (16). Eph-ephrin
signaling is required for apoptosis in some cell types, supported by the observation that
stimulation with recombinant ephrin-A5 promotes apoptosis in Epha7-expressing mouse
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cortical progenitor cells, while apoptosis is suppressed by loss of Epha7 (19).
Furthermore, Epha2-/- mouse embryonic fibroblasts are resistant to UV-induced apoptosis
compared to Epha2+/+ controls (20). Given the observations that expression of Efna4 and
Efna5 is higher in atretic bovine antral follicles than in healthy follicles (16) and the
increased numbers of follicles containing expanded COCs in ovaries of superovulated
Efna5-/- females, it is reasonable to speculate that Eph-ephrin signaling contributes to
follicular atresia. During the follicular phase of the ovarian cycle, a decline in serum FSH
concentration is thought to be a key mediator of atresia, resulting in the death of
subordinate follicles and selection of the dominant follicle (21). If Efna5 is required for
follicular atresia in the mouse, the absence of ephrin-A5 may permit some fraction of
subordinate follicles to acquire some competency to respond to hCG, and achieve
cumulus expansion.
5.3.3 Putative Eph-ephrin signaling mechanisms in GCs
One of the most interesting questions raised by our findings pertains to the nature
of the signaling mechanisms that act downstream of Eph-ephrin signaling in GCs.
Chapter 2 demonstrated that FSH enhances expression of Efna5 and several genes that
encode its cognate receptors, affects GC morphology and adhesion, and identified betacatenin as a possible downstream signaling target. Chapter 3 provides evidence that
ephrin-A5, the sole ephrin ligand upregulated in response to FSH in GCs, is required for
a complete ovarian response to LH. Its loss impairs ovulation and attenuates LHstimulated expression of two genes known to be important for follicle rupture, Pgr and
Ptgs2. However, the molecular mechanism(s) by which activation of Eph-ephrin
signaling contributes to GC functions and gene expression is unknown.
5.3.3.1 Crosstalk at the RAF-MEK-ERK pathway
One possibility is that Eph-ephrin signaling in GCs contributes to activation of
extracellular regulated kinases 1 and 2 (ERK1/2). Mice that lack ERK1/2 in GCs exhibit
a compromised response to LH, including impairment of cumulus expansion, ovulation,
luteinization, and abolished expression of many LH-responsive genes, including Pgr and
Ptgs2 (22). Therefore, ERK1/2 play a critical role in mediating the response to LH in the
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mouse ovary. Consequently, signaling pathways that impinge on ERK1/2 may have the
potential to modulate the response to LH in GCs.
Eph-ephrin signaling has been reported to impinge on ERK1/2 signaling, increasing
phosphorylation in some cell types and decreasing phosphorylation in others. Eph
receptor activation decreases phosphorylation of ERK1/2 in pRNS1-1 and PC-3 human
prostatic epithelial cells, mouse embryonic fibroblasts, and primary bovine aortic cells
(23). Furthermore, treatment of EPHB2-expressing MCF-7 cells with the EphB2 cognate
ligand ephrin-B2 or an agonistic EPHB2 antibody results in activation of ERK1/2 (24).
However, Eph receptor activation increases phosphorylation of ERK1/2 in MDA-MB231 breast cancer cells (25), mouse neural progenitor cells (26), and rat PC12
pheochromocytoma cells (27). This suggests the possibility that in follicles growing
under the influence of FSH, enhanced expression of Efna5 and genes encoding its
cognate Eph receptors results in increased Eph-ephrin-mediated ERK1/2 activation.
Therefore it is reasonable to speculate that in GCs, Eph-ephrin and LH signaling
converge at ERK1/2 to promote expression of genes that are important for ovulation. In
the Efna5-/- mouse, absence of ephrin-A5 may result in ERK1/2 phosphorylation that is
insufficient to achieve optimal induction of Pgr and Ptgs2, which in turn impairs follicle
rupture during ovulation.
Another possible mechanism by which ephrin-A5 may impinge on ERK1/2
involves suppression of Eph receptor activation by co-expressed ephrin-A5. The current
body of evidence primarily describes interactions between Eph receptors and ephrins in
trans, that is, between Eph receptors expressed on one cell and ephrins expressed on an
adjacent cell. Several reports have described Eph receptor-ephrin interactions in cis, that
is, co-expressed Eph receptors and ephrins interacting within the same cell membrane,
although the body of evidence supporting cis as opposed to trans interactions is smaller.
In EPHA3-expressins human embryonic kidney 293 (HEK293) cells, co-expression of
EPHA3 and EFNA5 abolished activation of EPHA3 by soluble, recombinant ephrin-A5
(28). The physiological importance of Eph-ephrin interactions in cis was demonstrated in
a report describing how attenuation of Eph receptor signaling by co-expressed ephrins is
required for proper migration of chick spinal motor axons (29). In Chapter 2, we detected
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transcripts for a number of Efn and Eph genes in mouse GCs. Expression of a subset of
these genes, which included only one ephrin (ephrin-A5) was enhanced by eCG. This
suggests the possibility of a scenario where a basal level of Eph-ephrin signaling
suppresses phosphorylation of ERK1/2 in GCs, as has been previously described (23).
Increased expression of Efna5 in response to FSH may then serve to attenuate activation
of co-expressed Eph receptors in cis, thereby relieving suppression of ERK1/2 signaling.
In the Efna5-/- mouse, eCG does not enhance expression of Efna5, and relief of ERK1/2
suppression by attenuation of Eph receptor forward signaling would not occur. In this
scenario, ERK1/2 phosphorylation may be insufficient to achieve optimal expression of
Pgr and Ptgs2, resulting in impaired follicle rupture.
5.3.3.2 Ephrin-A5 alters beta-catenin protein levels in GFSHR-17 cells
In Chapter 2, we reported that ephrin-A5 has the capacity to alter beta-catenin
protein levels in the GFSHR-17 rat GC line. Specifically, stimulation with recombinant
ephrin-A5 resulted in decreased beta-catenin protein levels. Beta-catenin is known to
have dual functions in the cell, serving as a component of adherens junctions (30) and as
a transcriptional activator (31,32). Targeting of beta-catenin protein to proteasomal
degradation is mediated by a constitutively-active degradation complex that consists of
APC (Adenomatous polyposis coli), axin, GSK3 (glycogen synthase kinase 3), and CK1
(casein kinase 1), resulting in constant turnover of beta-catenin. Activation of cell
membrane-associated FZD (Frizzled) receptors by WNT (secreted wingless/int1) proteins
promotes dissociation of this degradation complex, which results in increased betacatenin protein levels by accumulation (33). In the context of the ovary, maintenance of
appropriate beta-catenin protein levels in GCs is critical for fertility. Mice expressing a
dominant-stable (resistant to degradation) form of beta-catenin in GCs exhibit impaired
ovulation and luteinization. The same study found that when stimulated with eCG and
hCG, these mice exhibit attenuated expression of Ptgs2 in GCs compared to controls
(34). Therefore, in mouse GCs, FSH-stimulated enhancement of Efna5 expression may
serve as a mechanism to promote degradation of beta-catenin. In GCs of Efna5-/- mice,
loss of ephrin-A5 may result in increased beta-catenin protein levels, contributing to the
reduced expression of Ptgs2 and impairment of ovulation we observed in these mice.
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5.3.3.3 Attenuated expression of Adamts4 in Efna5-/- mice
In Chapter 3, we present data indicating that hCG-stimulated enhancement of
whole-ovary A disintegrin and metalloproteinase with thrombospondin-like repeats-4
(Adamts4) expression at 14 h post-hCG is 80% lower in Efna5-/- than in Efna5+/+ mice. In
the mouse ovary, expression of Adamts4 exhibits a biphasic pattern of expression
following stimulation with hCG, increasing at 4 h and falling by 8 h, and then increasing
again at 12-16 h. The same study found that in hCG-treated progesterone receptor (PGR)null (Pgr-/-) mice, ovarian expression of Adamts4 increases normally at 4 h, but is
significantly reduced at 12 h compared to Pgr+/- mice, indicating that Pgr is required for
optimal Adamts4 induction (35). This is also consistent with the current view that PGR
regulates the expression of numerous proteases during the periovulatory period (36). This
suggests that in hCG-treated Efna5-/- females, attenuated expression of Pgr at 4 h
contributes to the absence of Adamts4 induction at 14 h. Previously published
immunohistochemistry studies revealed that at 16 h post-hCG, ADAMTS4 protein is
substantially enriched at the site of ovulation, suggesting that it is involved in tissue
remodeling at this site (35). However, Adamts4-/- mice are phenotypically normal and
have not been reported to exhibit reproductive defects, suggesting that other proteinases
can compensate for its loss (37) or that its contribution to fertility is too small to be
detected using reasonable sample sizes. In Efna5-/- females, attenuated induction of Pgr
may result in reduced expression of other proteases that would normally compensate for
the loss of Adamts4. Therefore, attenuation of Adamts4 expression in Efna5-/- ovaries at
14 h post-hCG may be caused by inadequate ovarian induction of Pgr in these mice.
5.3.3.4 Reduced prostaglandin synthesis in follicles of Efna5-/- mice may allow nonapical rupture
Our observations suggest that reduced expression of Pgr and Ptgs2 in ovaries of
Efna5-/- mice contributes to abnormal follicle rupture in these animals. Release of
ovulated oocytes into the extraovarian space requires that follicle rupture occurs at the
apical surface, which lies closest to the ovarian surface epithelium. Localization of
rupture to the apical surface of the follicle has been attributed to the observation that the
follicle is thinnest at this region, the apex (38). However, proper localization of rupture
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may also be regulated by prostaglandin-stimulated expression of proteolytic inhibitors. In
granulosa cells of primate follicles, hCG stimulates expression of PLAT (tissue-type
plasminogen activator) and SERPINE1 (plasminogen activator inhibitor, type I) in a
prostaglandin-dependent manner (39). Prostaglandin receptor expression in primate
follicles differs between GC subtypes, with PTGER1 (Prostaglandin E receptor 1,
subtype EP1) predominant in mural GCs and PTGER2 (Prostaglandin E receptor 1,
subtype EP2) and PTGER3 (Prostaglandin E receptor 1, subtype EP3) predominant in
cumulus cells. The same study demonstrated that while PLAT protein levels are
uniform in mural GCs, EP1 and SERPINE1 protein levels are lower in mural GCs at the
follicle apex than in non-apex mural GCs. This suggests that follicle rupture is regulated
by a balance of activation and inhibition of proteolysis, with reduced inhibition favouring
rupture at the apex (40). In Efna5-/- females, attenuated Ptgs2 expression may result in
reduced prostaglandin synthesis, such that prostaglandin levels are insufficient to inhibit
proteolysis at non-apex follicle sites. This could potentially result in occasional instances
of non-apical follicle rupture.
5.3.4 A potential link between abnormal follicle rupture and multi-oocyte follicle
formation
Multi-oocyte follicles (MOFs) have been reported in a number of mouse models,
most of which exhibit decreased fertility (41). Our observations indicate that at PND 120,
MOFs are more numerous in ovaries of adult Efna5-/- mice than in Efna5+/+ controls.
However, there is no difference in MOF number between genotypes at PND 21, an age at
which mice are reproductively immature. This suggests a gonadotropin-associated
mechanism underlying MOF formation, as well as the possibility that MOF formation in
these mice occurs by joining of follicles. Incomplete prenatal oocyte nest breakdown
during has been proposed to cause MOF formation (42), however the observation that
increased MOF number is not seen in immature Efna5-/- females but is observed in adults
indicates that MOF formation likely occurs by joining of follicles. Breaching of the
follicle wall resulting in joining of follicles has been proposed to underlie MOF
formation in oocyte-specific C1galt1 (core 1 synthase, glycoprotein-Nacetylgalactosamine 3-beta-galactosyltransferase, 1)-deficient mice (41).
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In Chapter 3, we present evidence that absence of ephrin-A5 results in non-apical
follicle rupture. Furthermore, we observed one occurrence of premature follicle rupture at
the antral stage. These observations suggest that ephrin-A5 is involved in localizing
follicle rupture to an apical region of the follicle wall, and may also be important for
maintaining integrity of the follicle wall. Based on the histological similarity between
ovaries of Efna5-/- mice and PTGS2 inhibitor (indomethacin)-treated rats, and the
observation that enhancement of Ptgs2 expression is blunted in Efna5-/- ovaries, it is
reasonable to speculate that reduced PTGS2 activity underlies non-apical rupture in
Efna5-/- mice. However, premature follicle rupture was not reported in indomethacintreated rats. This suggests that premature follicle rupture in Efna5-/- mice is caused by the
absence of ephrin-A5, but by a mechanism that is independent of that which underlies
non-apical follicle rupture. If ephrin-A5 is important for maintaining follicle wall
integrity, its loss may result in an increased occurrence of follicle wall breaching and
merging, resulting in an increased occurrence of MOFs.
5.3.5 cAMP-dependent pathways regulate Epha5 expression in GCs
In Chapter 2, we demonstrated that FSH enhances expression of Efna5 and genes
encoding several of its cognate Eph receptors, suggesting a role for Eph-ephrin signaling
in follicle growth and/or ovulation. However, since the FSH receptor is a G protein
coupled receptor (GPCR), this also suggested that expression of these genes is regulated
by cAMP-dependent pathways. In Chapter 4, we present evidence that eCG-stimulated
enhancement of Efna5, Epha3, Epha5, Epha8, and Ephb2 is attenuated in GCs of Esr2-/mice. Esr2-/- mice exhibit impaired cAMP production in GCs, and this defect is the
proposed basis of the severely attenuated expression of FSH-responsive genes observed
in GCs of these mice. Using reporter assays, we also demonstrated that the 1589 bp
genomic sequence upstream of the Epha5 5’ UTR in the mouse is responsive to cAMP,
and that this response is suppressed by co-treatment with an inhibitor of protein kinase A
(PKA), H-89. Our findings are consistent with the idea that H-89 inhibits GC
differentiation, which is promoted by both FSH and cell-permeable cAMP analogs (43),
and with the idea that Eph receptors are part of the response to gonadotropins.
Transcriptional regulation of Eph and Efn genes by cAMP-dependent pathways has not
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been previously described. Our studies suggest that regulation by cAMP may also occur
in other tissues. Furthermore, GPCRs make up the largest known family of signaling
molecules associated with the cell surface, and many GPCRs impinge on cAMPdependent pathways (44). Therefore, our findings suggest that Eph and Efn expression
may be altered, and Eph-ephrin signaling involved, in GPCR-associated signaling events
where Eph-ephrin signaling has not been previously investigated as a potential source of
cross-talk.

5.4 Experimental Considerations
5.4.1 Germline Efna5-/- mouse model
In Chapter 2, we demonstrated that in GCs, expression of Efna5 and genes
encoding several of its cognate receptors is enhanced by FSH. Based on this finding, we
performed a reproductive characterization of the Efna5-/- mouse. It should be noted that
this mouse model is a germline knockout, and therefore lacks Efna5 at all stages of
development in all cell types. Therefore, we cannot rule out the possibility that loss of
ephrin-A5 during embryonic development impairs ovarian function in the adult.
Furthermore, non-GC types in the ovary, such as the oocyte, thecal cells, endothelial
cells, or the ovarian stroma may require ephrin-A5 for normal function. In future studies,
these concerns may be addressed through the use of a Cre/loxP approach to generate a
GC-specific Efna5 knockout mouse. Cyp19-Cre transgenic mice have been previously
generated (45) and used as a model system to investigate the role of ERK signaling in
GCs during FSH-dependent follicle growth (22). To some extent, the breeding and serum
steroid concentration data presented in Chapter 3 address these concerns. We detected no
difference in litter frequency between Efna5+/+ and Efna5-/- females, suggesting that
estrous cyclicity is not affected by loss of ephrin-A5. This in turn suggests that regulation
of the hypothalamic-pituitary-gonadal (HPG) axis is normal in Efna5-/- females.
Furthermore, we detected no difference in serum concentrations of estradiol and
progesterone between superovulated Efna5+/+ and Efna5-/- females. This suggests that
ovarian production of estradiol and progesterone, steroid hormones that act on the
hypothalamus, pituitary, uterus, and other tissues, is normal in Efna5-/- females.
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5.5 Future Directions
5.5.1 Delineating Eph-ephrin signaling pathways in GCs
In Chapter 3, we demonstrated that loss of ephrin-A5 attenuates hCG-stimulated
enhancement of Pgr and Ptgs2 expression in the ovary. While the mechanism by which
ephrin-A5 contributes to increased expression of these genes in the ovary is not known,
we speculated on the possibility that Eph-ephrin signaling impinges on ERK1/2 in mouse
GCs. In order to identify signaling pathways regulated by ephrin-A5, immunoblotting
could be used to analyze GC lysates from gonadotropin-stimulated Efna5+/+ and Efna5-/mice. Proven antibodies against total and phosphorylated forms of candidate targets we
have proposed are readily available, such as RAF, MEK, and ERK. Furthermore,
commercially available phosphorylated protein kinase detection arrays may reveal
additional pathways regulated by ephrin-A5 in GCs. These arrays would permit rapid
screening of multiple kinase targets to determine whether other pathways are
differentially regulated between Efna5+/+ and Efna5-/- GCs in superovulated mice. Any
targets identified by such screens would then be verified by immunoblotting.
If and when ephrin-A5-regulated pathways are identified in GCs of intact mice, a
cell culture approach could be used to distinguish between forward (downstream of Eph
receptor activation) and reverse (downstream of ephrin activation). In Chapter 2, we
stimulated cultured GCs with recombinant ephrin-A5 or EphA5 to demonstrate effects on
morphology and adhesion. The same experimental system could be used to specifically
stimulate forward or reverse signaling, and immunoblotting would then be used to assess
activation of identified signaling targets.

5.6 Conclusion
The work presented in this thesis demonstrates that ephrin-A5 plays an important
role in ovarian function. In the mouse, FSH enhances expression of Efna5, Epha3,
Epha5, Epha8, and Ephb2 in GCs. Loss of Efna5 results in subfertility and a partially
impaired response to hCG that includes reduced ovulatory potential, attenuated
expression of Pgr, Ptgs2, and Adamts4 (Figure 5-1), as well as abnormal follicle rupture.
We also present evidence that cAMP is a transcriptional regulator for genes encoding
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several members of the Eph-ephrin family. In the case of Epha5, the proximal upstream
genomic region is activated by cAMP in a PKA-dependent manner, and contains a
conserved, putative consensus CRE half-site. This indicates that Eph and Efn expression
may be regulated by GPCRs in other tissues. The body of evidence indicating the
importance of Eph-ephrin signaling in the ovary has only recently begun to grow. Our
current knowledge of Eph-ephrin function in the ovary is limited, particularly with
respect to the signaling pathways by which these signaling elements influence the ovarian
response to gonadotropins. Continued investigation will delineate these mechanisms to
generate a more accurate model of ovarian function.

146

Figure 5-1: Putative model for Eph-ephrin involvement in gonadotropin-stimulated
gene expression in mouse granulosa cells.
Activation of FSHR (1) stimulates expression of Efna5, Epha3, Epha5, Epha8, and
Ephb2 via the protein kinase A (PKA) signaling pathway (1a). Stimulation of LHR and
Eph receptors cognate to ephrinA5 results in activation of the PKA (2a) and extracellular
signal regulated kinase (ERK1/2) (2b) signaling pathways, respectively. This results in
optimal expression of Pgr, Ptgs2, and Adamts4. Pgr and Ptgs2 are necessary for
ovulation, while Adamts4 may play a role in tissue remodeling at the follicle rupture site.
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6 Appendix
6.1 Supplementary Material, Chapter 2

Supplemental Figure 6-1: Screening study to determine mRNA levels of all known
mouse ephrin (Efn) genes in granulosa cells isolated from immature female mice in
response to FSH.
Wild-type postnatal day (PND) 23-28 C57Bl/6 mice were treated with saline or equine
chorionic gonadotropin (eCG) (5.0 IU per mouse) for 48 hours. Granulosa cells (GCs)
were isolated by ovarian puncture, pooled, and mRNA isolated. mRNA levels were
determined by quantitative RT-PCR and compared to an Rpl7 control. Data are expressed
as average gene expression compared with the Rpl7 control (± SEM of three independent
experiments). All resulting values were normalized to the Efna3 vehicle (the Efn gene
with the lowest expression level) to approximate relative levels of gene expression
between Efn genes.
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Supplemental Figure 6-2: Screening study to determine mRNA levels of all known
mouse ephrin receptor (Eph) genes in granulosa cells isolated from immature female
mice in response to FSH.
Wildtype postnatal day (PND) 23-28 C57Bl/6 mice were treated with saline or equine
chorionic gonadotropin (eCG) (5.0 IU per mouse) for 48 hours. Granulosa cells (GCs)
were isolated by ovarian puncture, pooled, and mRNA isolated. mRNA levels were
determined by quantitative RT-PCR and compared to an Rpl7 control. Data are expressed
as average gene expression compared with the Rpl7 control (± SEM of three independent
experiments). All resulting values were normalized to the Epha6 vehicle (the Eph gene
with the lowest expression level) to approximate relative levels of gene expression
between Eph genes.
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Supplemental Figure 6-3: Proteome Profiler Phospho-Kinase Arrays.
GFSHR-17 cells were seeded onto tissue culture surfaces coated with ephrinA5-Fc or Fc
(control protein). Protein lysates were generated, and analyzed using the Human
Phospho-Kinase Array at 15 min (A) and 20 min (B) post-seeding. Capture array layout
is represented in (C).
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Supplemental Table 6-1: Human Phospho-Kinase Array capture antibodies
Spot
A1, A2
A3, A4
A5, A6
A7, A8
A9, A10
A13, A14
A17, A18
B3, B4
B5, B6
B7, B8
B9, B10
B11, B12
B13, B14
C1, C2
C3, C4
C5, C6
C7, C8
C9, C10
C11, C12
C13, C14
C15, C16
C17, C18
D1, D2
D3, D4
D5, D6
D7, D8
D9, D10
D11, D12
D13, D14
D15, D16
D17, D18
E1, E2
E3, E4
E5, E6
E7, E8
E9, 10
E11, E12
E13, E14
E15, E16
E17, E18
F1, F2

Kinase target
Reference
p38-alpha
ERK1/2
Pan-Jnk
GSK-3-alpha/beta
p53 (S392)
Reference
MEK1/2
MSK1/2
AMPK-alpha-1
Akt (S473)
Akt (T308)
p53 (S46)
TOR
CREB
HSP27
AMPK-alpha-2
beta-catenin
p70 S6 kinase (T389)
p53 (S15)
p27 (T157)
Paxillin
Src
Lyn
Lck
STAT2
STAT5a
p70 S6 kinase (T421/S424)
RSK1/2/3
p27 (T157)
PLC-gamma-1
Fyn
Yes
Fgr
STAT3
STAT5b
p70 S6 kinase (T229)
RSK1/2
c-Jun
Pyk2
Hck
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F3, F4
F5, F6
F7, F8
F9, F10
F11, F12
F13, F14
F15, F16
F17, F18
G1, G2
G5, G6

Chk-2
FAK
STAT6
STAT5a/b
STAT1
STAT4
eNOS
Negative control
Reference
Negative control
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Supplemental Table 6-2: Phosphorylation of intracellular kinase targets in response
to ephrinA5-Fc, 15 min post-seeding.
Target
Pan-JNK
p38alpha
GSK-3alpha/beta
AMPKalpha1
MSK1/2
MEK1/2
c-Jun
STAT5a/b
Fgr
STAT5b
Chk-2
Akt - S473
Pyk2
Hck
Lyn
RSK1/2/3
FAK
Paxillin
CREB
Yes
STAT6
HSP27
STAT3
p53 S15
Src
Lck
Akt
p53
eNOS
p70 S6 kinase T229
STAT2
RSK1/2
PLCgamma-1
AMPKalpha2
p70 S6 kinase - T421/S424
Fyn
TOR
p53 S46
p70 S6 kinase
STAT4

Phosphorylation Ratio (ephrinA5-Fc / Fc)
2.30
1.54
1.46
1.44
1.21
1.19
1.15
1.09
1.08
1.07
1.07
1.06
1.03
1.02
1.02
1.02
1.00
1.00
0.99
0.98
0.98
0.95
0.94
0.92
0.92
0.89
0.88
0.87
0.86
0.86
0.85
0.84
0.83
0.81
0.81
0.81
0.77
0.76
0.73
0.71
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STAT1
p27 T157
p27 T198
STAT5a
beta-catenin

0.70
0.65
0.63
0.31
0.16
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Supplemental Table 6-3: Phosphorylation of intracellular kinase targets in response
to ephrinA5-Fc, 20 min post-seeding.
Target
p53 S46
p53
HSP27
Akt
Chk-2
CREB
TOR
Lyn
p53 S15
Fgr
Yes
RSK1/2
STAT1
MEK1/2
GSK-3alpha/beta
p70 S6 kinase
RSK1/2/3
STAT4
FAK
p27 T198
p70 S6 kinase T229
eNOS
p70 S6 kinase
Src
Pyk2
MSK1/2
STAT2
AMPKalpha2
c-Jun
PLCgamma-1
Fyn
Hck
p38alpha
Pan-Jnk
STAT6
STAT5a/b
Paxillin
STAT5a
p27 T157
Akt - S473

Phosphorylation Ratio (ephrinA5-Fc / Fc)
1.35
1.33
1.29
1.23
1.19
1.16
1.15
1.13
1.12
1.11
1.09
1.08
1.07
1.07
1.06
1.06
1.05
1.03
1.02
1.00
0.98
0.97
0.95
0.95
0.91
0.90
0.87
0.83
0.82
0.81
0.80
0.77
0.76
0.75
0.64
0.59
0.59
0.58
0.58
0.51
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beta-catenin
AMPKalpha1
Lck
STAT5b
STAT3

0.51
0.47
0.42
0.42
0.31
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6.2 Supplementary Material, Chapter 3

Supplemental Figure 6-4: EPHRIN-A5 protein levels are lower in granulosa cells of
Esr2-/- mice compared to Esr2+/+.
Immunoblot detection of EPHRIN-A5 in Esr2+/+ and Esr2-/- granulosa cells and in control
HEK293 cells overexpressing EPHRINA5 (CMV-SPORT6-Efna5, black arrows). Equal
protein loading for granulosa cell and HEK293 lysates was confirmed by detection of
ALPHA-TUBULIN.
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Supplemental Figure 6-5: Stimulation of KGN cells transfected with Epha5-Luc and
mutEpha5-Luc with dibutyryl cAMP.
Firefly luciferase activity normalized to Renilla luciferase activity (mean ±SEM) was
determined for water- and dbcAMP-treated KGN cells transfected with the Epha5-Luc
(A) or mutEpha5-Luc (B) luciferase reporter constructs. A) No statistically significant
difference was found between vehicle- and dbcAMP-treated KGN cells transfected with
Epha5-Luc, as determined by an unpaired, two-tailed Student’s unpaired t-test;
t(4)=1.725. p=0.1596. B) No statistically significant difference was found between
vehicle- and dbcAMP-treated KGN cells transfected with mutEpha5-Luc, as determined
by an unpaired, two-tailed Student’s t-test; t(4)=2.088. p=0.1051.
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